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A B S T R A C T
Background
Chronic bacterial prostatitis (CBP) is frequently diagnosed in men of fertile age, and is characterized by a disabling array of symptoms,
including pain in the pelvic area (for example, perineum, testicles), voiding symptoms (increased frequency and urgency, also at night;
pain or discomfort at micturition), and sexual dysfunction. Cure of CBP can be attempted by long-term therapy with antibacterial
agents, but relapses are frequent. Few antibacterial agents are able to distribute to the prostatic tissue and achieve sufficient concentrations
at the site of infection. These agents include fluoroquinolones, macrolides, tetracyclines and trimethoprim. After the introduction of
fluoroquinolones into clinical practice, a number of studies have been performed to optimize the antimicrobial treatment of CBP, and
to improve eradication rates and symptom relief.
Objectives
To assess and compare the efficacy and harm of antimicrobial treatments for chronic bacterial prostatitis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (PubMed), EMBASE, other national or
international databases and abstracts from conference proceedings on 8 August 2012.
Selection criteria
We included all randomized controlled comparisons of one antimicrobial agent versus placebo or one or more comparator antimicrobial
agents, combined or not with non-antimicrobial drugs. We also included trials comparing different doses, treatment durations, dosing
frequencies, or routes of administration of antimicrobial agents. We excluded studies in which patients were not diagnosed according
to internationally recommended criteria, or were not subjected to lower urinary tract segmented tests.
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Data collection and analysis
Study data were extracted independently by two review authors. Study outcomes were microbiological efficacy (pathogen eradication),
clinical efficacy (symptom cure or improvement, or symptom scores) at test-of-cure visits or at follow-up, or both, and adverse effects
of therapy. Secondary outcomes included microbiological recurrence rates.
Statistical analysis was performed using a fixed-effect model for microbiological outcomes and a random-effects model for clinical
outcomes and adverse effects. The results were expressed as risk ratios for dichotomous outcomes (with 95% confidence intervals) or
as standardized mean differences for continuous or non-dichotomous variables.
Main results
We identified 18 studies, enrolling a total of 2196 randomized patients. The oral fluoroquinolones ciprofloxacin, levofloxacin, lome-
floxacin, ofloxacin and prulifloxacin were compared. There were no significant differences in clinical or microbiological efficacy or in
the rate of adverse effects between these fluoroquinolones. In chlamydial prostatitis, (i) azithromycin showed improved eradication
rates and clinical cure rates compared to ciprofloxacin, with no significant differences regarding adverse effects; (ii) azithromycin was
equivalent to clarithromycin, both microbiologically and clinically; (iii) prulifloxacin appeared to improve clinical symptoms, but not
eradication rates, compared to doxycycline. In ureaplasmal prostatitis, the comparisons ofloxacin versus minocycline and azithromycin
versus doxycycline showed similar microbiological, clinical and toxicity profiles.
Authors’ conclusions
The microbiological and clinical efficacy, as well as the adverse effect profile, of different oral fluoroquinolones are comparable. No
conclusions can be drawn regarding the optimal treatment duration of fluoroquinolones in the treatment of CBP caused by traditional
pathogens.
Alternative antimicrobial agents tested for the treatment of CBP caused by traditional pathogens are co-trimoxazole, beta-lactams and
tetracyclines, but no conclusive evidence can be drawn regarding the role of non-fluoroquinolone antibiotics in the treatment of CBP
caused by traditional pathogens.
In patients with CBP caused by obligate intracellular pathogens, macrolides showed higher microbiological and clinical cure rates
compared to fluoroquinolones.
P L A I N L A N G U A G E S U M M A R Y
Interventions to treat chronic infection of the prostate gland (chronic bacterial prostatitis)
Chronic bacterial prostatitis (CBP) involves infection and inflammation of the prostate gland in men of all ages. It can cause problems
urinating, includingdiscomfort andpain, increased frequency andurge, or problems emptying the bladder. Bacteria infecting the prostate
are the cause of CBP. These bacteria may be sexually transmitted. To cure CBP, antibiotics must be administered for extended periods of
time (four weeks or longer), but a permanent cure is not always guaranteed. Other drugs may be combined with antibiotics to improve
CBP symptoms. This review found that fluoroquinolones like ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin or prulifloxacin have
equivalent effects and equivalent success rates in CBP patients. If atypical bacteria like chlamydia are suspected to cause CBP, macrolide
antibiotics such as azithromycinmay achieve better results compared to the fluoroquinolone ciprofloxacin. It must be taken into account
that some of the studies that have been performed are of poor quality or have been performed on small numbers of participants. More
studies are needed, focusing on new agents or on optimized doses of currently prescribed antibiotics.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Levofloxacin versus ciprofloxacin for chronic bacterial prostatitis
Patient or population: patients with chronic bacterial prostatitis
Settings: outpatient
Intervention: levofloxacin
Comparison: ciprofloxacin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Ciprofloxacin Levofloxacin
Microbiological efficacy -
pathogen eradication
667 per 1000 787 per 1000
(540 to 1000)
RR 1.18
(0.81 to 1.71)
669
(2 studies)
⊕©©©
very low1,2,3
Clinical efficacy - cure or im-
provement at end of treat-
ment
722 per 1000 838 per 1000
(672 to 1000)
RR 1.16
(0.93 to 1.46)
669
(2 studies)
⊕⊕©©
low1,2
Clinical efficacy - cure or
improvement at follow-up (6
months)
Follow-up: mean 6 months
710 per 1000 823 per 1000
(610 to 1000)
RR 1.16
(0.86 to 1.55)
669
(2 studies)
⊕©©©
very low1,2,3
Adverse effects of treatment
- any adverse effects
266 per 1000 229 per 1000
(187 to 282)
RR 0.86
(0.7 to 1.06)
785
(2 studies)
⊕⊕⊕©
moderate1,2
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; No.: Number; RR: Risk ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Bundrick 2003 - high risk of reporting bias.
2 Zhang 2012 - high risk of performance bias, reporting bias and other bias (study design).
3 Results show inconsistency/heterogeneity (Analysis 1).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Prostatitis syndromes represent the most frequent urological diag-
nosis in men below 50 years of age, and they are the third most
common diagnosis among individuals beyond that age (Collins
1998).
The prevalence of chronic prostatitis-like symptoms ranges be-
tween2%and13%worldwide, depending on the type of study and
on the population examined (Bartoletti 2007; Ejike 2008; Ferris
2010; Krieger 2008; Liang 2009; Mehik 2000; Nickel 2001; Rizzo
2003; Wallner 2009). Analysis of the United States (US) Kaiser
Permanente Northwest database (Portland, Oregon) showed that
between 2002 and 2004 the incidence of physician-diagnosed pro-
statitis was 4.9 per 1000 person-years (Clemens 2005).
The age-adjusted annualized visit rate for prostatitis is 17,980 per
million population in the US, and prostatitis accounted for a total
of 8,021,396 physician office visits (with any diagnosis) between
the years 1992 and 2000. The total US spending for the diagnosis
and management of prostatitis in year 2000, not including phar-
maceutical expenses, was 84 million USD (McNaughton-Collins
2007; Pontari 2007). The economic impact of visits and tests for
prostatitis in the US, assessed in year 2009, ranged between 3017
USD (Medicare rates) and 6534 USD (non-Medicare rates) per
patient per year (Clemens 2009).
Chronic prostatitis syndromes are traditionally classified as ’bac-
terial’ or ’abacterial’.
According to the most recent National Institutes of Health - Na-
tional Institute of Diabetes and Digestive and Kidney Diseases
(NIH-NIDDK) consensus definition, category II chronic bacte-
rial prostatitis (CBP) occurs when patients experience recurrent
symptomatic episodes of urinary tract infection caused by the same
organism (usually E. coli, or another Gram-negative organism (for
example,Klebsiella spp.,Proteus spp.,Pseudomonas spp.) orEnterococ-
cus faecalis). Between symptomatic episodes of bacteriuria, lower
urinary tract cultures can document an infected prostate gland
as the focus of these recurrent infections (Krieger 1999). Besides
these commonly recognized pathogens, Staphylococcus aureus is
frequently included among the causative agents of CBP (for ex-
ample, Naber 2008; British National Guidelines: www.bashh.org/
guidelines). Other bacteria have been investigated in recent years,
but a general consensus on their pathogenic role in CBP is still
awaited.
The vast majority of men with chronic prostatitis (about 90%
of all prostatitis cases) (Lipsky 2010; McNaughton-Collins 2007)
present with pelvic pain and voiding symptoms without evi-
dence of bacterial infection, and are diagnosed with chronic
(abacterial) prostatitis/chronic pelvic pain syndrome (CP/CPPS,
NIH-NIDDK category III) (Krieger 1999; McNaughton-Collins
2007). CP/CPPS is mainly characterized by pain in the perineum,
prostate, rectum, penis, testicles and abdomen. It is often associ-
ated with dysuria (painful voiding), with symptoms of obstruction
on voiding (for example, hesitancy, weak or intermittent stream),
with irritative symptoms (for example, increased frequency, ur-
gency, nocturia (night-time urination)), and sometimes with sex-
ual dysfunction (Mehik 2001).
Symptoms of CBP and CP/CPPS frequently overlap. Since the
clinical presentation of patients with CBP or CP/CPPS is similar,
and given that there is no gold standard diagnostic test for the
latter, CP/CPPS is mainly diagnosed by excluding the presence of
category II CBP (McNaughton-Collins 2007).
Although patients suffering from prostatitis with a recognized bac-
terial etiology are only 5% to 10% of all men showing symptoms
of chronic prostatitis (McNaughton-Collins 2007), bacterial in-
fection is reputed to be a possible pathogenic factor in the early
’etiological pathway’ of CP/CPPS (Daniels 2007; Nickel 2010;
Shoskes 2009).However, CP/CPPS is defined and diagnosed as an
abacterial form of chronic prostatitis and antimicrobial treatment
is not effective for this specific syndrome (Cohen 2012).
Microbiological diagnosis of CBP is based on nding substantially
lower (one tenth or less) bacterial counts in urine specimens from
the urethra (first-voided urine, or VB1) and bladder (midstream
urine, or VB2) compared with counts in prostatic secretions ex-
pressed during prostatic massage (EPS) or in post-massage voided
urine (VB3). Such segmented microbiological analysis of men’s
lower urinary tract is commonly referred to as the ’four-glass test’
according to Meares and Stamey (Stamey 1981). Although never
validated in a randomized setting, the four-glass test is considered
to be a standard analytical procedure for diagnosing CBP as well
as for discriminating between CBP and CP/CPPS. A test based on
bacteriological culture of the pre-massage and post-prostatic mas-
sage voided urine (PPMT, or ’two-glass’ assay) has been proposed
as a simplified alternative to the four-glass test (Nickel 2006).
Although a study comparing the two tests in patients diagnosed
with CP/CPPS showed that the PPMT could detect uropathogens
in fewer cases (44%) compared to the traditional four-glass assay
(Nickel 2006), the former is considered a preferable alternative to
simple urine or semen cultures.
Description of the intervention
The therapy of CBP is based on the administration of antibacterial
agents for several weeks.
Fluoroquinolones are currently indicated as first-choice antibac-
terial agents for treatment of category II CBP. International rec-
ommendations and guidelines indicate a four to 12-week course
of ciprofloxacin, lomefloxacin, ofloxacin, levofloxacin or nor-
floxacin for the eradication of susceptible pathogens (European
Association of Urology (EAU) Urological Infections Guidelines:
www.uroweb.org/guidelines/online-guidelines/;UnitedKingdom
(UK) National Guidelines: www.bashh.org/guidelines; Canadian
guidelines: www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-
eng.php; Lipsky 2010; Wagenlehner 2007).
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Trimethoprim, combined or not with sulfamethoxazole, was for-
merly the most prescribed drug for the treatment of CBP (Meares
1975). Due to the low eradication rates achieved with trimetho-
prim, this drug is now indicated as a second-choice agent in case of
bacterial resistance to fluoroquinolones or in case of poor tolerabil-
ity of the first-choice agents (EAU Guidelines: www.uroweb.org/
gls/pdf/18_Urological%20infections_LR.pdf).
Macrolides and tetracyclines are also recommended for treat-
ment of CBP, but their use is presently restricted to special in-
dications (for example, chlamydial infection) (EAU Guidelines:
www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf;
Lipsky 2010; Nickel 2008b).
Patients with frequent recurrences may be placed on antibiotic
prophylaxis for several months (for example, low-dose co-trimoxa-
zole). However, evidence-based proof of efficacy of such a strategy
is lacking.
How the intervention might work
The number of antibacterial agents suitable for treatment of cate-
gory II CBP is very limited. Fluoroquinolones, trimethoprim and
macrolides are among the few antibacterial agents that can pene-
trate the prostate sufficiently to reach levels exceeding the mini-
mal concentrations inhibiting the growth (MIC) of most infecting
pathogens (Foulds 1991).
Lipophilicity and a high pKa (acid dissociation constant) are con-
sidered important features of antibacterial agents for the treatment
of CBP (Shoskes 2001). To achieve suitable prostatic concentra-
tions, a drug must be sufficiently lipophilic to cross the many bar-
riers separating the prostatic vasculature from the target site of ac-
tion, and to reach the pathogens infecting the prostatic glands and
ducts and, in some cases, the intracellular compartments (Naber
2003; Perletti 2009).
The pH at the site of action can also affect the pharmacodynamic
properties of antibacterial agents. The milieu of the infected hu-
man prostate is alkaline (pH = 8.34) (Naber 2003). It has been
demonstrated that alkalinization of the pH can significantly de-
crease (10- to 30-fold) the MICs of fluoroquinolones against E.
coli and other uropathogens (Aagaard 1991; Gesu 1987; Kamberi
1999). The activity of macrolides is also influenced by the pH at
the site of action; for example, the MIC of azithromycin (pKa =
9.5) against Staphylococcus aureus is 64, 1 and 0.03 at pH 6, 7 and
8, respectively (Dalhoff 2005).
Why it is important to do this review
Firstly, most current therapeutic recommendations for CBP are
based on data from randomized trials, non-randomized clinical
evidence, or on the clinical experience and opinion of leading ex-
perts. The fact that contemporary guidelines are not based on sys-
tematic reviews of the literature and the meta-analysis of available
data represents a major limitation in this regard. One example is
’suppressive’ long-term therapy with low-dose trimethoprim. This
recommendation is not substantiated by clinical data.
Secondly, the current antibacterial dosing regimens for CBP are
mainly based on ’trial-and-error’ empirical strategies, regimens
adopted for other infectious diseases, or on safety data. Pharma-
cokinetic and pharmacodynamic parameters for the treatment of
CBP, focusing on dosage issues, are almost non-existent. The re-
sults of studies comparing different doses of antibacterial agents
or different durations of therapy should be analyzed and reviewed.
Thirdly, the adjuvant effect of compounds administered in combi-
nationwith antibacterials (for example, alpha-adrenoceptor block-
ers) is controversial. Few of these combinations have been tested in
the framework of randomized controlled trials (RCTs). The results
of these studies must be thoroughly analyzed to improve clinical
decision-making and patient management.
Fourthly, the efficacy of interventions different from established
long-term oral antibacterial regimens (for example, intraprostatic
injection of antibacterial agents) is debated. The results of RCTs
involving alternative administration routes for antibiotics must be
reviewed and thoroughly analyzed to improve clinical decision-
making and patient management.
Finally, the world-wide increasing fluoroquinolone resistance in
Gram-negative pathogens poses new therapeutical problems also
in the antibacterial treatment of CBP. For example, the activity
of second-generation fluoroquinolones like ciprofloxacin is ham-
pered by the novel resistance determinant aac (6’)-Ib-cr, whereas
unique structural features make molecules like levofloxacin unaf-
fected by aac (6’)-Ib-cr. Thus, fluoroquinolone clinical trials pub-
lished in the past must be reviewed in a contemporary perspective.
Moreover, studies published in the past may have lost relevance
due to diffuse drug resistance.
In conclusion, a systematic review may help improve current ther-
apeutic guidelines on the basis of the evidence available from qual-
ity RCTs, and may improve the nature and grade of clinical rec-
ommendations and the management of patients affected by CBP.
O B J E C T I V E S
To assess and compare the efficacy and harms of antimicrobial
treatments for CBP.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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All RCTs in which antimicrobial therapy was used to treat CBP.
Types of participants
Patients with category II (NIH-NIDDK) CBP (Krieger 1999),
or with CBP according to the earlier classification by Drach et al
(Drach 1978).
According to the Drach definition, CBP is diagnosed when
pathogenic bacteria are recovered in significant numbers from a
purulent prostatic fluid in the absence of concomitant urinary
tract infection or significant systemic signs (Drach 1978).
A clinical diagnosis of CBP is mainly based on three criteria: a
history of CBP, current clinical signs and symptoms of prostatitis,
and laboratory evidence of prostatic infection in expressed pro-
static secretions or post-massage voided urine.
Studies focusing on patients affected by category I acute bacterial
prostatitis, category III CP/CPPS, or category IV asymptomatic
inflammatory prostatitis (NIH-NIDDK criteria), or by acute bac-
terial prostatitis, chronic non-bacterial prostatitis or prostatodynia
(Drach 1978 classification) were excluded.
Studies not providing microbiological findings from adequate
lower urinary tract segmented tests (Meares and Stamey ’4-glass’
test, ’2-glass’ pre- and post-massage test) were excluded. Studies in-
cluding patients with poorly defined infections or conditions (for
example, unclassified ’prostatitis’ or ’chronic prostatitis’; ’prostato-
epididimo-vesiculitis’; ’genital tract infection including prostati-
tis’; etc.) were excluded.
Types of interventions
1. We considered all randomized controlled comparisons of
one antimicrobial agent versus placebo, versus a different
antimicrobial agent, or versus two or more combined
antimicrobial agents.
2. Trials comparing different doses, different treatment
durations, different dosing frequencies, or different routes of
administration of antimicrobial agents were also considered to be
acceptable for inclusion, as these regimens are likely to differ in
their pharmacodynamic and pharmacokinetic properties and
thus may differ in their efficacy.
3. We also considered randomized controlled comparisons of
antimicrobial agents alone with antimicrobial agents combined
with non-antibacterial drugs or physical interventions aimed at
improving the microbiological or clinical efficacy of therapy as
well as drug pharmacokinetics.
Types of outcome measures
Primary outcomes
1. Microbiological efficacy, defined as yielding at test-of-cure
(TOC) visit sterile cultures of expressed prostatic secretions or
post-massage urine, or positive cultures with a bacterial load
inferior to a defined threshold (e.g., 103 colony-forming units
(CFU)/mL).
2. Clinical efficacy, defined as cure, resolution or improvement
of signs and symptoms of CBP at the TOC visit or at follow-up,
or assessed with strategies based on subjective or objective
findings:
i) subjective clinical outcomes included symptom scores,
bother scores, quality of life (QoL) scores, global urinary or
systemic symptom reports, or patient self-declared status (e.g.,
improved, unchanged or worsened);
ii) objective clinical outcomes included the results of
urodynamic or sonographic evaluations, prostate examination
(tenderness, size, consistency, symmetry), microscopy of
specimens of lower urinary tract segmented tests (white blood
cell counts), biochemical markers (e.g., prostate-specific antigen
(PSA)).
3. Adverse effects of treatment subgrouped or not for type,
severity, or drug class.
Secondary outcomes
Microbiological recurrence, defined as reappearance of a pathogen
or increase of its load over a defined threshold (for example, > 103
CFU/mL) after (apparent) eradication, assessed at the TOC visit.
Search methods for identification of studies
Electronic searches
Clinical trials for CBP were identified through MEDLINE (1966
to 8 August 2012) by crossing the sensitivity-maximizing version
of the Cochrane highly sensitive search strategy for identifying
randomized trials in MEDLINE (2008 revision) (Higgins 2011)
with the Boolean logic structure (item #6 of the following list):
1. ’prostatitis[MeSH]’, (including all subheadings)
2. ’(prostatitis) NOT (prostatitis[MeSH Terms])’
3. ’(prostato-vesic*[Title/Abstract]) OR (prostatovesic*[Title/
Abstract]) OR (prostato ADJ vesic*[Title/Abstract])’
4. ’(vesiculo-prostat*[Title/Abstract]) OR
(vesiculoprostat*[Title/Abstract]) OR (vesiculo ADJ
prostat*[Title/Abstract])’
5. ’(prostate OR prostate[MeSH Terms]) AND (bacterial
infections and mycoses[MeSH Terms])’
6. #1 OR #2 OR #3 OR #4 OR #5
The specialized PROSTATE register of the Cochrane Prostatic
Diseases and Urologic Cancers Group, Cochrane Central Register
of Controlled Trials (CENTRAL) and EMBASE databases were
searched in an analogous fashion.
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Searching other resources
The meta-register of Current Controlled Trials (controlled-
trials.com) and the US registry of clinical trials (clinicaltrials.gov)
were searched for protocols and results of RCTs on CBP.
International and national databases (for example, LILACS, Pan-
teleimon, IMSEAR, WPRIM, IndMed, KoreaMed, PASCAL,
Australasian Medical Index, Eastern-Mediterranean Index Medi-
cus) were also searched.
Handsearching was performed on the web pages containing
the abstracts of all scientific contributions presented at interna-
tional meetings of the European Association of Urology (http:/
/www.uroweb.org/), American Urological Association (http://
www.auanet.org/), International Society of Chemotherapy (http:/
/www.ischemo.org/), and the International Continence Society
(http://www.icsoffice.org/Events/EventsIndex.aspx). The general
term ’prostatitis’ was used for the abstract search.
One systematic review of the literature was retrieved (Erickson
2008). This review was also searched for studies.
Data collection and analysis
Selection of studies
1. The titles and abstracts obtained with the search strategy
described above were screened independently by two review
authors (GP, EM). Studies deemed to be not eligible for the
systematic review were excluded. Reviews or manuscripts that
might include relevant data or information on studies were
retained initially.
2. Two review authors (GP, FMEW) independently assessed
the retrieved abstracts and, if necessary, the full text of these
studies to determine which studies satisfied the inclusion criteria.
3. Discrepancies in the eligibility of retrieved studies were
resolved by discussion. If necessary, the Cochrane Prostatic
Diseases and Urologic Cancers Group was involved for
arbitration.
Data extraction and management
Data extraction was performed independently by two review au-
thors (GP, FMEW), using a modified version of a standard data
extraction form provided by the Cochrane Renal Group.
Studies were eligible if they were randomized, involved a placebo
control group or an active drug comparison group, involved pa-
tients with CBP diagnosed according to NIH or Drach 1978 cri-
teria, and if diagnosis at enrolment was performed using an ad-
equate lower urinary tract segmented bacteriological test (4-glass
or 2-glass).
Discrepancies or disagreements were resolved by discussion and, if
necessary, by arbitration involving theCochrane Prostatic Diseases
and Urologic Cancers Group. Studies reported in non-English
language journals were tentatively translated before assessment,
asking for the collaboration of the original authors of the reports.
Any further information required from the original authors was
obtained by correspondence and, if relevant, was included in the
review. Where more than one publication of one trial was found,
reports were grouped together and the most complete data set was
used.
Assessment of risk of bias in included studies
The risk of bias of included studies was assessed by two indepen-
dent review authors (FMEW,GP), without blinding to authorship
or journal. The following items were assessed using the Cochrane
Collaboration tool for assessing risk of bias (Higgins 2011).
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective reporting.
7. Other sources of bias.
’Risk of bias’ tables were generated for each included study and
were summarized in a ’Risk of bias’ summary figure.
In the present review, risk of bias was a fundamental component
of the analysis of the quality of evidence according to the GRADE
approach (Higgins 2011). Quality of the evidence was graded as
high, moderate, low or very low. In the case of low risk of bias,
no downgrading of a study was deemed necessary. In the case of
unclear risk of bias, or in the presence of biases raising doubts about
the estimate of the effect and the results, a study was downgraded
one level (for example, ’moderate’ to ’low’). In the case of high
risk of bias, the quality of the evidence was downgraded one or
two levels (for example, ’moderate’ to ’very low’) depending on the
severity of biases seriously weakening confidence in the results.
Measures of treatment effect
For dichotomous outcomes (for example, microbiological efficacy
(number of patients showing eradication versus persistence), clin-
ical efficacy (number of patients undergoing cure or improvement
versus failure), adverse effects (number of patients showing the
adverse effect)) results were expressed as risk ratios (RRs).
In the presence of ordinal outcomes (for example, mild, moderate
or severe symptoms), these were dichotomized (for example, mild
versus moderate or severe symptoms).
Where non-dichotomous scales were used to assess the effects of
treatment (for example, symptom, bother or QoL scores), the
mean difference (MD) was calculated. If different scales were
adopted for the same outcome, the standardized mean difference
(SMD) was used for analysis.
Both dichotomous and categorical outcomes were expressed with
95% confidence intervals (CIs).
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Unit of analysis issues
Cluster-randomized trials were excluded from the meta-analysis
as they are in general more prone to bias and, in the context
of meta-analysis, they may cause overestimation of the effect of
interventions due to the tendency to show narrow CIs and smaller
P values (Chapter 16.3.1, Higgins 2011).
Cross-over trials were planned to be incorporated inmeta-analyses
by including only data from the very first period of randomized
treatment (for continuous outcomes). In addition, cross-over tri-
als were planned to be assessed for risk of bias by analyzing the
following items in the report and the protocol of the study.
1. Was use of a cross-over design appropriate?
2. Is it clear that the order of receiving treatments was
randomized?
3. Can it be assumed that the trial was not biased from carry-
over effects?
4. Are unbiased data available?
5. Are results of the second treatment period concealed?
If multiple treatments were compared within a single study, in-
direct comparisons were planned to be performed to provide an
indirect estimate of the relative effect of the single interventions.
The limits of this approach were taken into account during eval-
uation of the quality of evidence, according to GRADE criteria
(Guyatt 2008).
Dealing with missing data
Missing studies
The comprehensive search strategy described above has been de-
signed to minimize missing studies.
Missing outcomes
Studies not reporting information on a primary outcome were not
excluded from the present systematic review. The lack of relevant
outcomes from a study of interest was addressed in the discussion
section and during ’Risk of bias’ assessment.
Missing data or missing individuals
We attempted to request relevant missing data from the original
authors or trialists. If data were apparently missing at random, we
analyzed only the available information.
Because imputation strategies may significantly increase hetero-
geneity, we limited our analysis to participants for whomoutcomes
were obtained (available case analysis).
A high risk of selective reporting bias was assigned to trials when
study outcomes were described in themethods paragraph but were
not reported in the results section of the same article.
Assessment of heterogeneity
Evidence of heterogeneitywas initially assessed by visual inspection
of the forest plots. Heterogeneity was analyzed by calculating the
I2 statistic. A 50% threshold was set for further investigation of
heterogeneity by subgroup analysis.
Combined endpoints (for example, ’any adverse effects’, including
different lists of adverse effects for each trial) were assessed by the
random-effects model.
Assessment of reporting biases
To identify reporting biases, we performed a comprehen-
sive search of clinical trials registers (http://clinicaltrials.gov/;
www.controlled-trials.com) in order to compare the original pro-
tocols with published reports of the same trials. Reporting bias was
assessed by generating funnel plots in RevMan 5.1 and by testing
for funnel plot asymmetry (for example, Egger test). These tests
were planned to be performed if at least 10 studies were included
in the meta-analysis.
Data synthesis
We compared dichotomous as well as non-dichotomous outcomes
at the endpoint. We assessed effect size inconsistency as well as
clinical study design and statistical heterogeneity.
We used a fixed-effect model to compare microbiological efficacy
as standardized pathogen cultures performed on patients’ biologi-
cal samples evaluate exactly the same effect, and variations in this
case are likely to be due to sampling issues. Conversely, a random-
effects model was adopted to evaluate clinical efficacy, to take into
account the diverse strategies used in the included studies in or-
der to assess general clinical endpoints (for example, cure or im-
provement definitions). Adverse effects were also analyzed using
a random-effects model. Finally, data analyzed with a fixed-effect
model were analyzed using a random-effects model to investigate
heterogeneity among studies.
We reported non-dichotomous clinical outcomes (for example,
questionnaire scores) by comparing the SMDs. We were aware
that a limitation to this kind of analysis is the fact that the scores
of clinical questionnaires are often based on ordinal scales.
For both continuous and dichotomous outcomes we calculated
95% CIs.
Relevant data from pooled analyses were reported in ’Summary of
findings’ tables.
Subgroup analysis and investigation of heterogeneity
Where substantial heterogeneity was found among pooled studies
evaluated with a fixed-effect model, we repeated the analysis using
a random-effects model.
To explore possible sources of heterogeneity, we planned to per-
form subgroup analysis if an adequate number of pooled studies
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were available. Heterogeneity among study participants might be
related to the following criteria:
1. age of participants (< 55 years versus ≥ 55 years) (Berges
2011);
2. prostate volume (< 25 mL versus ≥ 25 mL) (Berges 2011);
3. severity of symptoms at baseline or on study enrolment
(assessed with National Institutes of Health Chronic Prostatitis
Symptom Index (NIH-CPSI) or other symptom scores, bother
scores, QoL scores, or patient self-declared status) (e.g., NIH-
CPSI total score < 15 versus ≥ 15) (Nickel 2001);
4. type, sensitivity or specificity of microbiological diagnostic
tests (4-glass versus 2-glass);
5. previous antibacterial treatment (naïve versus heavily or
chronically pretreated participants);
6. duration of antibacterial treatment (< 4 weeks versus ≥ 4
weeks);
7. duration of follow up (< 1 month versus ≥ 1 month);
8. different criteria for microbiological outcome (e.g.,
different bacterial load cutoff to define pathogen eradication, for
example, 105 versus 103 CFU/mL);
9. different tests used to measure clinical outcomes (e.g., NIH-
CPSI versus International Prostate Symptom Score (IPSS)).
Subgroup analysis was performed only in the presence of an ade-
quate number of studies and if subgroup data were available.
Sensitivity analysis
Sensitivity analysis was used to explore the robustness of the meta-
analysis in the presence of I2 values beyond the 50% threshold.
We performed sensitivity analysis in the presence of a sufficient
number of included studies by repeating the analysis taking into
account one or more of the following items:
1. specific parameters of study quality (e.g., low versus
moderate or high risk of bias);
2. different measures of effect size (secondary analysis
performed with odds ratios (ORs) in the case of the primary
analysis performed using RRs);
3. different statistical models (secondary analysis performed
with a random-effects model in the case of the primary analysis
performed using a fixed-effect model).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We identified 3394 potential studies from the article databases and
12 potential studies from the online congress abstract databases.
The databases searched and the number of retrieved articles for
each database are listed in Figure 1. From 104 potentially relevant
studies selected after title and abstract review, 12 articles were not
evaluable and 41 articles were excluded. Among the excluded pa-
pers, four did not involve antibacterial treatment, 26 were non-
RCT studies, and 11 did not include patients with CBP or in-
cluded patients showing CBP together with other concomitant
conditions. Among the remaining 51 articles, 18 were finally in-
cluded in this systematic review, 32 were excluded, and one awaits
classification (Drasa 2009).
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Figure 1. Flow chart of included and excluded studies.
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Included studies
Eighteen studies, including a total of 2196 randomized partici-
pants, met all inclusion criteria. Among these studies, 14 com-
pared two different antibacterial agents (AAs) in treatment arms
containing participants with CBP caused by different pathogens
(Bundrick 2003; Bustillo 1997; Cox 1989; Giannarini 2007; Koff
1996; Naber 2002; Paulson 1986; Zhang 2012), or CBP caused
by a single pathogen (Cai 2010; Ohkawa 1993; Skerk 2002; Skerk
2003; Skerk 2004a; Skerk 2006). One RCT compared an AAwith
an AA combined with a phosphodiesterase-5 inhibitor (PDE5-
I) (Aliaev 2008). Two RCTs compared two courses of different
lengths with the same AA (Skerk 2004b; Smith 1979). One article
compared the combination of an AA plus herbal supplement with
an AA administered as single-agent (Cai 2009).
Excluded studies
Thirty-two studies did not meet inclusion criteria. Two articles
(Nickel 2008a; Schaeffer 2005) presented subset analyses of an in-
cluded study (Bundrick 2003). Four articles were not focusing on
CBP (Gleckman 1979; Martino 1993; Sabbaj 1986; Shen 2004),
and one included participants with chronic prostatitis involving
protozoans as the etiological agents (Vickovic 2010). One study
included CBP patients (n = 2) within a treatment arm contain-
ing men and women with various urinary tract infections (Childs
1983). Two studies were non-comparative (Baert 1983; Wedren
1989), four were non-randomized (Brannan 1975; Colleen 1975;
Kozdoba 2007; Smelov 2004), and five were non-RCTs (Cox
1991; Kunishima 2008; Lee 2006; Panagopoulos 2009; Shafik
1992). In particular, in the study by Lee et al, participants af-
fected by category II and IIIa prostatitis were pooled together (Lee
2006). In three studies, participants were affected by CBP associ-
ated with other conditions, namely, vesiculitis (Kim 2006), ure-
thritis (Zhang 2004), and genital infection with oligoasthenoter-
atozoospermia (Cai 2011). In three articles, a lower urinary tract
segmented test was not mentioned or described in the methods
section (Deng 2004; Hu 2002; Vicari 2000). In one study, a mi-
crobiological diagnostic test was not required at enrolment, and a
past history of CBP was deemed sufficient to qualify a patient as
having CBP (Paglia 2010). In four studies, participants belonging
to a single treatment arm were treated with various antibiotics,
and the names of the drugs or the number of participants treated
with a given drug were not specified, or subgroup analysis was not
performed (Ateya 2006; Barbalias 1998; Liao 2004; Trapeznikova
2007). For one (Chinese) study, translationwas not available at the
review authors’ institutions, and was not provided by the authors
when requested (Xu 2010). Moreover, this study, together with
the Zhang 2004 and Liao 2004 trials, involved traditional Chi-
nese medications. One RCT compared two different techniques
of intraprostatic administration of AA. Thus, this was a trial eval-
uating neither alternative antibiotics, different doses or dosages,
nor different routes of administration (Yavaçao lu 1998).
Risk of bias in included studies
The risk of bias analysis is summarized in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Nine trials described adequately the procedure used for genera-
tion of the randomization sequences (Bundrick 2003; Giannarini
2007; Naber 2002; Skerk 2002; Skerk 2003; Skerk 2004a; Skerk
2004b; Skerk 2006; Zhang 2012). In seven reports (Aliaev 2008;
Cai 2009; Cai 2010; Cox 1989; Ohkawa 1993; Paulson 1986;
Smith 1979), randomization procedures were not described in de-
tail, though it was clearly stated that participants were random-
ized. In two studies, the sequence generation procedure was not
adequate (Koff 1996) or not disclosed (Bustillo 1997).
Allocation concealment
Allocation concealment procedures were not disclosed in all 18
included studies. Though concealment was probably adequate in
one study (Giannarini 2007), in the remaining 17 studies it was
unclear as towhether allocationwas concealed or not (Aliaev 2008;
Bundrick 2003; Bustillo 1997; Cai 2009; Cai 2010; Cox 1989;
Koff 1996; Naber 2002; Ohkawa 1993; Paulson 1986; Skerk
2002; Skerk 2003; Skerk 2004a; Skerk 2004b; Skerk 2006; Smith
1979; Zhang 2012).
Blinding
Three studies were double-blinded (Bundrick 2003; Giannarini
2007; Smith 1979).One studywas single-blinded (Paulson 1986).
The remaining 14 studies were open-label (Aliaev 2008; Bustillo
1997; Cai 2009; Cai 2010; Cox 1989; Koff 1996; Naber 2002;
Ohkawa 1993; Skerk 2002; Skerk 2003; Skerk 2004a; Skerk
2004b; Skerk 2006; Zhang 2012).
Lack of blinding was not deemed to be a major determinant of
performance bias in one study having as the sole primary out-
come a non-subjective endpoint, namely microbiological eradi-
cation (Koff 1996). Similarly, in the Smith paper (Smith 1979)
the sole outcome of the trial was not subjective (microbiological
eradication following antibiotic treatment), and the risk of both
performance and detection biases was deemed to be low. On the
contrary, primary outcomes based on clinical signs and symptoms
or QoL scores (Aliaev 2008; Bustillo 1997; Cai 2009; Cai 2010;
Cox 1989; Naber 2002; Ohkawa 1993; Skerk 2002; Skerk 2003;
Skerk 2004a; Skerk 2004b; Skerk 2006; Zhang 2012) were con-
sidered at risk of bias in the absence of blinding.
The Paulson study (Paulson 1986) was deemed to be at high risk of
bias. Although the study was single-blinded, participants in group
1 (oral minocycline twice daily) did not receive two additional
placebo tablets to equal participants in group 2 (cephalexin four
times/day).
The risk of detection bias was considered unclear if the blinding
of outcome assessors was not described or disclosed in the study
reports (Bundrick 2003; Bustillo 1997; Cai 2009; Cai 2010; Cox
1989; Koff 1996; Naber 2002; Ohkawa 1993; Paulson 1986;
Skerk 2002; Skerk 2003; Skerk 2004a; Skerk 2004b; Skerk 2006;
Zhang 2012). One open study was at high risk of bias due to
the specific nature of the experimental drug combination (Aliaev
2008).
Incomplete outcome data
Two studies included an intention-to-treat (ITT) analysis (
Bundrick 2003; Naber 2002). Three studies (Bustillo 1997; Cai
2010; Giannarini 2007) were considered as having low risk of at-
trition bias due to the low impact of missing data on microbio-
logical outcome estimates and the high expected frequency of the
outcome (pathogen eradication after fluoroquinolone therapy).
In seven studies, withdrawals and dropouts were not described
or were indefinite; the risk of attrition bias was unclear in these
studies (Aliaev 2008; Koff 1996; Skerk 2002; Skerk 2003; Skerk
2004a; Skerk 2004b; Skerk 2006). In one study, the risk of bias
was high due to the high rate of withdrawals (22.2% per treat-
ment arm) (Ohkawa 1993). Two studies were considered at high
risk of attrition bias as the reasons for study withdrawals were not
presented separately according to treatment group (Cai 2009) or
to disease group (Paulson 1986). One study showed high dropout
frequencies in both treatment arms (59% and 41.6%) but lacked
an ITT analysis (Cox 1989). This study was considered as having
a high risk of bias. Similarly, in the Smith study (Smith 1979) a
high number of withdrawals in the treatment groups and the low
expected therapeutic success of the experimental drug (co-trimox-
azole) suggested high attrition bias. In the Zhang 2012 study, al-
most 40% of the isolated pathogen strains were resistant to cipro-
floxacin. Nevertheless, patients harbouring resistant strains were
apparently treated with ciprofloxacin. Subgroup analysis on erad-
ication rates only in patients harboring sensitive strains was not
disclosed.
Selective reporting
Three trials were considered to be free of selective reporting
(Bustillo 1997; Cai 2010; Naber 2002). In the Smith paper, a sec-
tion addressing clinical results was not presented although clinical
assessments were described in the methods section (Smith 1979).
Fourteen trialswere considered at high risk of reporting bias (Aliaev
2008; Bundrick 2003; Cai 2009; Cox 1989; Giannarini 2007;
Koff 1996;Ohkawa 1993; Paulson 1986; Skerk 2002; Skerk 2003;
Skerk 2004a; Skerk 2004b; Skerk 2006; Zhang 2012).
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Other potential sources of bias
In one study, the per protocol-like design did not allow evaluating
the presence or absence of baseline imbalances (Aliaev 2008). Risk
of bias was unclear. In one high-risk trial, patients with different
urological conditions were pooled at enrolment (Paulson 1986).
This made evaluating baseline values impossible. In one study, the
trial design and methods were not described in sufficient detail
(Koff 1996), and risk of bias was rated ’unclear’. One high risk of
bias studywas poorly designed as participantswith acute prostatitis
were included in a cohort of CBP participants (Cox 1989). In one
high-risk study, ’additional agents’ were administered to a fraction
of the participants in both treatment arms; names and dosages of
these agents were not disclosed (Zhang 2012). Moreover, the de-
sign of the 4-glass lower urinary tract diagnostic segmented testwas
modified, and assessment of concomitant bacterial urethritis was
impossible (Zhang 2012). In the same study, resistance to study
drugs was not an exclusion criterion. In the remaining studies, risk
of bias was considered low (Bundrick 2003; Bustillo 1997; Cai
2009; Cai 2010; Giannarini 2007; Naber 2002; Ohkawa 1993;
Skerk 2002; Skerk 2003; Skerk 2004a; Skerk 2004b; Skerk 2006;
Smith 1979).
Effects of interventions
See: Summary of findings for the main comparison
Levofloxacin versus ciprofloxacin for chronic bacterial prostatitis;
Summary of findings 2 Lomefloxacin versus comparator
fluoroquinolone for chronic bacterial prostatitis; Summary of
findings 3 Ciprofloxacin versus comparator fluoroquinolone for
chronic bacterial prostatitis; Summary of findings 4 Levofloxacin
versus comparator fluoroquinolone for chronic bacterial prostatitis
Eighteen RCTs were included in this review.
Different antibacterial agents
Fourteen parallel-group studies compared different antibacterial
agents.
Comparisons between different fluoroquinolones
Levofloxacin versus ciprofloxacin
Two studies, involving a total of 791 participants (Bundrick 2003,
383 participants; Zhang 2012, 408 participants), compared lev-
ofloxacin (500 mg once daily for four weeks in both trials) to
ciprofloxacin (500 mg twice daily for four weeks in both trials)
in patients affected by CBP (Summary of findings for the main
comparison). The Bundrick study was double-blind, whereas the
Zhang study was open-label. Both studies included an ITT analy-
sis. The studies had similar microbiological and clinical outcomes
(microbiological eradication at the end of therapy; clinical success
(cured or improved) at the end of therapy and after a six-month
follow-up; adverse effects of treatment).
• Microbiological efficacy (pathogen eradication) did not
differ significantly between groups in the Bundrick study (RR
0.98, 95% CI 0.85 to 1.12), whereas in the Zhang study
levofloxacin was found to significantly increase the RR for
microbiological eradication (RR 1.42, 95% CI 1.25 to 1.61)
(Analysis 1.1). When data were pooled (levofloxacin versus
ciprofloxacin comparison), a significant increase in RR for
eradication was observed (RR 1.22, 95% CI 1.11 to 1.34, fixed-
effect model). Substantial heterogeneity was found between the
studies (Chi2 = 15.82 (P < 0.0001); I2 = 94%). When a random-
effects model was adopted to analyze the pooled eradication data,
the difference lost statistical significance (RR 1.18, 95% CI 0.81
to 1.71) (Analysis 1.2). Sensitivity analysis was performed by
calculating ORs in place of RRs for the microbiological efficacy
primary outcome. Results from the Bundrick study were not
substantially affected (OR 0.91, 95% CI 0.51 to 1.60 (fixed-
effect and random-effects models; forest plot not shown)).
Conversely, results from the Zhang study were substantially
influenced by this strategy (OR 3.99, 95% CI 2.43 to 6.35
(fixed-effect model); OR 3.93, 95% CI 2.43 to 6.35 (random-
effects model; forest plot not shown)). Consequently, pooled
results were also affected (OR 2.16, 95% CI 1.52 to 3.07 (fixed-
effect model); OR 1.90, 95% CI 0.45 to 8.01 (random-effects
model; forest plot not shown)).
• In the Bundrick study, clinical efficacy (cure or
improvement) did not differ significantly between groups when
assessed at the end of therapy (RR 1.03, 95% CI 0.89 to 1.19) or
after a six-month follow-up (RR 0.99, 95% CI 0.85 to 1.16)
(Analysis 1.3). In the Zhang study, levofloxacin was found to
significantly increase the RR for clinical efficacy (cure or
improvement) both at the end of therapy (RR 1.30, 95% CI
1.18 to 1.43) and at follow-up (RR 1.33, 95% CI 1.21 to 1.46).
When data were pooled, clinical efficacy did not differ
significantly between treatment arms, both at the end of therapy
(RR 1.16, 95% CI 0.93 to 1.46) and at follow-up (RR 1.16,
95% CI 0.86 to 1.55) (Analysis 1.3). Also in this case significant
heterogeneity was observed between the studies (end of therapy:
Chi2 = 7.06 (P = 0.008); I2 = 86%; follow-up: Chi2 = 10.35 (P =
0.001); I2 = 90%). Sensitivity analysis was performed by
calculating ORs in place of RRs for clinical efficacy (forest plots
not shown). Results from the Bundrick study were not
substantially affected (OR 1.12, 95% CI 0.64 to 1.95 (end of
therapy); OR 0.97, 95% CI 0.57 to 1.66 (follow-up)). Results
from the Zhang study were substantially influenced by this
strategy (OR 5.45, 95% CI 2.92 to 10.18 (end of therapy); OR
6.75, 95% CI 3.50 to 13.04 (follow-up)). Consequently, pooled
results were also affected (OR 2.46, 95% CI 0.52 to 11.63 (end
of therapy); OR 2.54, 95% CI 0.38 to 17.14 (follow-up)).
• The rate of adverse effects did not differ significantly
between treatment groups in both studies (Analysis 1.4). With
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the exception of the ’dizziness’ effect (Chi2 = 3.68 (P = 0.06); I2
= 73%), heterogeneity was not detected for the adverse effects of
treatment outcome.
Prulifloxacin versus levofloxacin
In one study involving 96 participants (Giannarini 2007),
prulifloxacin (600 mg once daily for four weeks) was compared to
levofloxacin (500 mg once daily for four weeks).
• Microbiological efficacy (pathogen eradication) did not
differ significantly between groups (RR 1.02, 95% CI 0.79 to
1.33) (Analysis 2.1).
• Clinical efficacy (total NIH-CPSI scores) did not differ
significantly between groups when assessed at the end of therapy
(SMD -0.03, 95% CI -0.45 to 0.39) (Analysis 2.2).
• The rate of adverse effects did not differ significantly
between treatment groups (RR 0.82, 95% CI 0.36 to 1.88 (any
adverse effects)) (Analysis 2.3).
Lomefloxacin versus ofloxacin
In one study involving 33 participants (Koff 1996), lomefloxacin
(400 mg once daily for six weeks) was compared to ofloxacin (200
mg twice daily for six weeks).
• Microbiological efficacy (pathogen eradication) after a six-
month follow-up did not differ significantly between groups (RR
1.11, 95% CI 0.66 to 1.88) (Analysis 3.1).
• The rate of adverse effects did not differ significantly
between the treatment groups (RR 0.42, 95% CI 0.16 to 1.12
(any adverse effects)) (Analysis 3.2).
Lomefloxacin versus ciprofloxacin
In one study involving 182 participants (Naber 2002) lome-
floxacin (400 mg once daily for four weeks) was compared to ci-
profloxacin (500 mg twice daily for four weeks). In this study,
equivalence between lomefloxacin and ciprofloxacin was defined
as a 95% CI within 15% of the observed differences.
Intention-to-treat (ITT) analysis
• Microbiological efficacy (pathogen eradication) did not
differ significantly between groups at the end of therapy (RR
0.96, 95% CI 0.82 to 1.11) or for follow-up at four weeks (RR
0.87, 95% CI 0.72 to 1.06), three months (RR 0.90, 95% CI
0.74 to 1.09) or six months (RR 0.87, 95% CI 0.67 to 1.12)
(Analysis 4.1).
• Clinical efficacy (cure or improvement) did not differ
significantly between groups when assessed at the end of therapy
(RR 1.01, 95% CI 0.94 to 1.09) or for follow-up at four weeks
(RR 0.91, 95% CI 0.78 to 1.05), three months (RR 0.97, 95%
CI 0.82 to 1.15) or six months (RR 0.91, 95% CI 0.75 to 1.11)
(Analysis 4.3).
• The rate of adverse effects did not differ significantly
between treatment groups (RR 0.82, 95% CI 0.40 to 1.68 (any
adverse effects)) (Analysis 4.5).
Per protocol analysis
• Microbiological efficacy (pathogen eradication) did not
differ significantly between groups at the end of therapy (RR
0.98, 95% CI 0.89 to 1.09) or for follow-up at four weeks (RR
1.00, 95% CI 0.94 to 1.07), three months (RR 1.03, 95% CI
0.94 to 1.12) or six months (RR 0.94, 95% CI 0.80 to 1.09)
(Analysis 4.2).
• Clinical efficacy (cure or improvement) did not differ
significantly between groups when assessed at the end of therapy
(RR 0.96, 95% CI 0.89 to 1.03) or for follow-up at four weeks
(RR 1.00, 95% CI 0.86 to 1.18), three months (RR 1.07, 95%
CI 0.94 to 1.21) or six months (RR 0.88, 95% CI 0.77 to 1.01)
(Analysis 4.4).
Lomefloxacin versus comparator fluoroquinolone
Two trials (Koff 1996; Naber 2002) compared a cycle of treatment
with lomefloxacin (400 mg once daily) with a comparator second-
generation fluoroquinolone (Koff 1996: ofloxacin; Naber 2002:
ciprofloxacin) (Summary of findings 2).
• The trials were pooled for microbiological efficacy
(pathogen eradication) at follow-up (six months). The RR
analysis showed no significant difference between the treatment
arms (RR 0.96, 95% CI 0.80 to 1.16) (Analysis 5.1).
• The trials were also pooled for adverse effects. Men in the
lomefloxacin arm were not at a significantly different risk than
men in the comparator fluoroquinolone arm for total adverse
effects (RR 0.64, 95% CI 0.34 to 1.21), gastrointestinal effects
(RR 0.58, 95% CI 0.27 to 1.23), headache (RR 0.56, 95% CI
0.07 to 4.43) or dizziness (RR 0.88, 95% CI 0.09 to 8.60)
(Analysis 5.2). Heterogeneity was not detected for the adverse
effects outcome.
Ciprofloxacin versus comparator fluoroquinolone
Three trials (Bundrick 2003; Naber 2002; Zhang 2012) compared
a cycle of treatment with ciprofloxacin (500 mg twice daily for
four weeks) with a comparator second-generation fluoroquinolone
(Bundrick 2003 and Zhang 2012: levofloxacin 500 mg once daily
for four weeks; Naber 2002: lomefloxacin 400 mg once daily for
four weeks) (Summary of findings 3).
• When microbiological efficacy outcome data were pooled,
the RR for pathogen eradication was 0.87 (95% CI 0.80 to 0.94)
(Analysis 6.1, fixed-effect model). Substantial heterogeneity was
found between the studies (Chi² = 22.32 (P value < 0.0001); I² =
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91%). When a random-effects model was adopted to further
analyze the pooled eradication data, the difference lost statistical
significance (RR 0.91, 95% CI 0.70 to 1.18) (Analysis 6.2).
When the Zhang study (identified as the likely source of
heterogeneity by visual inspection of the forest plot) was
excluded from the pooled analysis, the I2 value changed from
91% to 0% and the RR for a random-effects model was 1.03
(95% CI 0.93 to 1.14) (Analysis 6.2). Sensitivity analysis was
performed by calculating ORs in place of RRs for the
microbiological efficacy outcome. The OR for pathogen
eradication for a fixed-effect model was 0.56 (95% CI 0.41 to
0.77) (I2 = 90%; forest plot not shown). The OR for pathogen
eradication for a random-effects model was 0.69 (95% CI 0.24
to 2.02) (I2 = 90%; forest plot not shown). When the Zhang
study was excluded from the pooled studies, the I2 value changed
from 90% to 0% and the OR for a random-effects model was
1.15 (95% CI 0.74 to 1.80; forest plot not shown).
• When clinical efficacy (cure or improvement) data were
pooled, results did not differ significantly between treatment
arms, both at the end of therapy (RR 0.90, 95% CI 0.75 to
1.08) and at follow-up (RR 0.93, 95% CI 0.72 to 1.20). Also in
this case significant heterogeneity was observed between the
studies (end of therapy: Chi² = 19.30 (P value < 0.0001); I² =
90%; follow-up: Chi² = 18.31 (P value = 0.0001); I² = 89%)
(Analysis 6.3). Exclusion of the Zhang study reduced the I2 value
to 0%. Sensitivity analysis was performed by calculating ORs in
place of RRs for the clinical efficacy primary outcome. The OR
for clinical efficacy at the end of therapy for a random-effects
model was 0.49 (95% CI 0.15 to 1.56) (I2 = 86%; forest plot
not shown). The OR for clinical efficacy at follow-up with a
random-effects model was 0.59 (95% CI 0.16 to 2.18) (I2 =
93%; forest plot not shown). Exclusion of the Zhang study
reduced the I2 value to 0%.
• The rate of adverse effects did not differ significantly
between treatment groups in both studies (Analysis 6.4) and,
when feasible, in pooled analyses. Heterogeneity was not
detected for the adverse effects outcome.
Levofloxacin versus comparator fluoroquinolone
Three trials (Bundrick 2003;Giannarini 2007; Zhang 2012) com-
pared a cycle of treatment with levofloxacin (500mg once daily for
four weeks) with a comparator fluoroquinolone (Bundrick 2003
and Zhang 2012: ciprofloxacin 500 mg twice daily for four weeks;
Giannarini 2007: prulifloxacin 600 mg once daily for four weeks)
(Summary of findings 4).
• When microbiological efficacy outcome data were pooled, a
significant increase in RR for pathogen eradication was observed
(RR 1.19, 95% CI 1.09 to 1.30, fixed-effect model) (Analysis
7.1). Substantial heterogeneity was found between the studies
(Chi² = 17.85 (P value = 0.0001); I² = 89%). When a random-
effects model was adopted to further analyze the pooled
pathogen eradication data the difference lost statistical
significance (RR 1.12, 95% CI 0.84 to 1.48) (Analysis 7.2).
When the Zhang study (identified as the likely source of
heterogeneity by visual inspection of the forest plot) was
excluded from the pooled analysis, the I2 value changed from
89% to 0% and the RR for the random-effects model was 0.98
(95% CI 0.87 to 1.10) (Analysis 7.2). Sensitivity analysis was
performed by calculating ORs in place of RRs for the
microbiological efficacy outcome. The OR for pathogen
eradication with a fixed-effect model was 1.93 (95% CI 1.39 to
2.68) (I2 = 89%; forest plot not shown). The OR for pathogen
eradication with a random-effects model was 1.54 (95% CI 0.52
to 4.52) (I2 = 89%; forest plot not shown). When the Zhang
study was excluded from the pooled studies, the I2 value changed
from 90% to 0% and the OR for the random-effects model was
0.91 (95% CI 0.56 to 1.48; forest plot not shown).
• The rate of adverse effects did not differ significantly
between treatment groups (Analysis 7.3). Heterogeneity was not
detected for the adverse effects outcome.
Fluoroquinolones versus other antibacterial agents
Prulifloxacin versus doxycycline
In one study involving 221 participants (Cai 2010), prulifloxacin
(600 mg once daily for two weeks) was compared to doxycycline
(100mg twice daily for threeweeks) in patients affected by chlamy-
dial prostatitis.
• Microbiological efficacy, evaluated as the absence of both
chlamydial deoxyribonucleic acid (DNA) and anti-Chlamydia
immunoglobulin A (IgA) at the end of therapy, did not differ
significantly between groups (RR 1.12, 95% CI 0.93 to 1.36)
(Analysis 8.1).
• For clinical efficacy, a significant difference in the total
NIH-CPSI scores was observed for the prulifloxacin and
doxycycline comparison (SMD -0.66, 95% CI -0.94 to -0.39)
(Analysis 8.2).
• Clinical efficacy, defined as the fraction of asymptomatic
patients at the end of therapy, did not differ significantly between
treatment arms (RR 1.04, 95% CI 0.91 to 1.19) (Analysis 8.3).
• The rate of adverse effects did not differ significantly
between treatment groups (RR 1.17, 95% CI 0.32 to 4.24 (any
adverse effects)) (Analysis 8.4).
Ofloxacin versus minocycline
In one study involving 18 participants (Ohkawa 1993), ofloxacin
(200 mg thrice daily for two weeks) was compared to minocycline
(100 mg twice daily for two weeks) in patients affected by ure-
aplasmal prostatitis.
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• Microbiological efficacy (pathogen eradication) did not
differ significantly between groups (RR 1.00, 95% CI 0.78 to
1.29) (Analysis 9.1).
• Clinical efficacy (cure or improvement), assessed at the end
of therapy, did not differ significantly between groups (RR 0.87,
95% CI 0.59 to 1.26) (Analysis 9.2).
• The trial authors reported that neither group was affected
by adverse effects of therapy.
Ofloxacin versus carbenicillin
In one study involving 46 participants (Cox 1989), ofloxacin (300
mg twice daily for six weeks) was compared to carbenicillin (764
mg four times/day for six weeks).
• Microbiological efficacy (pathogen eradication) did not
differ significantly between groups (RR 1.04, 95% CI 0.76 to
1.42) (Analysis 10.1).
• Clinical efficacy (cure or improvement), assessed at the end
of treatment, did not differ significantly between groups (RR
1.06, 95% CI 0.85 to 1.32) (Analysis 10.2).
• The rate of adverse effects did not differ significantly
between the treatment groups (RR 0.73, 95% CI 0.31 to 1.71
(any adverse effects)) (Analysis 10.3).
Lomefloxacin versus trimethoprim-sulfamethoxazole (co-
trimoxazole)
In one study involving 30 participants (Bustillo 1997), lome-
floxacin (400 mg once daily for six weeks) was compared to co-
trimoxazole (160 + 800 mg twice daily for six weeks).
• Microbiological efficacy (pathogen eradication) did not
differ significantly between the groups at the end of therapy (RR
1.09, 95% CI 0.82 to 1.44) or at the end of a four-month
follow-up (RR 1.09, 95% CI 0.82 to 1.44) (Analysis 11.1).
• Clinical efficacy (cure or improvement) did not differ
significantly between groups when assessed at the end of therapy
(RR 1.00, 95% CI 0.87 to 1.15) or at the end of a four-month
follow-up (RR 1.00, 95% CI 0.87 to 1.15) (Analysis 11.2).
• The rate of adverse effects did not differ significantly
between treatment groups (RR 0.43, 95% CI 0.04 to 4.25 (any
adverse effects)) (Analysis 11.3).
Ciprofloxacin versus azithromycin
In one study involving 89 participants affected by chlamydial pro-
statitis (Skerk 2003), ciprofloxacin (500 mg twice daily for 20
days) was compared to azithromycin (500 mg once daily, thrice-
weekly (first three consecutive days of each week) for three weeks).
• There was a significant increase in pathogen eradication in
the azithromycin arm (RR 0.48, 95% CI 0.32 to 0.72) (Analysis
12.1).
• There was a significant increase in clinical success (cure or
improvement) in the azithromycin arm (RR 0.64, 95% CI 0.46
to 0.90) (Analysis 12.2).
• The rate of adverse effects did not differ significantly
between the treatment groups (RR 0.34, 95% CI 0.01 to 8.15
(any adverse effects)) (Analysis 12.3).
Comparisons between different non-fluoroquinolone
antibiotics
Minocycline versus cephalexin
In one study involving 27 participants (Paulson 1986), minocy-
cline (100 mg twice daily for four weeks) was compared to
cephalexin (500 mg four times/day for four weeks).
• Microbiological efficacy (pathogen eradication and
eradication plus superinfection) did not differ significantly
between groups at the end of therapy (RR 1.70, 95% CI 0.54 to
5.34) (Analysis 13.1).
• Microbiological recurrence rates did not differ significantly
between groups at the end of therapy (RR 0.98, 95% CI 0.37 to
2.59) (Analysis 13.3).
• Clinical efficacy (cure or improvement), assessed at the end
of therapy, did not differ significantly between groups (RR 2.04,
95% CI 0.83 to 4.99) (Analysis 13.2).
• Adverse effects of therapy were not reported.
Azithromycin versus clarithromycin
In one study involving 91 participants affected by chlamydial pro-
statitis (Skerk 2002), azithromycin (500 mg once daily, thrice
weekly (first three consecutive days of each week) for three weeks)
was compared to clarithromycin (500 mg twice daily for two
weeks).
• Microbiological efficacy (pathogen eradication at the test-
of-cure (TOC) visit) did not differ significantly between groups
(RR 1.01, 95% CI 0.82 to 1.23) (Analysis 14.1).
• Clinical efficacy (cure rate) did not differ significantly
between groups when assessed at the end of therapy (RR 0.98,
95% CI 0.75 to 1.28) (Analysis 14.2).
• The rate of adverse effects did not differ significantly
between the treatment groups (RR 1.96, 95% CI 0.18 to 20.83
(any adverse effects)) (Analysis 14.3).
Azithromycin versus doxycycline in chlamydial prostatitis
In one study involving 125 participants affected by chlamydial
prostatitis (Skerk 2004a), azithromycin (1000 mg once weekly for
four weeks) was compared to doxycycline (100 mg twice daily for
four weeks).
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• Microbiological efficacy (pathogen eradication at the end of
therapy) did not differ significantly between groups (RR 1.03,
95% CI 0.85 to 1.26) (Analysis 15.1).
• Clinical efficacy assessed as inflammatory findings at the
end of therapy (number of participants with white blood cell
counts in EPS/VB3 < 10 per high power field) did not differ
significantly between groups (RR 1.08, 95% CI 0.66 to 1.78)
(Analysis 15.2).
• Clinical efficacy (cure or improvement) did not differ
significantly between groups when assessed at the end of therapy
(RR 0.95, 95% CI 0.76 to 1.19) (Analysis 15.2).
• The rate of adverse effects did not differ significantly
between the treatment groups (RR 0.21, 95% CI 0.04 to 1.04
(any adverse effects)) (Analysis 15.3).
Azithromycin versus doxycycline in ureaplasmal prostatitis
In one study involving 63 participants affected by ureaplasmal
prostatitis (Skerk 2006), azithromycin (500 mg once daily, thrice
weekly (first three consecutive days of each week) for three weeks)
was compared to doxycycline (100 mg twice daily for three weeks).
• Microbiological efficacy (pathogen eradication at the end of
therapy) did not differ significantly between groups (RR 1.05,
95% CI 0.80 to 1.39) (Analysis 16.1).
• Clinical efficacy (cure) did not differ significantly between
groups when assessed at the end of therapy (RR 1.01, 95% CI
0.72 to 1.42) (Analysis 16.2).
• The rate of adverse effects did not differ significantly
between the treatment groups (RR 0.09, 95% CI 0.01 to 1.53
(any adverse effects)) (Analysis 16.3).
Different duration of therapy courses for the same
antibacterial agent
Azithromycin 4.5 g versus 6.0 g (total dose) in chlamydial
prostatitis
In one study focusing on chlamydial prostatitis (Skerk 2004b), 89
participants were randomly divided into a treatment arm receiving
a total dose of 4.5 g azithromycin (500mgonce daily, thrice weekly
(first three consecutive days of each week) for three weeks) and a
treatment arm receiving total 6.0 g azithromycin (500 mg once
daily, thrice weekly (first three consecutive days of each week) for
four weeks).
• Microbiological efficacy (pathogen eradication at the end of
therapy) did not differ significantly between groups (RR 0.99,
95% CI 0.81 to 1.21) (Analysis 17.1).
• Clinical efficacy (cure) did not differ significantly between
groups when assessed at the end of therapy (RR 0.96, 95% CI
0.74 to 1.26) (Analysis 17.2).
• The rate of adverse effects did not differ significantly
between treatment groups (RR 0.19, 95% CI 0.01 to 3.79 (any
adverse effects)) (Analysis 17.3).
Co-trimoxazole 480 mg twice daily for 12 weeks versus 10
days
In one study involving 38 participants affected by chronic bacte-
rial prostatitis (Smith 1979), oral co-trimoxazole (480 mg twice
daily), administered for a period of 12 weeks, was compared to
480 mg oral co-trimoxazole (400 mg sulfamethoxazole; 80 mg
trimethoprim), administered twice daily for 10 days.
• There was a significant increase in pathogen eradication in
the 12-week treatment arm (RR 3.00, 95% CI 1.01 to 8.95)
(Analysis 18.1).
• The rate of adverse effects did not differ significantly
between the treatment groups (RR 0.53, 95% CI 0.05 to 5.31
(any adverse effects)) (Analysis 18.2).
Antibacterial agents combined with other
medications or supplements
Fluoroquinolone plus phosphodiesterase-5 inhibitors versus
fluoroquinolone
In one study involving 103 participants divided into three treat-
ment arms (Aliaev 2008), a combination of levofloxacin (500 mg
once daily for four weeks) with vardenafil, administered at fixed
daily doses (10 mg once daily) or on-demand (a single 10 mg
tablet), was compared with levofloxacin as single-agent (500 mg
once daily for four weeks). The two regimens of combined therapy
were also directly compared.
Levofloxacin plus vardenafil at fixed daily dose versus
levofloxacin
• Microbiological efficacy (pathogen eradication at the end of
therapy) did not differ significantly between groups (RR 1.04,
95% CI 0.90 to 1.19) (Analysis 19.1).
• Clinical efficacy, assessed as NIH-CPSI pain, voiding and
QoL impact scores, did not differ significantly between groups
when assessed at the end of therapy (pain score: SMD -0.13,
95% CI -0.62 to 0.35; voiding score: SMD -0.30, 95% CI -0.78
to 0.19; QoL impact score: SMD -0.24, 95% CI -0.72 to 0.25)
(Analysis 19.2).
• Clinical efficacy, defined as improvement of inflammatory
findings (number of participants with leukocytosis in post-
massage urine specimens at the end of treatment), did not differ
significantly between groups (RR 0.54, 95% CI 0.17 to 1.66)
(Analysis 19.3).
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• Clinical efficacy, expressed as urinary peak flow rates
(Qmax, mL/s), did not differ significantly between treatment
groups (SMD 0.24, 95% CI -0.25 to 0.72) (Analysis 19.4).
Levofloxacin plus vardenafil on-demand versus levofloxacin
• Microbiological efficacy (pathogen eradication at the end of
therapy) did not differ significantly between groups (RR 1.01,
95% CI 0.88 to 1.17) (Analysis 20.1).
• NIH-CPSI pain and voiding scores did not differ
significantly between groups when assessed at the end of therapy
(pain score: SMD -0.06, 95% CI -0.53 to 0.42; voiding score:
SMD 0.27, 95% CI -0.20 to 0.75) (Analysis 20.2).
• The scores of the NIH-CPSI domain focusing on the
impact of the disease on the QoL of participants differed
between groups, in favor of treatment with levofloxacin alone
(SMD 0.52, 95% CI 0.04 to 1.01) (Analysis 20.2).
• Clinical efficacy, defined as improvement of inflammatory
findings (number of participants with leukocytosis in post-
massage urine specimens at the end of treatment), did not differ
significantly between groups (RR 0.74, 95% CI 0.28 to 1.98)
(Analysis 20.3).
• Clinical efficacy, expressed as urinary peak flow rates
(Qmax, mL/s), did not differ significantly between treatment
groups (SMD 0.10, 95% CI -0.37 to 0.57) (Analysis 20.4).
Levofloxacin plus vardenafil at fixed daily dose versus
levofloxacin plus vardenafil on-demand
• Microbiological efficacy (pathogen eradication at the end of
therapy) did not differ significantly between groups (RR 1.02,
95% CI 0.90 to 1.16) (Analysis 21.1).
• The NIH-CPSI pain score did not differ significantly
between groups when assessed at the end of therapy (SMD -
0.09, 95% CI -0.55 to 0.38) (Analysis 21.2).
• The scores of the NIH-CPSI domains focusing on voiding
symptoms and on the impact of the disease on the QoL of
participants differed between groups, in favor of the fixed-dose
scheme (voiding score: SMD -0.64, 95% CI -1.11 to -0.16; QoL
impact score: SMD -0.69, 95% CI -1.17 to -0.21) (Analysis
21.2).
• Clinical efficacy, expressed as improvement of inflammatory
findings (number of participants with leukocytosis in post-
massage urine specimens at the end of treatment), did not differ
significantly between groups (RR 0.73, 95% CI 0.22 to 2.35)
(Analysis 21.3).
• Clinical efficacy, expressed as urinary peak flow rates
(Qmax, mL/s), did not differ significantly between treatment
groups (SMD 0.15, 95% CI -0.31 to 0.62) (Analysis 21.4).
Fluoroquinolone plus herbal extracts or supplements versus
fluoroquinolone
In one study, 154 participants were randomized to receive
prulifloxacin (600 mg once daily for two weeks) combined with
the products ProstaMEV and FlogMEV (Serenoa repens, oral, 160
mg once daily; Urtica dioica, oral, 120 mg once daily; Curcuma
longa, oral, 200 mg once daily; quercetin, oral, 100 mg once daily
for two weeks), or prulifloxacin alone (600 mg once daily for two
weeks) (Cai 2009).
• Total NIH-CPSI scores were significantly different between
groups, when assessed both at the end of therapy (SMD -2.56,
95% CI -3.04 to -2.08) and after a six-month follow-up period
(SMD -3.78, 95% CI -4.36 to -3.20) (Analysis 22.1). The
comparison between groups was in favor of the combined
therapy.
• IPSS scores were significantly different between groups,
when assessed both at the end of therapy (SMD -2.21, 95% CI -
2.66 to -1.75) and after a six-month follow-up period (SMD -
2.50, 95% CI -2.98 to -2.03) (Analysis 22.2). The comparison
between groups was in favor of the combined therapy.
• The rate of adverse effects did not differ significantly
between the treatment groups (RR 1.05, 95% CI 0.11 to 9.76)
(Analysis 22.3).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Lomefloxacin versus comparator fluoroquinolone for chronic bacterial prostatitis
Patient or population: patients with chronic bacterial prostatitis
Settings: outpatient
Intervention: lomefloxacin
Comparison: comparator fluoroquinolone1
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Comparator
fluoroquinolone
Lomefloxacin
Microbiological efficacy
- pathogen eradication
at follow-up (6 months)
Follow-up: mean 6
months
804 per 1000 771 per 1000
(643 to 932)
RR 0.96
(0.8 to 1.16)
116
(2 studies)
⊕⊕©©
low2,3
Clinical efficacy - cure
or improvement at end
of treatment
See comment See comment Not estimable 0
(0)
See comment No study reported or pro-
vided useable data for this
outcome
Clinical efficacy - cure or
improvement at follow-
up (6 months)
See comment See comment Not estimable 0
(0)
See comment No study reported or pro-
vided useable data for this
outcome
Adverse effects of treat-
ment - any adverse ef-
fects
212 per 1000 135 per 1000
(72 to 256)
RR 0.64
(0.34 to 1.21)
215
(2 studies)
⊕⊕⊕©
moderate2,3
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; No.: Number; RR: Risk ratio2
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The comparator fluoroquinolone was ofloxacin (Koff 1996) or ciprofloxacin (Naber 2002).
2 Naber 2002 - high risk of performance bias.
3 Koff 1996 - high risk of selection bias and reporting bias.
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Ciprofloxacin versus comparator fluoroquinolone for chronic bacterial prostatitis
Patient or population: patients with chronic bacterial prostatitis
Settings: outpatient
Intervention: ciprofloxacin
Comparison: comparator fluoroquinolone1
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Comparator fluoroquinolone Ciprofloxacin
Microbiological efficacy -
pathogen eradication at end
of treatment
806 per 1000 733 per 1000
(564 to 951)
RR 0.91
(0.7 to 1.18)
851
(3 studies)
⊕©©©
very low2,3,4,5
Clinical efficacy - cure or im-
provement at end of treat-
ment
879 per 1000 791 per 1000
(659 to 949)
RR 0.9
(0.75 to 1.08)
851
(3 studies)
⊕©©©
very low2,3,4,5
Clinical efficacy - cure or
improvement at follow-up (6
months)
Follow-up: mean 6 months
808 per 1000 752 per 1000
(582 to 970)
RR 0.93
(0.72 to 1.2)
851
(3 studies)
⊕©©©
very low2,3,4,5
Adverse effects of treatment
- any adverse effects
212 per 1000 246 per 1000
(202 to 302)
RR 1.16
(0.95 to 1.42)
967
(3 studies)
⊕⊕⊕©
moderate2,3,4
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; No.: Number; RR: Risk ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The comparator fluoroquinolone was levofloxacin (Bundrick 2003; Zhang 2012) or lomefloxacin (Naber 2002).
2 Bundrick 2003 - high risk of reporting bias.
3 Naber 2002 - high risk of performance bias.
4 Zhang 2012 - high risk of performance bias, reporting bias and other bias (study design).
5 Zhang 2012 is the most likely source of increased heterogeneity (Analysis 6).
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Levofloxacin versus comparator fluoroquinolone for chronic bacterial prostatitis
Patient or population: patients with chronic bacterial prostatitis
Settings: outpatient
Intervention: levofloxacin
Comparison: comparator fluoroquinolone1
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Comparator
fluoroquinolone
Levofloxacin
Microbiological efficacy
- pathogen eradication
674 per 1000 755 per 1000
(566 to 997)
RR 1.12
(0.84 to 1.48)
758
(3 studies)
⊕©©©
very low2,3,4,5
Clinical efficacy - cure
or improvement at end
of treatment
See comment See comment Not estimable 0
(0)
See comment No study reported or pro-
vided useable data for this
outcome
Clinical efficacy - cure or
improvement at follow-
up (6 months)
See comment See comment Not estimable 0
(0)
See comment No study reported or pro-
vided useable data for this
outcome
Adverse effects of treat-
ment - any adverse ef-
fects
258 per 1000 227 per 1000
(186 to 278)
RR 0.88
(0.72 to 1.08)
874
(3 studies)
⊕⊕⊕©
moderate2,3,4
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; No.: Number; RR: Risk ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The comparator fluoroquinolone was ciprofloxacin (Bundrick 2003; Zhang 2012) or prulifloxacin (Giannarini 2007).
2 Bundrick 2003 - high risk of reporting bias.
3 Giannarini 2007 - high risk of reporting bias.
4 Zhang 2012 - high risk of performance bias, reporting bias and other bias (study design).
5 Zhang 2012 is the most likely source of increased heterogeneity (Analysis 7).
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D I S C U S S I O N
Summary of main results
Therapy of infection caused by traditional pathogens
Fluoroquinolones are universally recommended as first-line agents
for CBP. The results of four out of five studies directly compar-
ing two different fluoroquinolones indicate substantial equiva-
lence between levofloxacin and ciprofloxacin, prulifloxacin and
levofloxacin, lomefloxacin and ofloxacin, and lomefloxacin and
ciprofloxacin. Equivalence was shown both at the microbiological
(eradication of diverse causative pathogens) and clinical levels, at
the end of treatment and at follow-up (Bundrick 2003;Giannarini
2007; Koff 1996; Naber 2002). The rates of adverse effects of
therapy also appeared to be equivalent in the compared treatment
arms.
Pooled analysis of lomefloxacin versus comparator fluoro-
quinolones confirmed such equivalence (RR for microbiological
efficacy at follow-up 0.96, 95% CI 0.80 to 1.16) (Summary of
findings 2).
In contrast to the Bundrick trial (Bundrick 2003), the study by
Zhang and colleagues indicated increasedmicrobiological eradica-
tion rates and increased rates of cured or improved participants in
the levofloxacin arm, both at the end of treatment and at the end
of a six-month follow-up period (Zhang 2012). When the Bun-
drick and Zhang pooled studies were analyzed by a random-effects
model, the difference between levofloxacin and ciprofloxacin was
not significant (microbiological efficacy: RR 1.18, 95% CI 0.81
to 1.71; clinical efficacy at the end of therapy: RR 1.16, 95% CI
0.93 to 1.46) (Summary of findings for the main comparison).
The discrepancy between these studies influenced the outcomes
of pooled analyses 1, 6 and 7. Summary of findings tables 1, 3
and 4 present in a synthetic form the outcome of such meta-anal-
yses (Summary of findings for the main comparison; Summary of
findings 3; Summary of findings 4). The possible reasons for this
discrepancy are discussed in the ’Quality of the evidence’ section
below.
Lomefloxacin is not inferior to co-trimoxazole at both the micro-
biological and clinical levels (Bustillo 1997). To be effective, the
latter agent should be administered for extended periods of time
(six to 12 weeks) (Smith 1979).
Beta-lactams were shown in two low powered studies to be not
inferior to fluoroquinolones (ofloxacin) or tetracyclines (minocy-
cline) at themicrobiological and clinical levels (Cox 1989; Paulson
1986).
Therapy of infection caused by obligate or facultative
intracellular pathogens
Macrolides were shown to bemore effective than fluoroquinolones
in chlamydial prostatitis. Microbiological and clinical outcomes
were superior for azithromycin when compared to ciprofloxacin
(Skerk 2003). The rate of adverse effects of therapy did not differ
between the treatment arms.
Different macrolides, like azithromycin and clarithromycin,
showed equivalent activity against chlamydial CBP (Skerk 2002).
Therapy with thrice weekly doses of azithromycin (500 mg once
daily) may last as little as three weeks without apparent loss of
microbiological or clinical efficacy compared to longer courses of
treatment (Skerk 2004b).Macrolides were also equivalent to tetra-
cyclines in both chlamydial and ureaplasmal prostatitis, both at
the microbiological and clinical levels (Skerk 2004a; Skerk 2006).
Fluoroquinolones (prulifloxacin) were shown to be as effective as
tetracyclines (doxycycline) in chlamydial prostatitis (Cai 2010).
Although prulifloxacin was more effective in attenuating clinical
symptoms at the test-of-cure (TOC) visit, equivalent numbers of
participants were asymptomatic at the same time point. Similarly,
fluoroquinolones (ofloxacin) and tetracyclines (minocycline) show
comparable microbiological and clinical efficacy and an equivalent
safety profile in ureaplasmal prostatitis (Ohkawa 1993).
In summary, macrolides appear to be the most effective agents
against CBP caused by intracellular pathogens.
Combination therapy - all pathogens
Combination of a fluoroquinolone with a phosphodiesterase-5 in-
hibitor (levofloxacin plus vardenafil) neither improves microbio-
logical eradication nor attenuates pain or voiding symptoms when
compared to therapy with the fluoroquinolone alone. However,
the impact of the disease on patients’ QoL is significantly im-
proved by the sole fluoroquinolone when compared to therapy
with the fluoroquinolone plus phosphodiesterase-5 inhibitor on-
demand, though the difference was not observed when the phos-
phodiesterase-5 inhibitor was administered at a fixed daily dose
(10 mg once daily) (Aliaev 2008).
Combination of a fluoroquinolone (prulifloxacin) with various
herbal preparations may attenuate clinical symptoms without in-
creasing the rate of adverse effects (Cai 2009).
Overall completeness and applicability of
evidence
The evidence resulting from this systematic review is applicable
to patients broadly fulfilling the specific inclusion and exclusion
criteria of the study.
Patients should be diagnosed and classified according to the NIH
(Schaeffer 2004) or Drach’s criteria (Drach 1978).
The microbiological diagnosis should be based on correctly per-
formed standard lower urinary tract segmented tests (for example,
4-glass or 2-glass tests) for the isolation of causative pathogens
from expressed prostatic secretions or post-massage urine. A diag-
nosis of CBP based on the sole sperm or midstream urine culture
is doubtful and methodologically incorrect.
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The antimicrobial agents described in this review must be admin-
istered at the correct doses, and the therapy should be long-term,
as demonstrated in all included studies. This is an essential re-
quirement for correct and effective applicability of the evidence
described in this review.
The massive worldwide onset of chemoresistance that occurred in
the last two decades has likely hindered the relevance and applica-
bility in contemporary practice of evidence derived from studies
focusing on drugs like co-trimoxazole or extended-spectrum beta-
lactamase (ESBL) targeted beta-lactam antibiotics. This should be
taken into account in clinical decision-making and therapy design
processes.
Quality of the evidence
The overall quality of the evidence described in this review is
affected by the methodological limitations of the included studies.
In particular, the more recent and better-designed trials on novel
fluoroquinolones (levofloxacin, lomefloxacin, prulifloxacin) were
de facto characterized by equivalency or non-inferiority designs.
It is well-known that non-inferiority studies have a number of
inherent weaknesses compared to superiority studies (Njue 2011).
Seven out of 18 studies described antimicrobial treatment against
CBP caused by a single pathogen: five studies were focusing on
chlamydial infections (Cai 2010; Skerk 2002; Skerk 2003; Skerk
2004a; Skerk 2004b), and two studies included only participants
withCBPcaused byUreaplasma urealyticum (Ohkawa 1993; Skerk
2006). The remaining 11 studies included participants with infec-
tion caused by any pathogen (Gram-positive or Gram-negative).
Pooled pathogens may represent a limitation and a confounding
factor for the resulting evidence since certain antimicrobials are
more active against a particular family or group of pathogens (for
example, first-generation fluoroquinolones are less active against
Gram-positive bacteria than fourth-generation agents).
Three out of 18 included studies were double-blinded (Bundrick
2003; Giannarini 2007; Smith 1979), and one was single-blinded
(Paulson 1986). Four studies assessed clinical symptoms using
an internationally validated scoring system (NIH-CPSI) (Aliaev
2008; Cai 2009; Cai 2010; Giannarini 2007). The remaining
studies adopted non-validated qualitative evaluation systems (for
example, ’cure’ versus ’failure’).Only two studies reported in detail
the randomization procedure or the system adopted for allocation
concealment (Bundrick 2003; Giannarini 2007).
A clinical outcome was absent in two studies (Koff 1996; Smith
1979), and adverse effects of treatment were not reported in three
studies (Aliaev 2008; Ohkawa 1993; Paulson 1986). Eradication
data at the TOC visit (end of therapy) were not disclosed in one
study (Koff 1996).
In general, most of the included studies were characterized by a
very low sample size.
Meta-analysis was performed to compare levofloxacin versus ci-
profloxacin (two studies: Analysis 1.1; Summary of findings for
the main comparison), lomefloxacin versus a comparator fluoro-
quinolone (Analysis 5.1; Summary of findings 2), ciprofloxacin
versus a comparator fluoroquinolone (Analysis 6.1; Summary of
findings 3), and levofloxacin versus a comparator fluoroquinolone
(Analysis 7.1; Summary of findings 4). Three out of four pooled
analyses (Analysis 1.1; Analysis 6.1; Analysis 7.1) showed very
high heterogeneity of microbiological outcomes (I2 = 94, 91 and
89, respectively). The Zhang 2012 study was identified as the
likely source of heterogeneity. This trial included a fraction of par-
ticipants with CBP caused by ciprofloxacin-resistant pathogens
(about 40% of the isolated pathogens). In the same patient pop-
ulation, 21% of isolates were resistant to levofloxacin. Thus, each
group randomized to ciprofloxacin or levofloxacin contained un-
balanced fractions of ciprofloxacin or levofloxacin resistant cases,
and the lower eradication rate achieved by ciprofloxacin in this
study is the probable source of substantial heterogeneity in the
meta-analysis. When the Zhang study was excluded from meta-
analysis of microbiological efficacy, heterogeneity became zero in
pooled analyses 6.2.2 and 7.2.2. In addition, microbiological ef-
ficacy lost significance in pooled analyses 1, 6 and 7 when the
original fixed-effectmodel was changed to a random-effects model
(Analysis 1.2; Analysis 6.2; Analysis 7.2).
Agreements and disagreements with other
studies or reviews
A single systematic review focusing on both chronic bacterial and
abacterial prostatitis was retrieved from the PubMed database (
Erickson 2008). This systematic review included both randomized
and observational trials and did not contain a meta-analysis. The
primary outcomes of this review were symptom improvement,
urodynamics, QoL, rates of bacteriological cure and adverse effects
of treatment. The quality of the evidence was rated according to
the GRADE criteria (Guyatt 2008). EMBASE, CENTRAL and
PubMed international databases were searched.
The Bundrick 2003, Giannarini 2007 and Naber 2002 compar-
isons between different fluoroquinolones were analyzed. The con-
clusions drawn in the Erickson paper and in the present review
are similar: lomefloxacin or levofloxacin are as effective as cipro-
floxacin at increasing bacteriological cure rates, and prulifloxacin
and levofloxacin are equally effective at increasing microbiolog-
ical eradication rates in men with chronic bacterial prostatitis
(Erickson 2008).
The Erickson review included a randomized study by Hu and
coworkers focusing on intraprostatic administration of aminogly-
cosides (Hu 2002).We excluded the study from the present review
because the description of the microbiological diagnostic methods
was considered insufficient.
The present review differed from Erickson 2008 concerning the
evaluation of the quality of evidence according to the GRADE
system. In general, the quality rating given to the included studies
is lower in the present systematic review. We attribute this differ-
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ential evaluation to the downgrading effect of selection, perfor-
mance, detection, attrition and reporting biases, assessed with the
Cochrane Collaboration risk of bias tool.
Beta-lactams were shown in two studies to be not inferior to flu-
oroquinolones (ofloxacin) or tetracyclines (minocycline) at the
microbiological and clinical levels (Cox 1989; Paulson 1986).
This evidence appears to be in contrast with more recent findings
demonstrating very limited distribution, and hence low activity, of
beta-lactam antibiotics into the prostatic tissue (Charalabopoulos
2003).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The following implications for practice in the treatment of patients
with chronic bacterial prostatitis (CBP) have been identified:
1. Patients with CBP are discriminated according to their
etiologic cause into infections caused by traditional pathogens
and infections caused by intracellular pathogens.
2. In patients with CBP caused by traditional pathogens, the
majority of studies were performed with oral fluoroquinolones at
treatment durations of three, four and six weeks. There are no
significant differences in microbiological and clinical efficacy,
and in adverse effect rates, between the oral fluoroquinolones
ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin and
prulifloxacin.
3. No conclusion can be drawn regarding the optimal
treatment duration of fluoroquinolones in the treatment of CBP
caused by traditional pathogens.
4. Alternative antimicrobial agents tested for treatment of CBP
caused by traditional pathogens are co-trimoxazole, beta-lactams
and tetracyclines, tested for four and six weeks duration. The
studies were underpowered, therefore no conclusive evidence can
be drawn regarding the role of non-fluoroquinolone antibiotics
in the treatment of CBP caused by traditional pathogens.
5. In patients with CBP caused by intracellular pathogens,
macrolides had higher microbiological and clinical cure rates
compared to fluoroquinolones at treatment durations of three
weeks. There are no significant differences regarding adverse
effects. There are no significant differences in microbiological
and clinical efficacy and adverse effects between oral
azithromycin and clarithromycin in chlamydial prostatitis.
6. There are also no significant differences in microbiological
and clinical efficacy and adverse effect rates between macrolides
and tetracyclines (viz., azithromycin versus doxycycline) in
patients with CBP caused by facultative or obligate intracellular
pathogens.
7. There is inconclusive randomized controlled evidence
regarding the role of combination treatments of CBP with
antimicrobial and non-antimicrobial substances, such as
phosphodiesterase-5 inhibitors or herbal preparations.
Implications for research
Further RCTs are required to determine the microbiological and
clinical efficacy in the treatment of:
• CBP caused by traditional pathogens with non-
fluoroquinolone antimicrobial agents;
• CBP caused by fluoroquinolone-resistant pathogens with
non-fluoroquinolone antimicrobial agents in the light of the
increasing fluoroquinolone resistance reported in CBP isolates;
and
• CBP caused by traditional as well as intracellular pathogens
with antimicrobial and non-antimicrobial substances as
combination treatments.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aliaev 2008
Methods Randomized, parallel group, open-label, active drug-controlled study
Participants Geographic region: Russia
Enrolled participants: n = 103
Randomization:
GROUP 1, n = 32
GROUP 2, n = 44
GROUP 3, n = 37
Age (mean, overall): 36.2 ± 8.4
Inclusion: diagnosis of CBP, and history of CBP (NIH criteria). Microbiological diag-
nosis: 2-glass test
Exclusion: criteria not specified
Study discontinuations: n = 0
Study duration: 8 weeks (4 weeks, treatment; 4 weeks, follow-up)
Interventions GROUP 1
Levofloxacin, oral, 500 mg once daily, for 4 weeks
GROUP 2
Levofloxacin, oral, 500 mg once daily, plus vardenafil, oral, 10 mg once daily, for 4 weeks
GROUP 3
Levofloxacin, oral, 500 mg once daily, plus vardenafil, oral, 10 mg on-demand, for 4
weeks
Outcomes Microbiological eradication per patient
Clinical improvement (NIH-CPSI test, uroflowmetry, leukocyte counts in VB3)
Notes The original study article (Aliaev 2008) was not retrieved from online databases. One
author (NDA) was contacted and provided a full written report of the study, partly
translated into English (abstract, tables). This report was used for the present review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “This study was of the randomized type”.
No additional information provided
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The use of a PDE5 inhibitor may signifi-
cantly influence the outcome of symptom
questionnaires likeNIH-CPSI.NIH-CPSI
includes a QoL item
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Aliaev 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk See above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Per protocol-like analysis does not allow to
evaluate number of dropouts and reason for
study discontinuation
Selective reporting (reporting bias) High risk Information on isolated pathogens and on
per pathogen eradication are missing. In-
formation on adverse effects of treatment
is missing
Other bias Unclear risk No apparent baseline imbalances. Per pro-
tocol-like design
Bundrick 2003
Methods Randomized, parallel group, double-blind, active drug-controlled, multicenter, phase 3/
b study
Participants Geographic region: USA
Enrolled participants: n = 383 (intent-to-treat, n = 377; per protocol, n = 325; microbi-
ologically/clinically assessable, n = 321)
FOR MICROBIOLOGICAL OUTCOME:
Randomization:
GROUP 1, n = 170
GROUP 2, n = 151
Study discontinuations: n = 60
GROUP 1, n = 34
GROUP 2, n = 26
FOR SAFETY OUTCOME:
Randomization:
GROUP 1, n = 199
GROUP 2, n = 184
Study discontinuations: n = 6
GROUP 1, n = 2
GROUP 2, n = 4
Age: not available
Inclusion: history of CBP, clinically and microbiologically diagnosed CBP. Microbiolog-
ical diagnosis: 4-glass test
Exclusion: < 18 years old; prostate cancer; ongoing therapy with drugs affecting bladder/
prostate function; prostate biopsy; cystoscopy; current or recent treatment with antimi-
crobials; parenteral therapy for prostatitis; pathogen resistant to study drugs; allergy to
fluoroquinolones; creatinine clearance < 50 ml/min; TURP, indwelling catheters, cys-
tostomy, nephrostomy
Study duration: 7 months (4 weeks therapy; 6 months follow-up)
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Bundrick 2003 (Continued)
Interventions GROUP 1
Levofloxacin, oral, 500 mg once daily, plus placebo, once daily, for 28 days
GROUP 2
Ciprofloxacin, oral, 500 mg twice daily, for 28 days
Outcomes Microbiological eradication per patient and per pathogen
Clinical success (cured/improved)
Adverse effects of treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients randomized by a computer-gen-
erated schedule”. Randomization was per-
formed by study center
Allocation concealment (selection bias) Unclear risk “Tablets were over-encapsulated to main-
tain blinding”. It is unclear whether medi-
cal personnel was informed about the con-
tent of the encapsulated tablets. Moreover,
generation of the randomization sequence
was performed locally and not centrally
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blind. “Tablets were
over-encapsulated to maintain blinding”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified
Incomplete outcome data (attrition bias)
All outcomes
Low risk Both drugs are equally active, belong to the
same drug family (fluoroquinolones) and
are known to have similar safety profiles.
Reasons for participant withdrawal are ex-
pected to be similar. ITT analysis was per-
formed
Selective reporting (reporting bias) High risk Outcome variables 2, 3, 7, and 8 from the
original protocol (2, one-month post-study
microbiologic relapse by subject’s infection
for subjects who were cured or improved at
the post-therapy visit; 3, one-month post-
study microbiologic relapse by pathogen
for subjects who were cured or improved
at the post-therapy visit; 7, the transition
37Antimicrobial therapy for chronic bacterial prostatitis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bundrick 2003 (Continued)
in scores from the prostatitis symptoms in-
dex fromadmission topost-therapy; 8, one-
month post-study clinical success for sub-
jects who were cured or improved at the
post-therapy visit) are not reported in the
study article
Other bias Low risk No apparent baseline imbalance
Bustillo 1997
Methods Randomized, parallel group, open-label, active drug-controlled study
Participants Geographic region: Mexico
Enrolled participants: n = 30
Randomization:
GROUP 1, n = 15
GROUP 2, n = 15
Age (mean):
GROUP 1, 36.9 years
GROUP 2, 38.4 years
Inclusion: history and diagnosis of CBP (NIH criteria). Microbiological diagnosis: 4-
glass test
Exclusion: < 18 years old; medications affecting absorption of study drugs (anti-acid,
sucralfate); recent treatment with antimicrobials; hypersensitivity to fluoroquinolones
or co-trimoxazole; terminal disease, cystostomy or urinary catheter; immune disorders;
alteration of creatinine, transaminases or bilirubin values
Study discontinuations: n = 4
GROUP 1, n = 2 (of which 1 available at follow-up)
GROUP 2, n = 2 (of which 1 available at follow-up)
Study duration: ~162 days (6 weeks, treatment; 4 months, follow-up)
Interventions GROUP 1
Lomefloxacin, oral, 400 mg once daily, for 42 days
GROUP 2
Trimethoprim-sulfamethoxazole, oral, 160+800 mg twice daily, for 42 days
Outcomes Microbiological eradication per patient and per pathogen
Clinical success (cure/improvement)
Adverse effects of treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
38Antimicrobial therapy for chronic bacterial prostatitis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bustillo 1997 (Continued)
Random sequence generation (selection
bias)
High risk Sequence generation procedure not dis-
closed
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome of this open-label
study is subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts are 2 and 2 participants in groups
1 and 2, respectively, and expected micro-
biological success is over 40%. High attri-
tion is unlikely
Selective reporting (reporting bias) Low risk
Other bias Low risk
Cai 2009
Methods Randomized, parallel group, open-label, active drug-controlled study
Participants Geographic region: Italy
Eligible participants: n = 206
Enrolled participants: n = 154
Randomization:
GROUP 1, n = 106
GROUP 2, n = 37
Age (mean of overall population): 31.7 years
GROUP 1, 30.8 years
GROUP 2, 31.9 years
Inclusion: diagnosis of CBP (NIH criteria, with history of CBP). Microbiological diag-
nosis: 4-glass test
Exclusion: < 18 and > 45 years old; prostatitis category I, III or IV (NIH classification);
prostate cancer; other genitourinary cancers; anatomical abnormalities of the urinary tract
or evidence of other urological diseases; allergy to fluoroquinolones; recent (< 4 weeks)
oral/parenteral treatment or prophylaxis with antibacterials; positive tests for Chlamydia
trachomatis, Ureaplasma urealyticum, Neisseria gonorrhoeae, herpes simplex viruses (HSV-
1, HSV-2) and human papillomavirus; urinary culture positive for multiple pathogens
or for fluoroquinolone-resistant pathogens.
Study discontinuations: n = 11 (lost to follow-up)
Study duration: 6 months (2 weeks treatment; 5 months and 2 weeks follow-up)
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Cai 2009 (Continued)
Interventions GROUP 1
Prulifloxacin, oral, 600 mg once daily, plus ProstaMEV/FlogMEV (Serenoa repens, oral,
160 mg once daily; Urtica dioica, oral, 120 mg once daily; Curcuma longa, oral, 200 mg
once daily; quercetin, oral, 100 mg once daily), for 2 weeks
GROUP 2
Prulifloxacin, oral, 600 mg once daily, for 2 weeks
Outcomes Microbiological eradication per patient
Clinical improvement (NIH-CPSI total score, IPSS, total score)
Adverse effects of treatment
Notes Microbiological tests at end of treatment were performed only in participants showing
clinical symptom relapse. Microbiological efficacy was not evaluable
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized at a ratio of 3:
1”. No additional detail on randomization
procedure provided
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Since microbiological evaluation at the end
of therapy was performed only on partici-
pants showing clinical relapse, it does not
represent a study outcome. The only pri-
mary (clinical) outcome of the study was
based on subjective symptomandquality of
life scores. Such evaluations require blind-
ing to minimize bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for withdrawal from study are not
presented separately, according to treat-
ment group
Selective reporting (reporting bias) High risk Microbiological evaluation at the end of
therapy performed only on participants
showing clinical relapse. Adverse events not
specified in detail (only overall rates dis-
closed)
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Cai 2009 (Continued)
Other bias Low risk No apparent baseline imbalances
Cai 2010
Methods Randomized, parallel group, open-label, active drug-controlled study
Participants Geographic region: Italy
Enrolled participants: n = 221
Randomization:
GROUP 1, n = 117
GROUP 2, n = 104
Age (mean):
GROUP 1, 35.2 ± 7.8 years
GROUP 2, 33.1 ± 6.9 years
Inclusion: diagnosis of CBP; class II (NIH criteria). Infection by Chlamydia trachomatis
only. Microbiological diagnosis: 4-glass test.
Exclusion: < 18 and > 45 years old; unspecified comorbidity; recent treatment with
antimicrobials (< 4 weeks); anatomical urogenital abnormalities; prostate surgery; allergy
to fluoroquinolones; liver/kidney failure
Study discontinuations: n = 10
GROUP 1, n = 8
GROUP 2, n = 2
Study duration: 51 days (14 (GROUP 1) or 21 (GROUP 2) days treatment; 30 days
follow-up)
Interventions GROUP 1
Prulifloxacin, oral, 600 mg once daily, for 14 days
GROUP 2
Doxycycline, oral, 100 mg twice daily, for 21 days
Outcomes Microbiological eradication per patient
Clinical improvement (NIH-CPSI total score, and number of patients with residual
symptoms)
Adverse effects of treatment
Notes Chlamydia infection and resolution of infection tested with a mucosal IgA immunoper-
oxidase assay at enrolment and at test-of-cure visit (30 days off-therapy). In this review,
only participants showing both IgA and DNA findings were evaluated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation procedure not speci-
fied. Randomization: 1:1
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report
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Cai 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (NIH-CPSI
symptom score) of this open-label study is
subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts are 7 and 2% in groups 1 and 2,
respectively, and expected microbiological
success is over 60%. High attrition is un-
likely
Selective reporting (reporting bias) Low risk
Other bias Low risk No apparent baseline imbalance
Cox 1989
Methods Randomized, parallel group, open-label, active drug-controlled, study
Participants Geographic region: USA
Enrolled participants: n = 46
Randomization:
GROUP 1, n = 22
GROUP 2, n = 24
Age (mean):
GROUP 1, 40.3 years
GROUP 2, 43.2 years
Inclusion: diagnosis of CBP, and history of CBP and urinary tract infection (UTI)
symptoms. Microbiological diagnosis: 4-glass test
Exclusion: < 18 years old; other criteria not specified
Study discontinuations: n = 23
GROUP 1, n = 13
GROUP 2, n = 10
Study duration: 11 weeks (6 weeks, treatment; 5 weeks, follow-up)
Interventions GROUP 1
Ofloxacin, oral, 300 mg twice daily, for 6 weeks
GROUP 2
Carbenicillin, oral, 764 mg four times daily, for 6 weeks
Outcomes Microbiological eradication per patient
Clinical improvement (cure/improvement/failure)
Adverse effects of treatment
Notes
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Cox 1989 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned to oral
therapy”. Sequence generation procedure
not specified
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome of this open-label
study is subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
High risk High number of dropouts. Eradication
rates expected for the beta-lactam are low
(poor prostate penetration in non-acute pa-
tients)
ITT analysis is missing
Selective reporting (reporting bias) High risk ITT analysis is missing
Other bias High risk Questionable study design: patient cohort
may be ’contaminated’ by presence of few
patients with acute prostatitis
Giannarini 2007
Methods Randomized, parallel group, double-blind, active drug-controlled study
Participants Geographic region: Italy
Enrolled participants: n = 96
Randomization:
GROUP 1, n = 48
GROUP 2, n = 48
Age: 44 years (median), 31 years to 58 years (range)
Inclusion: > 18 years old, history and diagnosis of CBP (NIH criteria). Microbiological
diagnosis: 4-glass test
Exclusion: prostate cancer; other genitourinary cancers; liver or kidney failure; neurologic
diseases or other diseases affecting bladder function; infections (sexually transmitted
diseases (STD)); genitourinary abnormalities; bladder neck obstruction; prostate surgery;
hypersensitivity to fluoroquinolones
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Giannarini 2007 (Continued)
Study discontinuations: n = 3 (4 more participants lost at follow-up (group 1, n = 2;
group 2, n = 2))
GROUP 1, n = 2
GROUP 2, n = 1
Study duration: ~7 months (4 weeks therapy; 6 months follow-up)
Interventions GROUP 1
Prulifloxacin, oral, 600 mg once daily, for 4 weeks
GROUP 2
Levofloxacin, oral, 500 mg once daily, for 4 weeks
Outcomes Microbiological eradication per patient and per pathogen
Clinical improvement (NIH-CPSI total score, and number of participants with residual
symptoms at TOC visit)
Adverse effects of treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients (were) randomized by a com-
puter-generated schedule”
Allocation concealment (selection bias) Low risk “All tablets were overencapsulated and de-
livered by a specialized research nurse of
the outpatient clinic to maintain double-
blinding”. Allocation was likely concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Adequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Both drugs are equally active, and belong
to the same drug family. Reasons for partic-
ipant withdrawal are expected to be similar.
Dropouts are 4.1 and 2% in groups 1 and
2, respectively, and expected microbiologi-
cal success is over 70%. Attrition is unlikely
Selective reporting (reporting bias) High risk Clinical outcome at follow-up is unclear
Other bias Low risk No apparent baseline imbalance
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Koff 1996
Methods Randomized, parallel group, open-label, active drug-controlled, study
Participants Geographic region: Brazil
Enrolled participants: n = 33
Randomization:
GROUP 1, n = 18
GROUP 2, n = 15
Age (mean): 47 years
Age range: 21 years to 65 years
Inclusion: diagnosis of CBP (NIH criteria). Microbiological diagnosis: 4-glass test
Exclusion: not reported.
Study discontinuations: n = 0
Study duration: 7 months and 2 weeks (6 weeks, treatment; 6 months, follow-up)
Interventions GROUP 1
Lomefloxacin, oral, 400 mg once daily, for 6 weeks
GROUP 2
Ofloxacin, oral, 200 mg twice daily, for 6 weeks
Outcomes Microbiological eradication per patient
Adverse effects of treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Sequence generation procedure not ade-
quate
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Primary outcome is not subjective (micro-
biological culture data)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported in this study
Selective reporting (reporting bias) High risk Clinical outcome was not provided. Eradi-
cation data at TOC visit (end of treatment)
not provided
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Koff 1996 (Continued)
Other bias Unclear risk Study methodology not described in suffi-
cient detail
Naber 2002
Methods Randomized, parallel group, open-label, active drug-controlled study
Participants Geographic region: Europe (Germany - UK)
Enrolled participants: n = 182
Randomization:
GROUP 1, n = 93
GROUP 2, n = 89
Age (range): 18 years to 70 years
Inclusion: diagnosis of CBP (NIH criteria) and history of CBP and UTI symptoms (>
2 years). Microbiological diagnosis: 4-glass test.
Exclusion: < 18 years old; category I, III or IV prostatitis; prostate cancer; other cancers
(genitourinary); other medications (fenbuprofen, sucralfate, anti-acids); comorbidities
(kidney or liver impairment); recent prior treatment with antimicrobials; history of
tendinitis; hypersensitivity to fluoroquinolones; seizure; resistance to fluoroquinolones;
sepsis.
Study discontinuations: n = 9 (plus 5 lost during follow-up)
GROUP 1, n = 5 (plus 2 lost during follow-up)
GROUP 2, n = 4 (plus 3 lost during follow-up)
Study duration: ~7 months (4 weeks, treatment; 6 months, follow-up)
Interventions GROUP 1
Lomefloxacin, oral, 400 mg once daily, for 4 weeks
GROUP 2
Ciprofloxacin, oral, 500 mg twice daily, for 4 weeks
Outcomes Microbiological eradication per patient and per pathogen
Clinical improvement (cure/improvement/failure)
Adverse effects of treatment
Notes The study contains ITT and per protocol cohorts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized”. Author (KN)
was contacted, and confirmed centralized
randomization procedure
Allocation concealment (selection bias) Unclear risk Allocation procedure not specified in re-
port
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Naber 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (disease symp-
toms) of this open-label study is subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified
Incomplete outcome data (attrition bias)
All outcomes
Low risk Both drugs are equally active, and belong
to the same drug family. Reasons for partic-
ipant withdrawal are expected to be similar.
Modified ITT analysis was performed
Selective reporting (reporting bias) Low risk All study data were disclosed
Other bias Low risk No baseline imbalance
Ohkawa 1993
Methods Randomized, parallel group, open-label, active drug-controlled, study
Participants Geographic region: Japan
Enrolled participants: n = 18
Randomization:
GROUP 1, n = 9
GROUP 2, n = 9
Age (mean): 47.6 years
Inclusion: diagnosis of CBP. Infection by Ureaplasma urealyticum only. (history of CBP,
not known). Microbiological diagnosis: 4-glass test
Exclusion: criteria not specified
Study discontinuations: n = 4
GROUP 1, n = 2
GROUP 2, n = 2
Study duration: 2 weeks (2 weeks, treatment; no follow-up data available)
Interventions GROUP 1
Ofloxacin, oral, 200 mg thrice daily, for 2 weeks
GROUP 2
Minocycline, oral, 100 mg twice daily, for 2 weeks
Outcomes Microbiological eradication per patient and per pathogen
Clinical improvement (cure/improvement/failure)
Adverse effects of treatment
Notes
Risk of bias
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Ohkawa 1993 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “(...) 18 patients randomly treated with ei-
ther (...) ofloxacin (...) or (...)minocycline”.
No additional details disclosed
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (disease signs/
symptoms) of this open-label study is sub-
jective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
High risk High number of withdrawals (22.2%) in
treatment groups. Reasons for withdrawal
not specified
Selective reporting (reporting bias) High risk Follow-up data are missing. Leukocyte
counts in prostatic fluid post-therapy not
provided
Other bias Low risk
Paulson 1986
Methods Randomized,multicentre, parallel group, single-blind, active drug-controlled study. Sub-
study of a randomized trial including participants with acute and chronic bacterial pro-
statitis
Participants Geographic region: USA
Enrolled/eligible participants: n = 88 (including 44 patients with complete outcome
data, showing acute prostatitis (n=9), chronic prostatitis (n=27), and acute exacerbations
of chronic prostatitis (n=8), and 44 patients excluded from efficacy analysis)
Randomization:
GROUP 1, n = 10 per-protocol patients
GROUP 2, n = 17 per-protocol patients
Age (mean):
GROUP 1, 47.1 years
GROUP 2, 45.7 years
Age range (overall): 25 years to 71 years
Inclusion: diagnosis of CBP (with previous history of CBP). Microbiological diagnosis:
4-glass test
Exclusion: < 17 years old; prostate cancer; comorbidity (kidney and liver failure); re-
cent (< 10 weeks) prior treatment with antimicrobials; hypersensitivity to study drugs;
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Paulson 1986 (Continued)
premature termination of the study (dropout); UTIs; general debility; terminal illness;
immunoparesis
Study duration: 10 weeks (4 weeks, treatment; 6 weeks, follow-up)
Interventions GROUP 1
Minocycline, oral, 100 mg twice daily, for 4 weeks
GROUP 2
Cephalexin, oral, 500 mg four times a day, for 4 weeks
Outcomes Microbiological eradication per patient
Clinical improvement (cure/improvement/failure/recurrence)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “This was a randomized, single-blind, par-
allel-group investigation (...)”. Additional
information not provided
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study described as single-blind, but partic-
ipants in group 1 (active drug twice-daily)
did not receive two additional placebo
tablets, to equal participants in group 2 (ac-
tive drug 4 times/day)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for withdrawal from study are not
presented separately, according to disease
group (acute prostatitis versus chronic pro-
statitis versus post-chronic, relapsing acute
prostatitis)
Selective reporting (reporting bias) High risk Eradication per pathogen data are missing.
Adverse effect outcomes not stratified ac-
cording to disease group
Other bias High risk Due to the peculiar design of the study (par-
ticipants with different conditions pooled
at enrolment) baseline imbalances are not
evaluable
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Skerk 2002
Methods Randomized, parallel group, open-label, active drug-controlled, study
Participants Geographic region: Croatia
Eligible participants: n = 123
Enrolled participants: n = 91
Randomization:
GROUP 1, n = 46
GROUP 2, n = 45
Age range: 20 years to 49 years
Age (mean):
GROUP 1, 38.9 ± 12.7 years
GROUP 2, 39.2 ± 12.6 years
Inclusion: diagnosis of CBP (with history of CBP; NIH criteria). Infection byChlamydia
trachomatis only. Microbiological diagnosis: 4-glass test
Exclusion: recent (< 2 weeks) prior treatment with antimicrobials; hypersensitivity to
macrolides; renal impairment; liver impairment (AST or ALT > 2X upper limit); chronic
diarrhea or gastrointestinal condition preventing drug absorption
Study discontinuations: n = 0
Maximum study duration: 9 weeks (GROUP 1: 3 weeks, treatment; TOC visit: 4 to 6
weeks off-therapy; GROUP 2: 2 weeks, treatment; TOC visit: 4 to 6 weeks off-therapy)
Interventions GROUP 1
Azithromycin, oral, 500 mg once daily, thrice weekly (first three consecutive days of each
week), for 3 weeks
GROUP 2
Clarithromycin, oral, 500 mg twice daily, for 2 weeks
Outcomes Microbiological eradication per-patient (evaluated 4 to 6 weeks after completion of
treatment)
Clinical improvement (cure/failure) (to be evaluated during treatment, at the end of
treatment and 4 to 6 weeks after completion of treatment)
Adverse effects of treatment (to be evaluated during treatment, at the end of treatment
and 4 to 6 weeks after completion of treatment)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized according to a
computerized randomization list”
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report. This was a single-
center study; the randomization sequence
was probably generated in the study center
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Skerk 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (disease symp-
toms) of this open-label study is subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported in this study
Selective reporting (reporting bias) High risk In methods section authors state: “Clini-
cal efficacy and tolerability (...) as well as
possible adverse events were evaluated dur-
ing, at the end and 4-6 weeks after comple-
tion of therapy”. In results section, the clin-
ical outcome is reported only once, and the
time point for this evaluation is not speci-
fied. Similarly, tolerability data and adverse
event rates are reported only once (time
point: unknown)
Other bias Low risk
Skerk 2003
Methods Randomized, parallel group, open-label, active drug-controlled study
Participants Geographic region: Croatia
Eligible participants: n = 89
Enrolled participants: n = 89
Randomization:
GROUP 1, n = 45
GROUP 2, n = 44
Age range: 18 years to 69 years
Age (mean):
GROUP 1, 40.89 ± 11.96 years
GROUP 2, 39.48 ± 12.75 years
Inclusion: diagnosis of CBP (with history of CBP; NIH criteria). Infection byChlamydia
trachomatis only. Microbiological diagnosis: 4-glass test
Exclusion: age < 18 years; recent (< 2 weeks) prior treatment with antimicrobials; hy-
persensitivity to fluoroquinolones and macrolides; renal impairment; liver impairment
(AST or ALT > 2X upper limit); chronic diarrhea or gastrointestinal condition prevent-
ing drug absorption
Study discontinuations: n = 0
Maximum study duration: 9 weeks (GROUP 1: 3 weeks, treatment; TOC visit: 4 to 6
weeks off-therapy; GROUP 2: 20 days, treatment; TOC visit: 4 to 6 weeks off-therapy)
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Skerk 2003 (Continued)
Interventions GROUP 1
Azithromycin, oral, 500 mg once daily, thrice weekly (first three consecutive days of each
week), for 3 weeks
GROUP 2
Ciprofloxacin, oral, 500 mg twice daily, for 20 days
Outcomes Microbiological eradication per patient (evaluated 4 to 6 weeks after completion of
treatment)
Clinical improvement (cure/improvement/failure) (to be evaluated during treatment, at
the end of treatment and 4 to 6 weeks after completion of treatment)
Adverse effects of treatment (to be evaluated during treatment, at the end of treatment
and 4 to 6 weeks after completion of treatment)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized according to a
computerized randomization list”
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report. This was a single-
center study; the randomization sequence
was probably generated in the study center
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (disease symp-
toms) of this open-label study is subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported in this study
Selective reporting (reporting bias) High risk In methods section authors state: “Clinical
efficacy and tolerability (...) as well as pos-
sible adverse events were evaluated during,
at the end and 4 to 6 weeks after comple-
tion of therapy”. In results section, the clin-
ical outcome is reported only once, and the
time point for this evaluation is not speci-
fied. Similarly, tolerability data and adverse
event rates are reported only once (time
point: unknown)
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Skerk 2003 (Continued)
Other bias Low risk
Skerk 2004a
Methods Randomized, parallel group, open-label, active drug-controlled, study
Participants Geographic region: Croatia
Eligible participants: n = 125
Enrolled participants: n = 125
Randomization:
GROUP 1, n = 82
GROUP 2, n = 43
Age (mean):
GROUP 1, 37.5 ± 12.6 years
GROUP 2, 32 ± 10.7 years
Inclusion: diagnosis of CBP (with history of CBP; NIH criteria). Infection byChlamydia
trachomatis only. Microbiological diagnosis: 4-glass test
Exclusion: age < 18 years; recent (< 2 weeks) prior treatment with antimicrobials; hyper-
sensitivity to macrolides and tetracyclines; renal impairment; liver impairment (AST or
ALT > 2X upper limit); chronic diarrhea or gastrointestinal condition preventing drug
absorption
Study discontinuations: n = 0
Maximum study duration: 10 weeks (4 weeks, treatment; TOC visit: 4 to 6 weeks off-
therapy)
Interventions GROUP 1
Azithromycin, oral, 1000 mg once weekly, for 4 weeks
GROUP 2
Doxycycline, oral, 100 mg twice daily, for 4 weeks
Outcomes Microbiological eradication per patient (evaluated 4 to 6 weeks after completion of
treatment)
Clinical improvement (cure/improvement/failure) (to be evaluated during treatment, at
the end of treatment and 4 to 6 weeks after completion of treatment)
Adverse effects of treatment (to be evaluated during treatment, at the end of treatment
and 4 to 6 weeks after completion of treatment)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Patients were randomized according to a
computerized randomization list, in the ra-
tio “2/1 azithromycin/doxycycline”
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Skerk 2004a (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report. This was a single-
center study; the randomization sequence
was probably generated in the study center
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (disease symp-
toms) of this open-label study is subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported in this study
Selective reporting (reporting bias) High risk In methods section authors state: “Clini-
cal efficacy and tolerability (...) as well as
possible adverse events were evaluated dur-
ing, at the end and 4-6 weeks after comple-
tion of therapy”. In results section, the clin-
ical outcome is reported only once, and the
time point for this evaluation is not speci-
fied. Similarly, tolerability data and adverse
event rates are reported only once (time
point: unknown)
Other bias Low risk
Skerk 2004b
Methods Randomized, parallel group, open-label, active drug-controlled, study
Participants Geographic region: Croatia
Eligible participants: n = 209
Enrolled participants: n = 89
Randomization:
GROUP 1, n = 46
GROUP 2, n = 43
Age (mean):
GROUP 1, 39 ± 10.24 years
GROUP 2, 33 ± 8.98 years
Inclusion: diagnosis of CBP (with history of CBP; NIH criteria). Infection byChlamydia
trachomatis only. Microbiological diagnosis: 4-glass test
Exclusion: age < 18 years; recent (< 2 weeks) prior treatment with antimicrobials; hyper-
sensitivity to macrolides; renal impairment; liver impairment (AST or ALT > 2X upper
limit); chronic diarrhea or gastrointestinal condition preventing drug absorption
Study discontinuations: n = 0
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Skerk 2004b (Continued)
Maximum study duration: 10 weeks (GROUP 1: 3 weeks, treatment; GROUP 2: 4
weeks, treatment; TOC visit: 4 to 6 weeks off-therapy)
Interventions GROUP 1
Azithromycin, oral, 500 mg once daily, thrice weekly (first three consecutive days of each
week), for 3 weeks
GROUP 2
Azithromycin, oral, 500 mg once daily, thrice weekly (first three consecutive days of each
week), for 4 weeks
Outcomes Microbiological eradication per-patient (evaluated 4 to 6 weeks after completion of
treatment)
Clinical improvement (cure/failure) (to be evaluated during treatment, at the end of
treatment and 4 to 6 weeks after completion of treatment)
Adverse effects of treatment (to be evaluated during treatment, at the end of treatment
and 4 to 6 weeks after completion of treatment)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized according to a
computerized randomization list”
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report. This was a single-
center study; the randomization sequence
was probably generated in the study center
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (disease symp-
toms) of this open-label study is subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported in this study
Selective reporting (reporting bias) High risk In methods section authors state: “Clini-
cal efficacy and tolerability (...) as well as
possible adverse events were evaluated dur-
ing, at the end and 4-6 weeks after comple-
tion of therapy”. In results section, the clin-
ical outcome is reported only once, and the
time point for this evaluation is not speci-
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Skerk 2004b (Continued)
fied. Similarly, tolerability data and adverse
event rates are reported only once (time
point: unknown)
Other bias Low risk
Skerk 2006
Methods Randomized, parallel group, open-label, active drug-controlled, study
Participants Geographic region: Croatia
Enrolled participants: n = 63
Randomization:
GROUP 1, n = 32
GROUP 2, n = 31
Age (mean):
GROUP 1, 38.2 ± 9.96 years
GROUP 2, 38.1 ± 9.95 years
Inclusion: diagnosis ofCBP (with history ofCBP;NIHcriteria). Infection byUreaplasma
urealyticum (UU) (> 104 color-changing units UU/mL of EPS/VB3). Absence of UU
from urethral swabs. Absence of other CBP pathogens from urethral swabs, VB1, VB2,
EPS or VB3 specimens. Microbiological diagnosis: 4-glass test
Exclusion: age < 18 years; infection by pathogens other than U. urealyticum
Study discontinuations: n = 0
Maximum study duration: 9 weeks (3 weeks, treatment; TOC visit: 4 to 6 weeks off-
therapy)
Interventions GROUP 1
Azithromycin, oral, 500 mg once daily, thrice weekly (first three consecutive days of each
week), for 3 weeks
GROUP 2
Doxycycline, oral, 100 mg twice daily, for 3 weeks
Outcomes Microbiological eradication per patient
Clinical improvement (clinical cure) (to be evaluated during treatment, at the end of
treatment and 4 to 6 weeks after completion of treatment)
Adverse effects of treatment (to be evaluated during treatment, at the end of treatment
and 4 to 6 weeks after completion of treatment)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized according to a
computerized randomization list”
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Skerk 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment procedure not de-
scribed in study report. This was a single-
center study; the randomization sequence
was probably generated in the study center
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (disease symp-
toms) of this open-label study is subjective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported in this study
Selective reporting (reporting bias) High risk In methods section authors state: “Clini-
cal efficacy and tolerability (...) as well as
possible adverse events were evaluated dur-
ing, at the end and 4-6 weeks after comple-
tion of therapy”. In results section, the clin-
ical outcome is reported only once, and the
time point for this evaluation is not speci-
fied. Similarly, tolerability data and adverse
event rates are reported only once (time
point: unknown)
Other bias Low risk
Smith 1979
Methods Randomized, double-blind, parallel group trial
Participants Geographic region: North America/Sweden
Eligible participants: n = 46
Enrolled participants: n = 38
Randomization:
GROUP 1, n = 20
GROUP 2, n = 18
Age (median): 69 years (range: 41 years to 88 years)
Inclusion: bacteriuria (> 100,000 CFU/mL Enterobacteriaceae) and 2 previous episodes
of infection. Microbiological diagnosis: 4-glass test
Exclusion: liver impairment (AST or ALT > 2X upper limit), hematopoietic disease,
systemic lupus erythematosus, any disease with life expectancy < 6 months, kidney im-
pairment (serum creatinine > 2.1mg/dL), calculosis, allergy to co-trimoxazole, resistance
of isolates to co-trimoxazole, unwillingness to be compliant
Study discontinuations:
GROUP 1, n = 5
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Smith 1979 (Continued)
GROUP 2, n = 3
Maximum study duration: 12 weeks
Interventions GROUP 1
Co-trimoxazole, oral, 480 mg (400 mg sulfamethoxazole; 80 mg trimethoprim) twice
daily, for 10 days
GROUP 2
Co-trimoxazole, oral, 480 mg twice daily, for 12 weeks (participants were pre-treated
with 100 mg nitrofurantoin four times/day for 3 days prior to 4-glass test)
Outcomes Microbiological eradication per patient
Adverse effects of treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization system not disclosed
Allocation concealment (selection bias) Unclear risk Not disclosed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Microbiological eradication as sole out-
come.Detection bias is low, due to the non-
subjective nature of the outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk High number of withdrawals in treatment
groups, and low expected therapeutic suc-
cess indicate high attrition bias
Selective reporting (reporting bias) Unclear risk A clinical assessment section is absent
Other bias Low risk
Zhang 2012
Methods Randomized, open-label, parallel group trial
Participants Geographic region: China
Enrolled participants: n = 408
Randomization:
GROUP 1, n = 209
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Zhang 2012 (Continued)
GROUP 2, n = 199
Age (mean):
Overall, 33.8 ± 9.2 years (range: 19 years to 54 years)
GROUP 1, 33.4 ± 8.1 years
GROUP 2, 33.5 ± 8.5 years
Inclusion: diagnosis of CBP (with history and signs/symptoms of CBP)
Exclusion: age < 18 years; comorbidities (heart, liver, lung, or kidney failure); psychotic
disorders, severe benign prostatic hyperplasia
Study discontinuations: n = 0
Maximum study duration: ~7 months and 1 week (4 weeks, treatment; TOC visit: 1
week off therapy; follow-up: 6 months)
Interventions GROUP 1
Levofloxacin, oral, 500 mg once daily, for 4 weeks
GROUP 2
Ciprofloxacin, oral, 500 mg twice daily, for 4 weeks
Outcomes Microbiological eradication per patient
Clinical success (cured/improved)
Adverse effects of treatment
Notes Intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized (...) using com-
puter-generated random tables for each
centre”
Allocation concealment (selection bias) Unclear risk Not disclosed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Primary clinical outcome (disease signs/
symptoms) of this open-label study is sub-
jective
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Bacteria were isolated in 209 pa-
tients from the levofloxacin-treated group
and 199 patients from the ciprofloxacin-
treated group
A total of 165 (78.95%) and 123 (61.
81%) patients showed sensitivity to lev-
ofloxacin and ciprofloxacin, respectively,
and was significantly different between the
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Zhang 2012 (Continued)
two groups (p<0.05%). (…) At visit 5, the
bacteria clearance rate in those with con-
firmed bacterial infection was significantly
higher in the levofloxacin-treated group (.
..) [85.65% (179/209)] than in the cipro-
floxacin-treated group (...) [60.30% (120/
199); P<0.05)]”
Comment: Participants with CBP caused
by ciprofloxacin-resistant pathogens (al-
most 40% of isolated pathogens) were
probably treated with ciprofloxacin. Thus,
eradication data refer to treatment cohorts
containing participants infected by resis-
tant strains. Eradication rates for partici-
pants harboring only ciprofloxacin-suscep-
tible pathogens were not disclosed. The
levofloxacin-treated cohort contained lev-
ofloxacin-resistant CBP cases, too. The
fraction of levofloxacin-resistant and cipro-
floxacin-resistant cases are unbalanced in
treatment cohorts (21% and 38.2%, re-
spectively)
No dropouts were reported for a total co-
hort of 408 participants, and for the inten-
tion-to-treat analysis
Selective reporting (reporting bias) High risk Microbiological findings at follow-up (6
months) not disclosed
Other bias High risk The first-voided urine specimen of partici-
pants (VB1) was discarded and not sent for
microbiological analysis. Thus, the fraction
of participants with concomitant urethral
infection is unknown
Participants with CBP caused by ciproflo-
xacin-resistant pathogens (almost 40% of
isolated pathogenswere ciprofloxacin-resis-
tant), were nevertheless treated with cipro-
floxacin
“Additional agents” were administered in
total 42 participants together with antibac-
terial agents. Name and dosage of these
agents, as well as therapy duration were
not disclosed. These unspecified drugs may
have acted as confounders in microbiolog-
ical or clinical assessments
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ateya 2006 Multiple antimicrobial agents in a single treatment arm. Dosing not disclosed. Subgroup analysis not feasible
Baert 1983 Non-comparative study
Barbalias 1998 Multiple antimicrobial agents in a single treatment arm. Types, doses and dosing of antimicrobial agents not
disclosed
Brannan 1975 Non-randomized study
Cai 2011 Included patients with “genital infection”, associated with oligoasthenoteratozoospermia
Childs 1983 A study focusing on urinary tract infection in men and women, involving a very small fraction (n = 2) of
patients with CBP
Colleen 1975 Non-randomized study
Cox 1991 Not an RCT
Deng 2004 Lower urinary tract segmented test not defined. Doses and dosing of antimicrobial agents not clearly defined
Gleckman 1979 A randomized study focusing on bacteriuria, possibly involving an undefined fraction of patients with CBP
Hu 2002 Lower urinary tract segmented test not clearly defined
Kim 2006 This study pooled patients with prostatitis and prostato-vesiculitis/vesiculitis
Kozdoba 2007 Non-randomized study
Kunishima 2008 Not an RCT
Lee 2006 Not an RCT. Patients with category II CBP and category III CP/CPPS were pooled in the same treatment
arms
Liao 2004 Involves traditional Chinese medication in combination with “antibacterial treatment” with unspecified an-
tibiotics
Martino 1993 The study included patients with category I acute bacterial prostatitis
Nickel 2008a An ancillary study of the Bundrick 2003 trial
Paglia 2010 In this study a lower urinary tract segmented microbiological test was not required at enrolment, and a past
history of CBP was deemed sufficient to qualify a patient as having CBP
Panagopoulos 2009 Not an RCT
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(Continued)
Sabbaj 1986 A randomized study including men with recurrent UTI with or without a history of CBP
Schaeffer 2005 An ancillary study of the Bundrick 2003 trial
Shafik 1992 Not an RCT
Shen 2004 Randomized population included patients with category II CBP or category III CP/CPPS. Subgroup analysis
of patient population not feasible
Smelov 2004 Non-randomized study
Trapeznikova 2007 Doses and dosage of antimicrobial agents not disclosed
Vicari 2000 Patients were not diagnosed with a lower urinary tract segmented test and were not divided into separate
treatment groups
Vickovic 2010 This study was performed on patients with protozoans as etiological determinants of chronic prostatitis
Wedren 1989 Outcomes from treatment arms (cephalosporin versus co-trimoxazole) not presented separately. Non-compar-
ative study
Xu 2010 Involves traditional Chinese medication (Qianlie-Jedu)
Yavaçao lu 1998 Comparison is between different techniques of intraprostatic administration. Route, drug and dosing are
identical
Zhang 2004 Involves traditional Chinese medication. In patients “chronic prostatitis” could be associated or not with
urethritis
Characteristics of studies awaiting assessment [ordered by study ID]
Drasa 2009
Methods Prospective, randomized, double-blind trial
Participants Geographic region: Albania
Enrolled participants: n = 123
Randomization:
GROUP 1, n = 41
GROUP 2, n = 41
GROUP 3, n = 41
Age (mean, overall): unknown
Age range: unknown
Inclusion: “clinical diagnosis of CBP”. Microbiological diagnosis: Meares-Stamey test
Exclusion criteria: unknown
Study discontinuations: n = unknown
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Drasa 2009 (Continued)
Study duration: treatment, 10 days, follow-up, 6 months
Interventions GROUP 1
Cefuroxime axetil 500 mg (“parenteral”?) twice daily for 10 days, and subsequently once daily for 10 days
GROUP 2
Ceftriaxone 1000 mg, “parenteral”, twice daily for 10 days
GROUP 3
Ceftriaxone 1000 mg, “parenteral”, twice daily for 10 days, and subsequently cefuroxime axetil 500 mg, twice daily
for 10 days, and subsequently cefuroxime axetil, once daily for 10 days
Outcomes Microbiological eradication
Clinical improvement, assessed with the “validated CBPSI” test
Notes Demographic data are missing. Study withdrawal data are missing. Results concerning the “CBPSI” are verbally
described in text (“At the end of the treatment the clinical improvement based on the CBPSI was a small difference
between the first and the second group, but for the third group was maximally reduce of (sic) the CBPSI”) but scores
or other numerical data are missing. Published report of this study could not be retrieved
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D A T A A N D A N A L Y S E S
Comparison 1. Different fluoroquinolones: levofloxacin versus ciprofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
- pathogen eradication
(fixed-effect model)
2 669 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [1.11, 1.34]
2 Microbiological efficacy
- pathogen eradication
(random-effects model)
2 669 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.81, 1.71]
3 Clinical efficacy 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Clinical efficacy (cure or
improvement) at the end of
treatment
2 669 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.93, 1.46]
3.2 Clinical efficacy (cure or
improvement) at follow-up (6
months)
2 669 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.86, 1.55]
4 Adverse effects of treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Any adverse effects 2 785 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.70, 1.06]
4.2 Gastrointestinal adverse
effects
2 785 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.42, 1.77]
4.3 Back pain 1 377 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.13, 2.26]
4.4 Headache 2 785 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.39, 1.76]
4.5 Dizziness 2 785 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.02, 22.13]
4.6 Arthralgia 1 377 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.49, 4.39]
4.7 Myalgia 1 377 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.37, 3.11]
4.8 Skeletal pain 1 377 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.13, 2.26]
4.9 Rhinitis 1 377 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.27, 3.10]
4.10 Upper respiratory tract
infection
1 377 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.31, 4.19]
4.11 Dermal toxicity 2 785 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.12, 1.90]
4.12 Allergy to experimental
agents
1 408 Risk Ratio (M-H, Random, 95% CI) 2.86 [0.12, 69.73]
4.13 Leukopenia 1 408 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.75]
4.14 Cough 1 408 Risk Ratio (M-H, Random, 95% CI) 2.86 [0.12, 69.73]
4.15 Insomnia 1 408 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.04, 5.21]
4.16 Altered transaminase
levels
1 408 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.04, 5.21]
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Comparison 2. Different fluoroquinolones: prulifloxacin versus levofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy -
pathogen eradication
1 89 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.79, 1.33]
2 Clinical efficacy - NIH-CPSI
total score at the end of
treatment
1 89 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.45, 0.39]
3 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 1 89 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.36, 1.88]
3.2 Gastrointestinal adverse
effects
1 89 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.25, 2.13]
3.3 Dermal toxicity 1 89 Risk Ratio (M-H, Random, 95% CI) 7.16 [0.38, 134.62]
3.4 Headache 1 89 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.01, 2.75]
Comparison 3. Different fluoroquinolones: lomefloxacin versus ofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy -
pathogen eradication at
follow-up (6 months)
1 33 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.66, 1.88]
2 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Any adverse effects 1 33 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.16, 1.12]
2.2 Gastrointestinal adverse
effects
1 33 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.19, 1.61]
2.3 Headache 1 33 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.01, 6.43]
2.4 Dizziness 1 33 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.01, 6.43]
Comparison 4. Different fluoroquinolones: lomefloxacin versus ciprofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(intention-to-treat analysis)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.82, 1.11]
1.2 Microbiological efficacy
(pathogen eradication) at
follow-up (4 weeks)
1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.72, 1.06]
65Antimicrobial therapy for chronic bacterial prostatitis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1.3 Microbiological efficacy
(pathogen eradication) at
follow-up (3 months)
1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.74, 1.09]
1.4 Microbiological efficacy
(pathogen eradication) at
follow-up (6 months)
1 182 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.67, 1.12]
2 Microbiological efficacy
(per-protocol analysis)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Microbiological efficacy
(pathogen eradication and
eradication plus superinfection)
at the end of treatment
1 87 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.89, 1.09]
2.2 Microbiological efficacy
(pathogen eradication and
eradication plus superinfection)
at follow-up (4 weeks)
1 83 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.94, 1.07]
2.3 Microbiological efficacy
(pathogen eradication and
eradication plus superinfection)
at follow-up (3 months)
1 77 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.94, 1.12]
2.4 Microbiological efficacy
(pathogen eradication and
eradication plus superinfection)
at follow-up (6 months)
1 66 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.80, 1.09]
3 Clinical efficacy
(intention-to-treat analysis)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Clinical efficacy (cure or
improvement) at the end of
treatment
1 182 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.94, 1.09]
3.2 Clinical efficacy (cure or
improvement) at follow-up (4
weeks)
1 182 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.05]
3.3 Clinical efficacy (cure or
improvement) at follow-up (3
months)
1 182 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.82, 1.15]
3.4 Clinical efficacy (cure or
improvement) at follow-up (6
months)
1 182 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.11]
4 Clinical efficacy (per-protocol
analysis)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Clinical efficacy (cure or
improvement) at the end of
treatment
1 87 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.89, 1.03]
4.2 Clinical efficacy (cure or
improvement) at follow-up (4
weeks)
1 83 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.86, 1.18]
4.3 Clinical efficacy (cure or
improvement) at follow-up (3
months)
1 65 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.94, 1.21]
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4.4 Clinical efficacy (cure or
improvement) at follow-up (6
months)
1 66 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.77, 1.01]
5 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Any adverse effects 1 182 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.40, 1.68]
5.2 Gastrointestinal adverse
effects
1 182 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.20, 1.76]
5.3 Headache 1 182 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.06, 15.07]
5.4 Dizziness 1 182 Risk Ratio (M-H, Random, 95% CI) 2.87 [0.12, 69.59]
5.5 Dry mouth 1 182 Risk Ratio (M-H, Random, 95% CI) 4.79 [0.23, 98.35]
5.6 Insomnia 1 182 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.73]
5.7 Hyperglycemia 1 182 Risk Ratio (M-H, Random, 95% CI) 2.87 [0.12, 69.59]
5.8 Dermal toxicity 1 182 Risk Ratio (M-H, Random, 95% CI) 2.87 [0.12, 69.59]
5.9 Abnormal semen 1 182 Risk Ratio (M-H, Random, 95% CI) 2.87 [0.12, 69.59]
5.10 Upper respiratory tract
infection
1 182 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.01, 1.95]
Comparison 5. Different fluoroquinolones: lomefloxacin versus comparator fluoroquinolone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy -
pathogen eradication at
follow-up (6 months)
2 116 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.80, 1.16]
2 Adverse effects of treatment 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Any adverse effects 2 215 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.34, 1.21]
2.2 Gastrointestinal adverse
effects
2 215 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.27, 1.23]
2.3 Headache 2 215 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.07, 4.43]
2.4 Dizziness 2 215 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.09, 8.60]
Comparison 6. Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy -
pathogen eradication at the
end of treatment (fixed-effect
model)
3 851 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.80, 0.94]
2 Microbiological efficacy -
pathogen eradication at the end
of treatment (random-effects
model)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 All studies 3 851 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.70, 1.18]
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2.2 Sensitivity analysis,
exclusion of Zhang 2012
2 443 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.93, 1.14]
3 Clinical efficacy 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Clinical efficacy (cure or
improvement) at the end of
treatment
3 851 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.75, 1.08]
3.2 Clinical efficacy (cure or
improvement) at follow-up (6
months)
3 851 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.72, 1.20]
4 Adverse effects of treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Any adverse effects 3 967 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.95, 1.42]
4.2 Gastrointestinal adverse
effects
3 967 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.76, 1.59]
4.3 Headache 3 967 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.58, 2.46]
4.4 Dizziness 3 967 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.09, 12.02]
4.5 Dermal toxicity 3 967 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.44, 5.75]
Comparison 7. Different fluoroquinolones: levofloxacin versus comparator fluoroquinolone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
- pathogen eradication
(fixed-effect model)
3 758 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [1.09, 1.30]
2 Microbiological efficacy
- pathogen eradication
(random-effects model)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 All studies 3 758 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.84, 1.48]
2.2 Sensitivity analysis,
exclusion of Zhang 2012
2 350 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.87, 1.10]
3 Adverse effects of treatment 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 3 874 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.72, 1.08]
3.2 Gastrointestinal adverse
effects
3 874 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.69, 1.44]
3.3 Dermal toxicity 3 874 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.11, 1.32]
3.4 Headache 3 874 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.26, 3.80]
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Comparison 8. Fluoroquinolone versus other antibacterial agent: prulifloxacin versus doxycycline in chlamydial
prostatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
- absence of Chlamydia
trachomatis DNA and IgA at
the end of treatment
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.93, 1.36]
2 Clinical efficacy - NIH-CPSI
total score at the end of
treatment
1 211 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.94, -0.39]
3 Clinical efficacy - number of
asymptomatic participants at
the end of therapy
1 211 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.91, 1.19]
4 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Any adverse effects 1 211 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.32, 4.24]
4.2 Gastrointestinal adverse
effects
1 211 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.16, 3.06]
4.3 Back pain 1 211 Risk Ratio (M-H, Random, 95% CI) 4.68 [0.23, 96.36]
Comparison 9. Fluoroquinolone versus other antibacterial agent: ofloxacin versus minocycline in ureaplasmal
prostatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy -
pathogen eradication
1 14 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.78, 1.29]
2 Clinical efficacy (cure or
improvement) at the end of
treatment
1 14 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.59, 1.26]
Comparison 10. Fluoroquinolone versus other antibacterial agent: ofloxacin versus carbenicillin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy -
pathogen eradication
1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.76, 1.42]
2 Clinical efficacy (cure or
improvement) at the end of
treatment
1 23 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.85, 1.32]
3 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 1 46 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.31, 1.71]
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3.2 Gastrointestinal adverse
effects
1 46 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.14, 1.59]
3.3 Dermal toxicity 1 46 Risk Ratio (M-H, Random, 95% CI) 3.26 [0.14, 76.10]
3.4 Nervous (sic) 1 46 Risk Ratio (M-H, Random, 95% CI) 5.43 [0.28, 107.33]
3.5 Special senses toxicity 1 46 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.01, 2.85]
3.6 Respiratory toxicity 1 46 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.02, 8.46]
Comparison 11. Fluoroquinolone versus other antibacterial agent: lomefloxacin versus co-trimoxazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Microbiological success
(pathogen eradication) at the
end of treatment
1 26 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.82, 1.44]
1.2 Microbiological success
(pathogen eradication) at
follow-up (4 months)
1 26 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.82, 1.44]
2 Clinical efficacy 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Clinical efficacy (cure or
improvement) at the end of
treatment
1 26 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.87, 1.15]
2.2 Clinical efficacy (cure or
improvement) at follow-up (4
months)
1 26 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.87, 1.15]
3 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 1 28 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.04, 4.25]
3.2 Gastrointestinal adverse
effects
1 28 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.04, 4.25]
Comparison 12. Fluoroquinolone versus other antibacterial agent: ciprofloxacin versus azithromycin in chlamydial
prostatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.32, 0.72]
2 Clinical efficacy (cure or
improvement) at the end of
treatment
1 89 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.46, 0.90]
3 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 1 89 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.15]
3.2 Gastrointestinal adverse
effects
1 89 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.15]
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3.3 Hepatic adverse effects
(increased transaminases)
1 89 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.15]
Comparison 13. Non-fluoroquinolone antibacterial agents: minocycline versus cephalexin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication and
eradication plus superinfection)
at the end of treatment
1 27 Risk Ratio (M-H, Fixed, 95% CI) 1.7 [0.54, 5.34]
2 Clinical efficacy (cure or
improvement) at the end of
treatment
1 27 Risk Ratio (M-H, Random, 95% CI) 2.04 [0.83, 4.99]
3 Microbiological recurrence 1 20 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.37, 2.59]
Comparison 14. Non-fluoroquinolone antibacterial agents: azithromycin versus clarithromycin in chlamydial
prostatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 91 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.82, 1.23]
2 Clinical efficacy (cure) at the end
of treatment
1 91 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.75, 1.28]
3 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 1 91 Risk Ratio (M-H, Random, 95% CI) 1.96 [0.18, 20.83]
3.2 Gastrointestinal adverse
effects
1 91 Risk Ratio (M-H, Random, 95% CI) 1.96 [0.18, 20.83]
3.3 Hepatic adverse effects
(increased transaminases)
1 91 Risk Ratio (M-H, Random, 95% CI) 1.96 [0.18, 20.83]
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Comparison 15. Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in chlamydial pro-
statitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 125 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.85, 1.26]
2 Clinical efficacy 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Clinical efficacy - presence
of inflammatory findings
(number of participants with
white blood cell counts in
EPS/VB3 < 10 per high power
field) at the end of therapy
1 125 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.66, 1.78]
2.2 Clinical efficacy (cure or
improvement) at the end of
therapy
1 125 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.76, 1.19]
3 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 1 125 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.04, 1.04]
3.2 Gastrointestinal adverse
effects
1 125 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.04, 1.04]
3.3 Hepatic adverse effects
(increased transaminases)
1 125 Risk Ratio (M-H, Random, 95% CI) 2.65 [0.13, 54.00]
Comparison 16. Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in ureaplasmal pro-
statitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 63 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.80, 1.39]
2 Clinical efficacy (cure) at the end
of treatment
1 63 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.72, 1.42]
3 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 1 63 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 1.53]
3.2 Gastrointestinal adverse
effects
1 63 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 1.53]
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Comparison 17. Different dosing regimens: azithromycin 4.5 g versus 6.0 g total doses in chlamydial prostatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 89 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.81, 1.21]
2 Clinical efficacy (cure) at the end
of therapy
1 89 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.26]
3 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Any adverse effects 1 89 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.01, 3.79]
3.2 Hepatic adverse effects
(increased transaminases)
1 89 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.01, 3.79]
Comparison 18. Different therapy duration: co-trimoxazole 480 mg twice daily for 12 weeks versus 10 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 30 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [1.01, 8.95]
2 Adverse effects of treatment 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Any adverse effects 1 33 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.05, 5.31]
2.2 Gastrointestinal/hepatic
adverse effects
1 33 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.01, 4.10]
2.3 Drop in leukocyte counts 1 33 Risk Ratio (M-H, Random, 95% CI) 3.18 [0.14, 72.75]
Comparison 19. Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus fluoroquinolone: lev-
ofloxacin plus vardenafil 10 mg/day versus levofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 66 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.90, 1.19]
2 Clinical efficacy - NIH-CPSI
score at the end of treatment
1 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 NIH-CPSI pain score 1 66 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.62, 0.35]
2.2 NIH-CPSI voiding
symptom score
1 66 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.78, 0.19]
2.3 NIH-CPSI quality of life
impact score
1 66 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.72, 0.25]
73Antimicrobial therapy for chronic bacterial prostatitis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3 Clinical efficacy - number of
participants with leukocytosis
in post-massage urine
specimens at the end of
treatment
1 66 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.17, 1.66]
4 Clinical efficacy - urine peak flow
rate at the end of treatment
(mL/s)
1 66 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.25, 0.72]
Comparison 20. Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus fluoroquinolone: lev-
ofloxacin plus vardenafil 10 mg on-demand versus levofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 69 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.88, 1.17]
2 Clinical efficacy - NIH-CPSI
score at the end of treatment
1 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 NIH-CPSI pain score 1 69 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.53, 0.42]
2.2 NIH-CPSI voiding
symptom score
1 69 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.20, 0.75]
2.3 NIH-CPSI quality of life
impact score
1 69 Std. Mean Difference (IV, Random, 95% CI) 0.52 [0.04, 1.01]
3 Clinical efficacy - number of
participants with leukocytosis
in post-massage urine
specimens at the end of
treatment
1 69 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.28, 1.98]
4 Clinical efficacy - urine peak flow
rate at the end of treatment
(mL/s)
1 69 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.37, 0.57]
Comparison 21. Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin plus vardenafil 10
mg/day versus levofloxacin plus vardenafil 10 mg on-demand
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological efficacy
(pathogen eradication) at the
end of treatment
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.90, 1.16]
2 Clinical efficacy - NIH-CPSI
score at the end of treatment
1 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 NIH-CPSI pain score 1 71 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.55, 0.38]
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2.2 NIH-CPSI voiding
symptom score
1 71 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-1.11, -0.16]
2.3 NIH-CPSI quality of life
impact score
1 71 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-1.17, -0.21]
3 Clinical efficacy - number of
participants with leukocytosis
in post-massage urine
specimens at the end of
treatment
1 71 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.22, 2.35]
4 Clinical efficacy - urine peak flow
rate at the end of treatment
(mL/s)
1 71 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.31, 0.62]
Comparison 22. Fluoroquinolone plus herbal extracts or supplements versus fluoroquinolone: prulifloxacin plus
supplements versus prulifloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical efficacy - NIH-CPSI
total score
1 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 NIH-CPSI total score at
the end of treatment
1 143 Std. Mean Difference (IV, Random, 95% CI) -2.56 [-3.04, -2.08]
1.2 NIH-CPSI total score at
follow-up (6 months)
1 143 Std. Mean Difference (IV, Random, 95% CI) -3.78 [-4.36, -3.20]
2 Clinical efficacy - IPSS score 1 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 IPSS score at the end of
treatment
1 143 Std. Mean Difference (IV, Random, 95% CI) -2.21 [-2.66, -1.75]
2.2 IPSS score at follow-up 1 143 Std. Mean Difference (IV, Random, 95% CI) -2.50 [-2.98, -2.03]
3 Adverse effects of treatment 1 143 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.11, 9.76]
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Analysis 1.1. Comparison 1 Different fluoroquinolones: levofloxacin versus ciprofloxacin, Outcome 1
Microbiological efficacy - pathogen eradication (fixed-effect model).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 1 Different fluoroquinolones: levofloxacin versus ciprofloxacin
Outcome: 1 Microbiological efficacy - pathogen eradication (fixed-effect model)
Study or subgroup Levofloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bundrick 2003 102/136 96/125 44.9 % 0.98 [ 0.85, 1.12 ]
Zhang 2012 179/209 120/199 55.1 % 1.42 [ 1.25, 1.61 ]
Total (95% CI) 345 324 100.0 % 1.22 [ 1.11, 1.34 ]
Total events: 281 (Levofloxacin), 216 (Ciprofloxacin)
Heterogeneity: Chi2 = 15.82, df = 1 (P = 0.00007); I2 =94%
Test for overall effect: Z = 4.23 (P = 0.000024)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favors ciprofloxacin Favors levofloxacin
Analysis 1.2. Comparison 1 Different fluoroquinolones: levofloxacin versus ciprofloxacin, Outcome 2
Microbiological efficacy - pathogen eradication (random-effects model).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 1 Different fluoroquinolones: levofloxacin versus ciprofloxacin
Outcome: 2 Microbiological efficacy - pathogen eradication (random-effects model)
Study or subgroup Levofloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bundrick 2003 102/136 96/125 49.7 % 0.98 [ 0.85, 1.12 ]
Zhang 2012 179/209 120/199 50.3 % 1.42 [ 1.25, 1.61 ]
Total (95% CI) 345 324 100.0 % 1.18 [ 0.81, 1.71 ]
Total events: 281 (Levofloxacin), 216 (Ciprofloxacin)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.82, df = 1 (P = 0.00007); I2 =94%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Different fluoroquinolones: levofloxacin versus ciprofloxacin, Outcome 3
Clinical efficacy.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 1 Different fluoroquinolones: levofloxacin versus ciprofloxacin
Outcome: 3 Clinical efficacy
Study or subgroup Levofloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinical efficacy (cure or improvement) at the end of treatment
Bundrick 2003 102/136 91/125 47.1 % 1.03 [ 0.89, 1.19 ]
Zhang 2012 195/209 143/199 52.9 % 1.30 [ 1.18, 1.43 ]
Subtotal (95% CI) 345 324 100.0 % 1.16 [ 0.93, 1.46 ]
Total events: 297 (Levofloxacin), 234 (Ciprofloxacin)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.06, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.30 (P = 0.19)
2 Clinical efficacy (cure or improvement) at follow-up (6 months)
Bundrick 2003 96/136 89/125 47.8 % 0.99 [ 0.85, 1.16 ]
Zhang 2012 197/209 141/199 52.2 % 1.33 [ 1.21, 1.46 ]
Subtotal (95% CI) 345 324 100.0 % 1.16 [ 0.86, 1.55 ]
Total events: 293 (Levofloxacin), 230 (Ciprofloxacin)
Heterogeneity: Tau2 = 0.04; Chi2 = 10.35, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 1.4. Comparison 1 Different fluoroquinolones: levofloxacin versus ciprofloxacin, Outcome 4
Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 1 Different fluoroquinolones: levofloxacin versus ciprofloxacin
Outcome: 4 Adverse effects of treatment
Study or subgroup Levofloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Bundrick 2003 86/197 90/180 94.5 % 0.87 [ 0.70, 1.08 ]
Zhang 2012 8/209 11/199 5.5 % 0.69 [ 0.28, 1.69 ]
Subtotal (95% CI) 406 379 100.0 % 0.86 [ 0.70, 1.06 ]
Total events: 94 (Levofloxacin), 101 (Ciprofloxacin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Gastrointestinal adverse effects
Bundrick 2003 40/197 36/180 83.4 % 1.02 [ 0.68, 1.52 ]
Zhang 2012 2/209 5/199 16.6 % 0.38 [ 0.07, 1.94 ]
Subtotal (95% CI) 406 379 100.0 % 0.86 [ 0.42, 1.77 ]
Total events: 42 (Levofloxacin), 41 (Ciprofloxacin)
Heterogeneity: Tau2 = 0.12; Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.40 (P = 0.69)
3 Back pain
Bundrick 2003 3/197 5/180 100.0 % 0.55 [ 0.13, 2.26 ]
Subtotal (95% CI) 197 180 100.0 % 0.55 [ 0.13, 2.26 ]
Total events: 3 (Levofloxacin), 5 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
4 Headache
Bundrick 2003 12/197 12/180 93.9 % 0.91 [ 0.42, 1.98 ]
Zhang 2012 0/209 2/199 6.1 % 0.19 [ 0.01, 3.94 ]
Subtotal (95% CI) 406 379 100.0 % 0.83 [ 0.39, 1.76 ]
Total events: 12 (Levofloxacin), 14 (Ciprofloxacin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
5 Dizziness
Bundrick 2003 1/197 7/180 54.9 % 0.13 [ 0.02, 1.05 ]
Zhang 2012 2/209 0/199 45.1 % 4.76 [ 0.23, 98.58 ]
Subtotal (95% CI) 406 379 100.0 % 0.66 [ 0.02, 22.13 ]
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(. . . Continued)
Study or subgroup Levofloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 3 (Levofloxacin), 7 (Ciprofloxacin)
Heterogeneity: Tau2 = 4.71; Chi2 = 3.68, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.23 (P = 0.82)
6 Arthralgia
Bundrick 2003 8/197 5/180 100.0 % 1.46 [ 0.49, 4.39 ]
Subtotal (95% CI) 197 180 100.0 % 1.46 [ 0.49, 4.39 ]
Total events: 8 (Levofloxacin), 5 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
7 Myalgia
Bundrick 2003 7/197 6/180 100.0 % 1.07 [ 0.37, 3.11 ]
Subtotal (95% CI) 197 180 100.0 % 1.07 [ 0.37, 3.11 ]
Total events: 7 (Levofloxacin), 6 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
8 Skeletal pain
Bundrick 2003 3/197 5/180 100.0 % 0.55 [ 0.13, 2.26 ]
Subtotal (95% CI) 197 180 100.0 % 0.55 [ 0.13, 2.26 ]
Total events: 3 (Levofloxacin), 5 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
9 Rhinitis
Bundrick 2003 5/197 5/180 100.0 % 0.91 [ 0.27, 3.10 ]
Subtotal (95% CI) 197 180 100.0 % 0.91 [ 0.27, 3.10 ]
Total events: 5 (Levofloxacin), 5 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
10 Upper respiratory tract infection
Bundrick 2003 5/197 4/180 100.0 % 1.14 [ 0.31, 4.19 ]
Subtotal (95% CI) 197 180 100.0 % 1.14 [ 0.31, 4.19 ]
Total events: 5 (Levofloxacin), 4 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
11 Dermal toxicity
Bundrick 2003 2/197 5/180 74.3 % 0.37 [ 0.07, 1.86 ]
Zhang 2012 1/209 1/199 25.7 % 0.95 [ 0.06, 15.12 ]
Subtotal (95% CI) 406 379 100.0 % 0.47 [ 0.12, 1.90 ]
Total events: 3 (Levofloxacin), 6 (Ciprofloxacin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
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(. . . Continued)
Study or subgroup Levofloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
12 Allergy to experimental agents
Zhang 2012 1/209 0/199 100.0 % 2.86 [ 0.12, 69.73 ]
Subtotal (95% CI) 209 199 100.0 % 2.86 [ 0.12, 69.73 ]
Total events: 1 (Levofloxacin), 0 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
13 Leukopenia
Zhang 2012 0/209 1/199 100.0 % 0.32 [ 0.01, 7.75 ]
Subtotal (95% CI) 209 199 100.0 % 0.32 [ 0.01, 7.75 ]
Total events: 0 (Levofloxacin), 1 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
14 Cough
Zhang 2012 1/209 0/199 100.0 % 2.86 [ 0.12, 69.73 ]
Subtotal (95% CI) 209 199 100.0 % 2.86 [ 0.12, 69.73 ]
Total events: 1 (Levofloxacin), 0 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
15 Insomnia
Zhang 2012 1/209 2/199 100.0 % 0.48 [ 0.04, 5.21 ]
Subtotal (95% CI) 209 199 100.0 % 0.48 [ 0.04, 5.21 ]
Total events: 1 (Levofloxacin), 2 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
16 Altered transaminase levels
Zhang 2012 1/209 2/199 100.0 % 0.48 [ 0.04, 5.21 ]
Subtotal (95% CI) 209 199 100.0 % 0.48 [ 0.04, 5.21 ]
Total events: 1 (Levofloxacin), 2 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
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Analysis 2.1. Comparison 2 Different fluoroquinolones: prulifloxacin versus levofloxacin, Outcome 1
Microbiological efficacy - pathogen eradication.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 2 Different fluoroquinolones: prulifloxacin versus levofloxacin
Outcome: 1 Microbiological efficacy - pathogen eradication
Study or subgroup Prulifloxacin Levofloxacin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Giannarini 2007 32/44 32/45 100.0 % 1.02 [ 0.79, 1.33 ]
Total (95% CI) 44 45 100.0 % 1.02 [ 0.79, 1.33 ]
Total events: 32 (Prulifloxacin), 32 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Different fluoroquinolones: prulifloxacin versus levofloxacin, Outcome 2 Clinical
efficacy - NIH-CPSI total score at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 2 Different fluoroquinolones: prulifloxacin versus levofloxacin
Outcome: 2 Clinical efficacy - NIH-CPSI total score at the end of treatment
Study or subgroup Prulifloxacin Levofloxacin
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Giannarini 2007 44 6.47 (3.79) 45 6.6 (4.71) 100.0 % -0.03 [ -0.45, 0.39 ]
Total (95% CI) 44 45 100.0 % -0.03 [ -0.45, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Different fluoroquinolones: prulifloxacin versus levofloxacin, Outcome 3
Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 2 Different fluoroquinolones: prulifloxacin versus levofloxacin
Outcome: 3 Adverse effects of treatment
Study or subgroup Prulifloxacin Levofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Giannarini 2007 8/44 10/45 100.0 % 0.82 [ 0.36, 1.88 ]
Subtotal (95% CI) 44 45 100.0 % 0.82 [ 0.36, 1.88 ]
Total events: 8 (Prulifloxacin), 10 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 Gastrointestinal adverse effects
Giannarini 2007 5/44 7/45 100.0 % 0.73 [ 0.25, 2.13 ]
Subtotal (95% CI) 44 45 100.0 % 0.73 [ 0.25, 2.13 ]
Total events: 5 (Prulifloxacin), 7 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.57)
3 Dermal toxicity
Giannarini 2007 3/44 0/45 100.0 % 7.16 [ 0.38, 134.62 ]
Subtotal (95% CI) 44 45 100.0 % 7.16 [ 0.38, 134.62 ]
Total events: 3 (Prulifloxacin), 0 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
4 Headache
Giannarini 2007 0/44 3/45 100.0 % 0.15 [ 0.01, 2.75 ]
Subtotal (95% CI) 44 45 100.0 % 0.15 [ 0.01, 2.75 ]
Total events: 0 (Prulifloxacin), 3 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
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Analysis 3.1. Comparison 3 Different fluoroquinolones: lomefloxacin versus ofloxacin, Outcome 1
Microbiological efficacy - pathogen eradication at follow-up (6 months).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 3 Different fluoroquinolones: lomefloxacin versus ofloxacin
Outcome: 1 Microbiological efficacy - pathogen eradication at follow-up (6 months)
Study or subgroup Lomefloxacin Ofloxacin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Koff 1996 12/18 9/15 100.0 % 1.11 [ 0.66, 1.88 ]
Total (95% CI) 18 15 100.0 % 1.11 [ 0.66, 1.88 ]
Total events: 12 (Lomefloxacin), 9 (Ofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Different fluoroquinolones: lomefloxacin versus ofloxacin, Outcome 2 Adverse
effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 3 Different fluoroquinolones: lomefloxacin versus ofloxacin
Outcome: 2 Adverse effects of treatment
Study or subgroup Lomefloxacin Ofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Koff 1996 4/18 8/15 100.0 % 0.42 [ 0.16, 1.12 ]
Subtotal (95% CI) 18 15 100.0 % 0.42 [ 0.16, 1.12 ]
Total events: 4 (Lomefloxacin), 8 (Ofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
2 Gastrointestinal adverse effects
Koff 1996 4/18 6/15 100.0 % 0.56 [ 0.19, 1.61 ]
Subtotal (95% CI) 18 15 100.0 % 0.56 [ 0.19, 1.61 ]
Total events: 4 (Lomefloxacin), 6 (Ofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
3 Headache
Koff 1996 0/18 1/15 100.0 % 0.28 [ 0.01, 6.43 ]
Subtotal (95% CI) 18 15 100.0 % 0.28 [ 0.01, 6.43 ]
Total events: 0 (Lomefloxacin), 1 (Ofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
4 Dizziness
Koff 1996 0/18 1/15 100.0 % 0.28 [ 0.01, 6.43 ]
Subtotal (95% CI) 18 15 100.0 % 0.28 [ 0.01, 6.43 ]
Total events: 0 (Lomefloxacin), 1 (Ofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
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Analysis 4.1. Comparison 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin, Outcome 1
Microbiological efficacy (intention-to-treat analysis).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin
Outcome: 1 Microbiological efficacy (intention-to-treat analysis)
Study or subgroup Lomefloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Microbiological efficacy (pathogen eradication) at the end of treatment
Naber 2002 72/93 72/89 100.0 % 0.96 [ 0.82, 1.11 ]
Subtotal (95% CI) 93 89 100.0 % 0.96 [ 0.82, 1.11 ]
Total events: 72 (Lomefloxacin), 72 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 Microbiological efficacy (pathogen eradication) at follow-up (4 weeks)
Naber 2002 60/93 66/89 100.0 % 0.87 [ 0.72, 1.06 ]
Subtotal (95% CI) 93 89 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 60 (Lomefloxacin), 66 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
3 Microbiological efficacy (pathogen eradication) at follow-up (3 months)
Naber 2002 60/93 64/89 100.0 % 0.90 [ 0.74, 1.09 ]
Subtotal (95% CI) 93 89 100.0 % 0.90 [ 0.74, 1.09 ]
Total events: 60 (Lomefloxacin), 64 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
4 Microbiological efficacy (pathogen eradication) at follow-up (6 months)
Naber 2002 49/93 54/89 100.0 % 0.87 [ 0.67, 1.12 ]
Subtotal (95% CI) 93 89 100.0 % 0.87 [ 0.67, 1.12 ]
Total events: 49 (Lomefloxacin), 54 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 4.2. Comparison 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin, Outcome 2
Microbiological efficacy (per-protocol analysis).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin
Outcome: 2 Microbiological efficacy (per-protocol analysis)
Study or subgroup Lomefloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Microbiological efficacy (pathogen eradication and eradication plus superinfection) at the end of treatment
Naber 2002 43/46 39/41 100.0 % 0.98 [ 0.89, 1.09 ]
Subtotal (95% CI) 46 41 100.0 % 0.98 [ 0.89, 1.09 ]
Total events: 43 (Lomefloxacin), 39 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 Microbiological efficacy (pathogen eradication and eradication plus superinfection) at follow-up (4 weeks)
Naber 2002 41/42 40/41 100.0 % 1.00 [ 0.94, 1.07 ]
Subtotal (95% CI) 42 41 100.0 % 1.00 [ 0.94, 1.07 ]
Total events: 41 (Lomefloxacin), 40 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
3 Microbiological efficacy (pathogen eradication and eradication plus superinfection) at follow-up (3 months)
Naber 2002 37/38 37/39 100.0 % 1.03 [ 0.94, 1.12 ]
Subtotal (95% CI) 38 39 100.0 % 1.03 [ 0.94, 1.12 ]
Total events: 37 (Lomefloxacin), 37 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
4 Microbiological efficacy (pathogen eradication and eradication plus superinfection) at follow-up (6 months)
Naber 2002 29/33 31/33 100.0 % 0.94 [ 0.80, 1.09 ]
Subtotal (95% CI) 33 33 100.0 % 0.94 [ 0.80, 1.09 ]
Total events: 29 (Lomefloxacin), 31 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
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Analysis 4.3. Comparison 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin, Outcome 3
Clinical efficacy (intention-to-treat analysis).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin
Outcome: 3 Clinical efficacy (intention-to-treat analysis)
Study or subgroup Lomefloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinical efficacy (cure or improvement) at the end of treatment
Naber 2002 88/93 83/89 100.0 % 1.01 [ 0.94, 1.09 ]
Subtotal (95% CI) 93 89 100.0 % 1.01 [ 0.94, 1.09 ]
Total events: 88 (Lomefloxacin), 83 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
2 Clinical efficacy (cure or improvement) at follow-up (4 weeks)
Naber 2002 70/93 74/89 100.0 % 0.91 [ 0.78, 1.05 ]
Subtotal (95% CI) 93 89 100.0 % 0.91 [ 0.78, 1.05 ]
Total events: 70 (Lomefloxacin), 74 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
3 Clinical efficacy (cure or improvement) at follow-up (3 months)
Naber 2002 68/93 67/89 100.0 % 0.97 [ 0.82, 1.15 ]
Subtotal (95% CI) 93 89 100.0 % 0.97 [ 0.82, 1.15 ]
Total events: 68 (Lomefloxacin), 67 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
4 Clinical efficacy (cure or improvement) at follow-up (6 months)
Naber 2002 61/93 64/89 100.0 % 0.91 [ 0.75, 1.11 ]
Subtotal (95% CI) 93 89 100.0 % 0.91 [ 0.75, 1.11 ]
Total events: 61 (Lomefloxacin), 64 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
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Analysis 4.4. Comparison 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin, Outcome 4
Clinical efficacy (per-protocol analysis).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin
Outcome: 4 Clinical efficacy (per-protocol analysis)
Study or subgroup Lomefloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinical efficacy (cure or improvement) at the end of treatment
Naber 2002 44/46 41/41 100.0 % 0.96 [ 0.89, 1.03 ]
Subtotal (95% CI) 46 41 100.0 % 0.96 [ 0.89, 1.03 ]
Total events: 44 (Lomefloxacin), 41 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 Clinical efficacy (cure or improvement) at follow-up (4 weeks)
Naber 2002 37/42 36/41 100.0 % 1.00 [ 0.86, 1.18 ]
Subtotal (95% CI) 42 41 100.0 % 1.00 [ 0.86, 1.18 ]
Total events: 37 (Lomefloxacin), 36 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
3 Clinical efficacy (cure or improvement) at follow-up (3 months)
Naber 2002 31/32 30/33 100.0 % 1.07 [ 0.94, 1.21 ]
Subtotal (95% CI) 32 33 100.0 % 1.07 [ 0.94, 1.21 ]
Total events: 31 (Lomefloxacin), 30 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
4 Clinical efficacy (cure or improvement) at follow-up (6 months)
Naber 2002 29/33 33/33 100.0 % 0.88 [ 0.77, 1.01 ]
Subtotal (95% CI) 33 33 100.0 % 0.88 [ 0.77, 1.01 ]
Total events: 29 (Lomefloxacin), 33 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
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Analysis 4.5. Comparison 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin, Outcome 5
Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 4 Different fluoroquinolones: lomefloxacin versus ciprofloxacin
Outcome: 5 Adverse effects of treatment
Study or subgroup Lomefloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Naber 2002 12/93 14/89 100.0 % 0.82 [ 0.40, 1.68 ]
Subtotal (95% CI) 93 89 100.0 % 0.82 [ 0.40, 1.68 ]
Total events: 12 (Lomefloxacin), 14 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Gastrointestinal adverse effects
Naber 2002 5/93 8/89 100.0 % 0.60 [ 0.20, 1.76 ]
Subtotal (95% CI) 93 89 100.0 % 0.60 [ 0.20, 1.76 ]
Total events: 5 (Lomefloxacin), 8 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
3 Headache
Naber 2002 1/93 1/89 100.0 % 0.96 [ 0.06, 15.07 ]
Subtotal (95% CI) 93 89 100.0 % 0.96 [ 0.06, 15.07 ]
Total events: 1 (Lomefloxacin), 1 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
4 Dizziness
Naber 2002 1/93 0/89 100.0 % 2.87 [ 0.12, 69.59 ]
Subtotal (95% CI) 93 89 100.0 % 2.87 [ 0.12, 69.59 ]
Total events: 1 (Lomefloxacin), 0 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
5 Dry mouth
Naber 2002 2/93 0/89 100.0 % 4.79 [ 0.23, 98.35 ]
Subtotal (95% CI) 93 89 100.0 % 4.79 [ 0.23, 98.35 ]
Total events: 2 (Lomefloxacin), 0 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
6 Insomnia
Naber 2002 0/93 1/89 100.0 % 0.32 [ 0.01, 7.73 ]
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Study or subgroup Lomefloxacin Ciprofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 93 89 100.0 % 0.32 [ 0.01, 7.73 ]
Total events: 0 (Lomefloxacin), 1 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
7 Hyperglycemia
Naber 2002 1/93 0/89 100.0 % 2.87 [ 0.12, 69.59 ]
Subtotal (95% CI) 93 89 100.0 % 2.87 [ 0.12, 69.59 ]
Total events: 1 (Lomefloxacin), 0 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
8 Dermal toxicity
Naber 2002 1/93 0/89 100.0 % 2.87 [ 0.12, 69.59 ]
Subtotal (95% CI) 93 89 100.0 % 2.87 [ 0.12, 69.59 ]
Total events: 1 (Lomefloxacin), 0 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
9 Abnormal semen
Naber 2002 1/93 0/89 100.0 % 2.87 [ 0.12, 69.59 ]
Subtotal (95% CI) 93 89 100.0 % 2.87 [ 0.12, 69.59 ]
Total events: 1 (Lomefloxacin), 0 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
10 Upper respiratory tract infection
Naber 2002 0/93 4/89 100.0 % 0.11 [ 0.01, 1.95 ]
Subtotal (95% CI) 93 89 100.0 % 0.11 [ 0.01, 1.95 ]
Total events: 0 (Lomefloxacin), 4 (Ciprofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
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Analysis 5.1. Comparison 5 Different fluoroquinolones: lomefloxacin versus comparator fluoroquinolone,
Outcome 1 Microbiological efficacy - pathogen eradication at follow-up (6 months).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 5 Different fluoroquinolones: lomefloxacin versus comparator fluoroquinolone
Outcome: 1 Microbiological efficacy - pathogen eradication at follow-up (6 months)
Study or subgroup Lomefloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Koff 1996 12/18 9/15 21.2 % 1.11 [ 0.66, 1.88 ]
Naber 2002 34/42 36/41 78.8 % 0.92 [ 0.77, 1.11 ]
Total (95% CI) 60 56 100.0 % 0.96 [ 0.80, 1.16 ]
Total events: 46 (Lomefloxacin), 45 (Other fluoroquinolone)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Different fluoroquinolones: lomefloxacin versus comparator fluoroquinolone,
Outcome 2 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 5 Different fluoroquinolones: lomefloxacin versus comparator fluoroquinolone
Outcome: 2 Adverse effects of treatment
Study or subgroup Lomefloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Koff 1996 4/18 8/15 37.0 % 0.42 [ 0.16, 1.12 ]
Naber 2002 12/93 14/89 63.0 % 0.82 [ 0.40, 1.68 ]
Subtotal (95% CI) 111 104 100.0 % 0.64 [ 0.34, 1.21 ]
Total events: 16 (Lomefloxacin), 22 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.20, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 1.37 (P = 0.17)
2 Gastrointestinal adverse effects
Koff 1996 4/18 6/15 50.7 % 0.56 [ 0.19, 1.61 ]
Naber 2002 5/93 8/89 49.3 % 0.60 [ 0.20, 1.76 ]
Subtotal (95% CI) 111 104 100.0 % 0.58 [ 0.27, 1.23 ]
Total events: 9 (Lomefloxacin), 14 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
3 Headache
Koff 1996 0/18 1/15 43.7 % 0.28 [ 0.01, 6.43 ]
Naber 2002 1/93 1/89 56.3 % 0.96 [ 0.06, 15.07 ]
Subtotal (95% CI) 111 104 100.0 % 0.56 [ 0.07, 4.43 ]
Total events: 1 (Lomefloxacin), 2 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
4 Dizziness
Koff 1996 0/18 1/15 50.9 % 0.28 [ 0.01, 6.43 ]
Naber 2002 1/93 0/89 49.1 % 2.87 [ 0.12, 69.59 ]
Subtotal (95% CI) 111 104 100.0 % 0.88 [ 0.09, 8.60 ]
Total events: 1 (Lomefloxacin), 1 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.11; Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.14, df = 3 (P = 0.99), I2 =0.0%
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Analysis 6.1. Comparison 6 Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone,
Outcome 1 Microbiological efficacy - pathogen eradication at the end of treatment (fixed-effect model).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 6 Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone
Outcome: 1 Microbiological efficacy - pathogen eradication at the end of treatment (fixed-effect model)
Study or subgroup Ciprofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bundrick 2003 96/125 102/136 28.5 % 1.02 [ 0.89, 1.17 ]
Naber 2002 72/89 72/93 20.5 % 1.04 [ 0.90, 1.21 ]
Zhang 2012 120/199 179/209 50.9 % 0.70 [ 0.62, 0.80 ]
Total (95% CI) 413 438 100.0 % 0.87 [ 0.80, 0.94 ]
Total events: 288 (Ciprofloxacin), 353 (Other fluoroquinolone)
Heterogeneity: Chi2 = 22.32, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone,
Outcome 2 Microbiological efficacy - pathogen eradication at the end of treatment (random-effects model).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 6 Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone
Outcome: 2 Microbiological efficacy - pathogen eradication at the end of treatment (random-effects model)
Study or subgroup Ciprofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Bundrick 2003 96/125 102/136 33.4 % 1.02 [ 0.89, 1.17 ]
Naber 2002 72/89 72/93 32.8 % 1.04 [ 0.90, 1.21 ]
Zhang 2012 120/199 179/209 33.8 % 0.70 [ 0.62, 0.80 ]
Subtotal (95% CI) 413 438 100.0 % 0.91 [ 0.70, 1.18 ]
Total events: 288 (Ciprofloxacin), 353 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.05; Chi2 = 22.32, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Sensitivity analysis, exclusion of Zhang 2012
Bundrick 2003 96/125 102/136 54.3 % 1.02 [ 0.89, 1.17 ]
Naber 2002 72/89 72/93 45.7 % 1.04 [ 0.90, 1.21 ]
Subtotal (95% CI) 214 229 100.0 % 1.03 [ 0.93, 1.14 ]
Total events: 168 (Ciprofloxacin), 174 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
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Analysis 6.3. Comparison 6 Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone,
Outcome 3 Clinical efficacy.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 6 Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone
Outcome: 3 Clinical efficacy
Study or subgroup Ciprofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinical efficacy (cure or improvement) at the end of treatment
Bundrick 2003 91/125 102/136 30.3 % 0.97 [ 0.84, 1.12 ]
Naber 2002 83/89 88/93 35.5 % 0.99 [ 0.92, 1.06 ]
Zhang 2012 143/199 195/209 34.2 % 0.77 [ 0.70, 0.85 ]
Subtotal (95% CI) 413 438 100.0 % 0.90 [ 0.75, 1.08 ]
Total events: 317 (Ciprofloxacin), 385 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.02; Chi2 = 19.30, df = 2 (P = 0.00006); I2 =90%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Clinical efficacy (cure or improvement) at follow-up (6 months)
Bundrick 2003 89/125 96/136 33.2 % 1.01 [ 0.86, 1.18 ]
Naber 2002 64/89 61/93 30.9 % 1.10 [ 0.90, 1.33 ]
Zhang 2012 141/199 197/209 36.0 % 0.75 [ 0.68, 0.83 ]
Subtotal (95% CI) 413 438 100.0 % 0.93 [ 0.72, 1.20 ]
Total events: 294 (Ciprofloxacin), 354 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.04; Chi2 = 18.31, df = 2 (P = 0.00011); I2 =89%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 6.4. Comparison 6 Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone,
Outcome 4 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 6 Different fluoroquinolones: ciprofloxacin versus comparator fluoroquinolone
Outcome: 4 Adverse effects of treatment
Study or subgroup Ciprofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Bundrick 2003 90/180 86/197 87.0 % 1.15 [ 0.92, 1.42 ]
Naber 2002 14/89 12/93 7.9 % 1.22 [ 0.60, 2.49 ]
Zhang 2012 11/199 8/209 5.1 % 1.44 [ 0.59, 3.52 ]
Subtotal (95% CI) 468 499 100.0 % 1.16 [ 0.95, 1.42 ]
Total events: 115 (Ciprofloxacin), 106 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Gastrointestinal adverse effects
Bundrick 2003 36/180 40/197 83.3 % 0.99 [ 0.66, 1.47 ]
Naber 2002 8/89 5/93 11.6 % 1.67 [ 0.57, 4.92 ]
Zhang 2012 5/199 2/209 5.1 % 2.63 [ 0.52, 13.38 ]
Subtotal (95% CI) 468 499 100.0 % 1.10 [ 0.76, 1.59 ]
Total events: 49 (Ciprofloxacin), 47 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
3 Headache
Bundrick 2003 12/180 12/197 87.4 % 1.09 [ 0.50, 2.37 ]
Naber 2002 1/89 1/93 6.9 % 1.04 [ 0.07, 16.45 ]
Zhang 2012 2/199 0/209 5.7 % 5.25 [ 0.25, 108.68 ]
Subtotal (95% CI) 468 499 100.0 % 1.19 [ 0.58, 2.46 ]
Total events: 15 (Ciprofloxacin), 13 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
4 Dizziness
Bundrick 2003 7/180 1/197 40.5 % 7.66 [ 0.95, 61.66 ]
Naber 2002 0/89 1/93 29.0 % 0.35 [ 0.01, 8.44 ]
Zhang 2012 0/199 2/209 30.5 % 0.21 [ 0.01, 4.35 ]
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Study or subgroup Ciprofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 468 499 100.0 % 1.04 [ 0.09, 12.02 ]
Total events: 7 (Ciprofloxacin), 4 (Other fluoroquinolone)
Heterogeneity: Tau2 = 2.71; Chi2 = 4.79, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 0.03 (P = 0.97)
5 Dermal toxicity
Bundrick 2003 5/180 2/197 62.2 % 2.74 [ 0.54, 13.93 ]
Naber 2002 0/89 1/93 16.2 % 0.35 [ 0.01, 8.44 ]
Zhang 2012 1/199 1/209 21.6 % 1.05 [ 0.07, 16.68 ]
Subtotal (95% CI) 468 499 100.0 % 1.59 [ 0.44, 5.75 ]
Total events: 6 (Ciprofloxacin), 4 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.33, df = 4 (P = 0.99), I2 =0.0%
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Analysis 7.1. Comparison 7 Different fluoroquinolones: levofloxacin versus comparator fluoroquinolone,
Outcome 1 Microbiological efficacy - pathogen eradication (fixed-effect model).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 7 Different fluoroquinolones: levofloxacin versus comparator fluoroquinolone
Outcome: 1 Microbiological efficacy - pathogen eradication (fixed-effect model)
Study or subgroup Levofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bundrick 2003 102/136 96/125 39.2 % 0.98 [ 0.85, 1.12 ]
Giannarini 2007 32/45 32/44 12.7 % 0.98 [ 0.75, 1.27 ]
Zhang 2012 179/209 120/199 48.1 % 1.42 [ 1.25, 1.61 ]
Total (95% CI) 390 368 100.0 % 1.19 [ 1.09, 1.30 ]
Total events: 313 (Levofloxacin), 248 (Other fluoroquinolone)
Heterogeneity: Chi2 = 17.85, df = 2 (P = 0.00013); I2 =89%
Test for overall effect: Z = 3.91 (P = 0.000090)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Different fluoroquinolones: levofloxacin versus comparator fluoroquinolone,
Outcome 2 Microbiological efficacy - pathogen eradication (random-effects model).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 7 Different fluoroquinolones: levofloxacin versus comparator fluoroquinolone
Outcome: 2 Microbiological efficacy - pathogen eradication (random-effects model)
Study or subgroup Levofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Bundrick 2003 102/136 96/125 35.3 % 0.98 [ 0.85, 1.12 ]
Giannarini 2007 32/45 32/44 28.9 % 0.98 [ 0.75, 1.27 ]
Zhang 2012 179/209 120/199 35.8 % 1.42 [ 1.25, 1.61 ]
Subtotal (95% CI) 390 368 100.0 % 1.12 [ 0.84, 1.48 ]
Total events: 313 (Levofloxacin), 248 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.05; Chi2 = 17.85, df = 2 (P = 0.00013); I2 =89%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Sensitivity analysis, exclusion of Zhang 2012
Bundrick 2003 102/136 96/125 78.3 % 0.98 [ 0.85, 1.12 ]
Giannarini 2007 32/45 32/44 21.7 % 0.98 [ 0.75, 1.27 ]
Subtotal (95% CI) 181 169 100.0 % 0.98 [ 0.87, 1.10 ]
Total events: 134 (Levofloxacin), 128 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 7.3. Comparison 7 Different fluoroquinolones: levofloxacin versus comparator fluoroquinolone,
Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 7 Different fluoroquinolones: levofloxacin versus comparator fluoroquinolone
Outcome: 3 Adverse effects of treatment
Study or subgroup Levofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Bundrick 2003 86/197 90/180 88.8 % 0.87 [ 0.70, 1.08 ]
Giannarini 2007 10/45 8/44 6.0 % 1.22 [ 0.53, 2.81 ]
Zhang 2012 8/209 11/199 5.2 % 0.69 [ 0.28, 1.69 ]
Subtotal (95% CI) 451 423 100.0 % 0.88 [ 0.72, 1.08 ]
Total events: 104 (Levofloxacin), 109 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Gastrointestinal adverse effects
Bundrick 2003 40/197 36/180 83.2 % 1.02 [ 0.68, 1.52 ]
Giannarini 2007 7/45 5/44 11.8 % 1.37 [ 0.47, 3.99 ]
Zhang 2012 2/209 5/199 5.1 % 0.38 [ 0.07, 1.94 ]
Subtotal (95% CI) 451 423 100.0 % 1.00 [ 0.69, 1.44 ]
Total events: 49 (Levofloxacin), 46 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.69, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
3 Dermal toxicity
Bundrick 2003 2/197 5/180 60.5 % 0.37 [ 0.07, 1.86 ]
Giannarini 2007 0/45 3/44 18.6 % 0.14 [ 0.01, 2.63 ]
Zhang 2012 1/209 1/199 20.9 % 0.95 [ 0.06, 15.12 ]
Subtotal (95% CI) 451 423 100.0 % 0.37 [ 0.11, 1.32 ]
Total events: 3 (Levofloxacin), 9 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
4 Headache
Bundrick 2003 12/197 12/180 67.3 % 0.91 [ 0.42, 1.98 ]
Giannarini 2007 3/45 0/44 16.8 % 6.85 [ 0.36, 128.83 ]
Zhang 2012 0/209 2/199 15.9 % 0.19 [ 0.01, 3.94 ]
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Study or subgroup Levofloxacin
Other
fluoro-
quinolone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 451 423 100.0 % 1.00 [ 0.26, 3.80 ]
Total events: 15 (Levofloxacin), 14 (Other fluoroquinolone)
Heterogeneity: Tau2 = 0.54; Chi2 = 2.84, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Chi2 = 2.24, df = 3 (P = 0.52), I2 =0.0%
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Analysis 8.1. Comparison 8 Fluoroquinolone versus other antibacterial agent: prulifloxacin versus
doxycycline in chlamydial prostatitis, Outcome 1 Microbiological efficacy - absence of Chlamydia trachomatis
DNA and IgA at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 8 Fluoroquinolone versus other antibacterial agent: prulifloxacin versus doxycycline in chlamydial prostatitis
Outcome: 1 Microbiological efficacy - absence of Chlamydia trachomatis DNA and IgA at the end of treatment
Study or subgroup Prulifloxacin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cai 2010 20/20 16/18 100.0 % 1.12 [ 0.93, 1.36 ]
Total (95% CI) 20 18 100.0 % 1.12 [ 0.93, 1.36 ]
Total events: 20 (Prulifloxacin), 16 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Fluoroquinolone versus other antibacterial agent: prulifloxacin versus
doxycycline in chlamydial prostatitis, Outcome 2 Clinical efficacy - NIH-CPSI total score at the end of
treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 8 Fluoroquinolone versus other antibacterial agent: prulifloxacin versus doxycycline in chlamydial prostatitis
Outcome: 2 Clinical efficacy - NIH-CPSI total score at the end of treatment
Study or subgroup Prulifloxacin Doxycycline
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cai 2010 109 6.1 (0.7) 102 6.6 (0.8) 100.0 % -0.66 [ -0.94, -0.39 ]
Total (95% CI) 109 102 100.0 % -0.66 [ -0.94, -0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.69 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Fluoroquinolone versus other antibacterial agent: prulifloxacin versus
doxycycline in chlamydial prostatitis, Outcome 3 Clinical efficacy - number of asymptomatic participants at
the end of therapy.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 8 Fluoroquinolone versus other antibacterial agent: prulifloxacin versus doxycycline in chlamydial prostatitis
Outcome: 3 Clinical efficacy - number of asymptomatic participants at the end of therapy
Study or subgroup Prulifloxacin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cai 2010 90/109 81/102 100.0 % 1.04 [ 0.91, 1.19 ]
Total (95% CI) 109 102 100.0 % 1.04 [ 0.91, 1.19 ]
Total events: 90 (Prulifloxacin), 81 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors doxycycline Favors prulifloxacin
102Antimicrobial therapy for chronic bacterial prostatitis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.4. Comparison 8 Fluoroquinolone versus other antibacterial agent: prulifloxacin versus
doxycycline in chlamydial prostatitis, Outcome 4 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 8 Fluoroquinolone versus other antibacterial agent: prulifloxacin versus doxycycline in chlamydial prostatitis
Outcome: 4 Adverse effects of treatment
Study or subgroup Prulifloxacin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Cai 2010 5/109 4/102 100.0 % 1.17 [ 0.32, 4.24 ]
Subtotal (95% CI) 109 102 100.0 % 1.17 [ 0.32, 4.24 ]
Total events: 5 (Prulifloxacin), 4 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Gastrointestinal adverse effects
Cai 2010 3/109 4/102 100.0 % 0.70 [ 0.16, 3.06 ]
Subtotal (95% CI) 109 102 100.0 % 0.70 [ 0.16, 3.06 ]
Total events: 3 (Prulifloxacin), 4 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
3 Back pain
Cai 2010 2/109 0/102 100.0 % 4.68 [ 0.23, 96.36 ]
Subtotal (95% CI) 109 102 100.0 % 4.68 [ 0.23, 96.36 ]
Total events: 2 (Prulifloxacin), 0 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 1.25, df = 2 (P = 0.54), I2 =0.0%
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Analysis 9.1. Comparison 9 Fluoroquinolone versus other antibacterial agent: ofloxacin versus minocycline
in ureaplasmal prostatitis, Outcome 1 Microbiological efficacy - pathogen eradication.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 9 Fluoroquinolone versus other antibacterial agent: ofloxacin versus minocycline in ureaplasmal prostatitis
Outcome: 1 Microbiological efficacy - pathogen eradication
Study or subgroup Ofloxacin Minocycline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ohkawa 1993 7/7 7/7 100.0 % 1.00 [ 0.78, 1.29 ]
Total (95% CI) 7 7 100.0 % 1.00 [ 0.78, 1.29 ]
Total events: 7 (Ofloxacin), 7 (Minocycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Fluoroquinolone versus other antibacterial agent: ofloxacin versus minocycline
in ureaplasmal prostatitis, Outcome 2 Clinical efficacy (cure or improvement) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 9 Fluoroquinolone versus other antibacterial agent: ofloxacin versus minocycline in ureaplasmal prostatitis
Outcome: 2 Clinical efficacy (cure or improvement) at the end of treatment
Study or subgroup Ofloxacin Minocycline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ohkawa 1993 6/7 7/7 100.0 % 0.87 [ 0.59, 1.26 ]
Total (95% CI) 7 7 100.0 % 0.87 [ 0.59, 1.26 ]
Total events: 6 (Ofloxacin), 7 (Minocycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Fluoroquinolone versus other antibacterial agent: ofloxacin versus
carbenicillin, Outcome 1 Microbiological efficacy - pathogen eradication.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 10 Fluoroquinolone versus other antibacterial agent: ofloxacin versus carbenicillin
Outcome: 1 Microbiological efficacy - pathogen eradication
Study or subgroup Ofloxacin Carbenicillin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cox 1989 8/9 12/14 100.0 % 1.04 [ 0.76, 1.42 ]
Total (95% CI) 9 14 100.0 % 1.04 [ 0.76, 1.42 ]
Total events: 8 (Ofloxacin), 12 (Carbenicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Fluoroquinolone versus other antibacterial agent: ofloxacin versus
carbenicillin, Outcome 2 Clinical efficacy (cure or improvement) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 10 Fluoroquinolone versus other antibacterial agent: ofloxacin versus carbenicillin
Outcome: 2 Clinical efficacy (cure or improvement) at the end of treatment
Study or subgroup Ofloxacin Carbenicillin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cox 1989 9/9 13/14 100.0 % 1.06 [ 0.85, 1.32 ]
Total (95% CI) 9 14 100.0 % 1.06 [ 0.85, 1.32 ]
Total events: 9 (Ofloxacin), 13 (Carbenicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Fluoroquinolone versus other antibacterial agent: ofloxacin versus
carbenicillin, Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 10 Fluoroquinolone versus other antibacterial agent: ofloxacin versus carbenicillin
Outcome: 3 Adverse effects of treatment
Study or subgroup Ofloxacin Carbenicillin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Cox 1989 6/22 9/24 100.0 % 0.73 [ 0.31, 1.71 ]
Subtotal (95% CI) 22 24 100.0 % 0.73 [ 0.31, 1.71 ]
Total events: 6 (Ofloxacin), 9 (Carbenicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
2 Gastrointestinal adverse effects
Cox 1989 3/22 7/24 100.0 % 0.47 [ 0.14, 1.59 ]
Subtotal (95% CI) 22 24 100.0 % 0.47 [ 0.14, 1.59 ]
Total events: 3 (Ofloxacin), 7 (Carbenicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
3 Dermal toxicity
Cox 1989 1/22 0/24 100.0 % 3.26 [ 0.14, 76.10 ]
Subtotal (95% CI) 22 24 100.0 % 3.26 [ 0.14, 76.10 ]
Total events: 1 (Ofloxacin), 0 (Carbenicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
4 Nervous (sic)
Cox 1989 2/22 0/24 100.0 % 5.43 [ 0.28, 107.33 ]
Subtotal (95% CI) 22 24 100.0 % 5.43 [ 0.28, 107.33 ]
Total events: 2 (Ofloxacin), 0 (Carbenicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
5 Special senses toxicity
Cox 1989 0/22 3/24 100.0 % 0.16 [ 0.01, 2.85 ]
Subtotal (95% CI) 22 24 100.0 % 0.16 [ 0.01, 2.85 ]
Total events: 0 (Ofloxacin), 3 (Carbenicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
6 Respiratory toxicity
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(. . . Continued)
Study or subgroup Ofloxacin Carbenicillin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cox 1989 0/22 1/24 100.0 % 0.36 [ 0.02, 8.46 ]
Subtotal (95% CI) 22 24 100.0 % 0.36 [ 0.02, 8.46 ]
Total events: 0 (Ofloxacin), 1 (Carbenicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 11.1. Comparison 11 Fluoroquinolone versus other antibacterial agent: lomefloxacin versus co-
trimoxazole, Outcome 1 Microbiological efficacy.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 11 Fluoroquinolone versus other antibacterial agent: lomefloxacin versus co-trimoxazole
Outcome: 1 Microbiological efficacy
Study or subgroup Lomefloxacin Co-trimoxazole Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Microbiological success (pathogen eradication) at the end of treatment
Bustillo 1997 12/13 11/13 100.0 % 1.09 [ 0.82, 1.44 ]
Subtotal (95% CI) 13 13 100.0 % 1.09 [ 0.82, 1.44 ]
Total events: 12 (Lomefloxacin), 11 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Microbiological success (pathogen eradication) at follow-up (4 months)
Bustillo 1997 12/13 11/13 100.0 % 1.09 [ 0.82, 1.44 ]
Subtotal (95% CI) 13 13 100.0 % 1.09 [ 0.82, 1.44 ]
Total events: 12 (Lomefloxacin), 11 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
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Analysis 11.2. Comparison 11 Fluoroquinolone versus other antibacterial agent: lomefloxacin versus co-
trimoxazole, Outcome 2 Clinical efficacy.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 11 Fluoroquinolone versus other antibacterial agent: lomefloxacin versus co-trimoxazole
Outcome: 2 Clinical efficacy
Study or subgroup Lomefloxacin Co-trimoxazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinical efficacy (cure or improvement) at the end of treatment
Bustillo 1997 13/13 13/13 100.0 % 1.00 [ 0.87, 1.15 ]
Subtotal (95% CI) 13 13 100.0 % 1.00 [ 0.87, 1.15 ]
Total events: 13 (Lomefloxacin), 13 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Clinical efficacy (cure or improvement) at follow-up (4 months)
Bustillo 1997 13/13 13/13 100.0 % 1.00 [ 0.87, 1.15 ]
Subtotal (95% CI) 13 13 100.0 % 1.00 [ 0.87, 1.15 ]
Total events: 13 (Lomefloxacin), 13 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 11.3. Comparison 11 Fluoroquinolone versus other antibacterial agent: lomefloxacin versus co-
trimoxazole, Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 11 Fluoroquinolone versus other antibacterial agent: lomefloxacin versus co-trimoxazole
Outcome: 3 Adverse effects of treatment
Study or subgroup Lomefloxacin Co-trimoxazole Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Bustillo 1997 1/15 2/13 100.0 % 0.43 [ 0.04, 4.25 ]
Subtotal (95% CI) 15 13 100.0 % 0.43 [ 0.04, 4.25 ]
Total events: 1 (Lomefloxacin), 2 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Gastrointestinal adverse effects
Bustillo 1997 1/15 2/13 100.0 % 0.43 [ 0.04, 4.25 ]
Subtotal (95% CI) 15 13 100.0 % 0.43 [ 0.04, 4.25 ]
Total events: 1 (Lomefloxacin), 2 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 12.1. Comparison 12 Fluoroquinolone versus other antibacterial agent: ciprofloxacin versus
azithromycin in chlamydial prostatitis, Outcome 1 Microbiological efficacy (pathogen eradication) at the end
of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 12 Fluoroquinolone versus other antibacterial agent: ciprofloxacin versus azithromycin in chlamydial prostatitis
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup Ciprofloxacin Azithromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Skerk 2003 17/44 36/45 100.0 % 0.48 [ 0.32, 0.72 ]
Total (95% CI) 44 45 100.0 % 0.48 [ 0.32, 0.72 ]
Total events: 17 (Ciprofloxacin), 36 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00036)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Fluoroquinolone versus other antibacterial agent: ciprofloxacin versus
azithromycin in chlamydial prostatitis, Outcome 2 Clinical efficacy (cure or improvement) at the end of
treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 12 Fluoroquinolone versus other antibacterial agent: ciprofloxacin versus azithromycin in chlamydial prostatitis
Outcome: 2 Clinical efficacy (cure or improvement) at the end of treatment
Study or subgroup Ciprofloxacin Azithromycin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Skerk 2003 22/44 35/45 100.0 % 0.64 [ 0.46, 0.90 ]
Total (95% CI) 44 45 100.0 % 0.64 [ 0.46, 0.90 ]
Total events: 22 (Ciprofloxacin), 35 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0096)
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 Fluoroquinolone versus other antibacterial agent: ciprofloxacin versus
azithromycin in chlamydial prostatitis, Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 12 Fluoroquinolone versus other antibacterial agent: ciprofloxacin versus azithromycin in chlamydial prostatitis
Outcome: 3 Adverse effects of treatment
Study or subgroup Ciprofloxacin Azithromycin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Skerk 2003 0/44 1/45 100.0 % 0.34 [ 0.01, 8.15 ]
Subtotal (95% CI) 44 45 100.0 % 0.34 [ 0.01, 8.15 ]
Total events: 0 (Ciprofloxacin), 1 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Gastrointestinal adverse effects
Skerk 2003 0/44 1/45 100.0 % 0.34 [ 0.01, 8.15 ]
Subtotal (95% CI) 44 45 100.0 % 0.34 [ 0.01, 8.15 ]
Total events: 0 (Ciprofloxacin), 1 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
3 Hepatic adverse effects (increased transaminases)
Skerk 2003 0/44 1/45 100.0 % 0.34 [ 0.01, 8.15 ]
Subtotal (95% CI) 44 45 100.0 % 0.34 [ 0.01, 8.15 ]
Total events: 0 (Ciprofloxacin), 1 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 13.1. Comparison 13 Non-fluoroquinolone antibacterial agents: minocycline versus cephalexin,
Outcome 1 Microbiological efficacy (pathogen eradication and eradication plus superinfection) at the end of
treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 13 Non-fluoroquinolone antibacterial agents: minocycline versus cephalexin
Outcome: 1 Microbiological efficacy (pathogen eradication and eradication plus superinfection) at the end of treatment
Study or subgroup Minocycline Cephalexin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Paulson 1986 4/10 4/17 100.0 % 1.70 [ 0.54, 5.34 ]
Total (95% CI) 10 17 100.0 % 1.70 [ 0.54, 5.34 ]
Total events: 4 (Minocycline), 4 (Cephalexin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 Non-fluoroquinolone antibacterial agents: minocycline versus cephalexin,
Outcome 2 Clinical efficacy (cure or improvement) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 13 Non-fluoroquinolone antibacterial agents: minocycline versus cephalexin
Outcome: 2 Clinical efficacy (cure or improvement) at the end of treatment
Study or subgroup Minocycline Cephalexin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Paulson 1986 6/10 5/17 100.0 % 2.04 [ 0.83, 4.99 ]
Total (95% CI) 10 17 100.0 % 2.04 [ 0.83, 4.99 ]
Total events: 6 (Minocycline), 5 (Cephalexin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Non-fluoroquinolone antibacterial agents: minocycline versus cephalexin,
Outcome 3 Microbiological recurrence.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 13 Non-fluoroquinolone antibacterial agents: minocycline versus cephalexin
Outcome: 3 Microbiological recurrence
Study or subgroup Minocycline Cephalexin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Paulson 1986 4/9 5/11 100.0 % 0.98 [ 0.37, 2.59 ]
Total (95% CI) 9 11 100.0 % 0.98 [ 0.37, 2.59 ]
Total events: 4 (Minocycline), 5 (Cephalexin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 Non-fluoroquinolone antibacterial agents: azithromycin versus clarithromycin
in chlamydial prostatitis, Outcome 1 Microbiological efficacy (pathogen eradication) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 14 Non-fluoroquinolone antibacterial agents: azithromycin versus clarithromycin in chlamydial prostatitis
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup Azithromycin Clarithromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Skerk 2002 37/46 36/45 100.0 % 1.01 [ 0.82, 1.23 ]
Total (95% CI) 46 45 100.0 % 1.01 [ 0.82, 1.23 ]
Total events: 37 (Azithromycin), 36 (Clarithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 Non-fluoroquinolone antibacterial agents: azithromycin versus
clarithromycin in chlamydial prostatitis, Outcome 2 Clinical efficacy (cure) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 14 Non-fluoroquinolone antibacterial agents: azithromycin versus clarithromycin in chlamydial prostatitis
Outcome: 2 Clinical efficacy (cure) at the end of treatment
Study or subgroup Azithromycin Clarithromycin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Skerk 2002 32/46 32/45 100.0 % 0.98 [ 0.75, 1.28 ]
Total (95% CI) 46 45 100.0 % 0.98 [ 0.75, 1.28 ]
Total events: 32 (Azithromycin), 32 (Clarithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 Non-fluoroquinolone antibacterial agents: azithromycin versus
clarithromycin in chlamydial prostatitis, Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 14 Non-fluoroquinolone antibacterial agents: azithromycin versus clarithromycin in chlamydial prostatitis
Outcome: 3 Adverse effects of treatment
Study or subgroup Azithromycin Clarithromycin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Skerk 2002 2/46 1/45 100.0 % 1.96 [ 0.18, 20.83 ]
Subtotal (95% CI) 46 45 100.0 % 1.96 [ 0.18, 20.83 ]
Total events: 2 (Azithromycin), 1 (Clarithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 Gastrointestinal adverse effects
Skerk 2002 2/46 1/45 100.0 % 1.96 [ 0.18, 20.83 ]
Subtotal (95% CI) 46 45 100.0 % 1.96 [ 0.18, 20.83 ]
Total events: 2 (Azithromycin), 1 (Clarithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
3 Hepatic adverse effects (increased transaminases)
Skerk 2002 2/46 1/45 100.0 % 1.96 [ 0.18, 20.83 ]
Subtotal (95% CI) 46 45 100.0 % 1.96 [ 0.18, 20.83 ]
Total events: 2 (Azithromycin), 1 (Clarithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
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Analysis 15.1. Comparison 15 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in
chlamydial prostatitis, Outcome 1 Microbiological efficacy (pathogen eradication) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 15 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in chlamydial prostatitis
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup Azithromycin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Skerk 2004a 65/82 33/43 100.0 % 1.03 [ 0.85, 1.26 ]
Total (95% CI) 82 43 100.0 % 1.03 [ 0.85, 1.26 ]
Total events: 65 (Azithromycin), 33 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in
chlamydial prostatitis, Outcome 2 Clinical efficacy.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 15 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in chlamydial prostatitis
Outcome: 2 Clinical efficacy
Study or subgroup Azithromycin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clinical efficacy - presence of inflammatory findings (number of participants with white blood cell counts in EPS/VB3 < 10 per high power field) at the end of
therapy
Skerk 2004a 31/82 15/43 100.0 % 1.08 [ 0.66, 1.78 ]
Subtotal (95% CI) 82 43 100.0 % 1.08 [ 0.66, 1.78 ]
Total events: 31 (Azithromycin), 15 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
2 Clinical efficacy (cure or improvement) at the end of therapy
Skerk 2004a 58/82 32/43 100.0 % 0.95 [ 0.76, 1.19 ]
Subtotal (95% CI) 82 43 100.0 % 0.95 [ 0.76, 1.19 ]
Total events: 58 (Azithromycin), 32 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
0.1 0.2 0.5 1 2 5 10
Favors doxycycline Favors azithromycin
117Antimicrobial therapy for chronic bacterial prostatitis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 15.3. Comparison 15 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in
chlamydial prostatitis, Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 15 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in chlamydial prostatitis
Outcome: 3 Adverse effects of treatment
Study or subgroup Azithromycin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Skerk 2004a 2/82 5/43 100.0 % 0.21 [ 0.04, 1.04 ]
Subtotal (95% CI) 82 43 100.0 % 0.21 [ 0.04, 1.04 ]
Total events: 2 (Azithromycin), 5 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
2 Gastrointestinal adverse effects
Skerk 2004a 2/82 5/43 100.0 % 0.21 [ 0.04, 1.04 ]
Subtotal (95% CI) 82 43 100.0 % 0.21 [ 0.04, 1.04 ]
Total events: 2 (Azithromycin), 5 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
3 Hepatic adverse effects (increased transaminases)
Skerk 2004a 2/82 0/43 100.0 % 2.65 [ 0.13, 54.00 ]
Subtotal (95% CI) 82 43 100.0 % 2.65 [ 0.13, 54.00 ]
Total events: 2 (Azithromycin), 0 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
0.005 0.1 1 10 200
Favors azithromycin Favors doxycycline
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Analysis 16.1. Comparison 16 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in
ureaplasmal prostatitis, Outcome 1 Microbiological efficacy (pathogen eradication) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 16 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in ureaplasmal prostatitis
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup Azithromycin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Skerk 2006 25/32 23/31 100.0 % 1.05 [ 0.80, 1.39 ]
Total (95% CI) 32 31 100.0 % 1.05 [ 0.80, 1.39 ]
Total events: 25 (Azithromycin), 23 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors doxycycline Favors azithromycin
Analysis 16.2. Comparison 16 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in
ureaplasmal prostatitis, Outcome 2 Clinical efficacy (cure) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 16 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in ureaplasmal prostatitis
Outcome: 2 Clinical efficacy (cure) at the end of treatment
Study or subgroup Azithromycin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Skerk 2006 22/32 21/31 100.0 % 1.01 [ 0.72, 1.42 ]
Total (95% CI) 32 31 100.0 % 1.01 [ 0.72, 1.42 ]
Total events: 22 (Azithromycin), 21 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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119Antimicrobial therapy for chronic bacterial prostatitis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 16.3. Comparison 16 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in
ureaplasmal prostatitis, Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 16 Non-fluoroquinolone antibacterial agents: azithromycin versus doxycycline in ureaplasmal prostatitis
Outcome: 3 Adverse effects of treatment
Study or subgroup Azithromycin Doxycycline Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Skerk 2006 0/32 5/31 100.0 % 0.09 [ 0.01, 1.53 ]
Subtotal (95% CI) 32 31 100.0 % 0.09 [ 0.01, 1.53 ]
Total events: 0 (Azithromycin), 5 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
2 Gastrointestinal adverse effects
Skerk 2006 0/32 5/31 100.0 % 0.09 [ 0.01, 1.53 ]
Subtotal (95% CI) 32 31 100.0 % 0.09 [ 0.01, 1.53 ]
Total events: 0 (Azithromycin), 5 (Doxycycline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
0.005 0.1 1 10 200
Favors azithromycin Favors doxycycline
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Analysis 17.1. Comparison 17 Different dosing regimens: azithromycin 4.5 g versus 6.0 g total doses in
chlamydial prostatitis, Outcome 1 Microbiological efficacy (pathogen eradication) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 17 Different dosing regimens: azithromycin 4.5 g versus 6.0 g total doses in chlamydial prostatitis
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup
Azithromycin
4.5 grams
Azithromycin
6.0 grams Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Skerk 2004b 37/46 35/43 100.0 % 0.99 [ 0.81, 1.21 ]
Total (95% CI) 46 43 100.0 % 0.99 [ 0.81, 1.21 ]
Total events: 37 (Azithromycin 4.5 grams), 35 (Azithromycin 6.0 grams)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors azithromycin 6.0 g Favors azithromycin 4.5 g
Analysis 17.2. Comparison 17 Different dosing regimens: azithromycin 4.5 g versus 6.0 g total doses in
chlamydial prostatitis, Outcome 2 Clinical efficacy (cure) at the end of therapy.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 17 Different dosing regimens: azithromycin 4.5 g versus 6.0 g total doses in chlamydial prostatitis
Outcome: 2 Clinical efficacy (cure) at the end of therapy
Study or subgroup
Azithromycin
4.5 grams
Azithromycin
6.0 grams Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Skerk 2004b 32/46 31/43 100.0 % 0.96 [ 0.74, 1.26 ]
Total (95% CI) 46 43 100.0 % 0.96 [ 0.74, 1.26 ]
Total events: 32 (Azithromycin 4.5 grams), 31 (Azithromycin 6.0 grams)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors azithromycin 6.0 g Favors azithromycin 4.5 g
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Analysis 17.3. Comparison 17 Different dosing regimens: azithromycin 4.5 g versus 6.0 g total doses in
chlamydial prostatitis, Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 17 Different dosing regimens: azithromycin 4.5 g versus 6.0 g total doses in chlamydial prostatitis
Outcome: 3 Adverse effects of treatment
Study or subgroup
Azithromycin
4.5 grams
Azithromycin
6.0 grams Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Skerk 2004b 0/46 2/43 100.0 % 0.19 [ 0.01, 3.79 ]
Subtotal (95% CI) 46 43 100.0 % 0.19 [ 0.01, 3.79 ]
Total events: 0 (Azithromycin 4.5 grams), 2 (Azithromycin 6.0 grams)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
2 Hepatic adverse effects (increased transaminases)
Skerk 2004b 0/46 2/43 100.0 % 0.19 [ 0.01, 3.79 ]
Subtotal (95% CI) 46 43 100.0 % 0.19 [ 0.01, 3.79 ]
Total events: 0 (Azithromycin 4.5 grams), 2 (Azithromycin 6.0 grams)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
0.005 0.1 1 10 200
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Analysis 18.1. Comparison 18 Different therapy duration: co-trimoxazole 480 mg twice daily for 12 weeks
versus 10 days, Outcome 1 Microbiological efficacy (pathogen eradication) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 18 Different therapy duration: co-trimoxazole 480 mg twice daily for 12 weeks versus 10 days
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup
Co-
trimoxazole
12 weeks
Co-
trimoxazole
10 days Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 1979 9/15 3/15 100.0 % 3.00 [ 1.01, 8.95 ]
Total (95% CI) 15 15 100.0 % 3.00 [ 1.01, 8.95 ]
Total events: 9 (Co-trimoxazole 12 weeks), 3 (Co-trimoxazole 10 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors co-trimoxazole 10 days Favors co-trimoxazole 12 weeks
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Analysis 18.2. Comparison 18 Different therapy duration: co-trimoxazole 480 mg twice daily for 12 weeks
versus 10 days, Outcome 2 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 18 Different therapy duration: co-trimoxazole 480 mg twice daily for 12 weeks versus 10 days
Outcome: 2 Adverse effects of treatment
Study or subgroup
Co-
trimoxazole
12 weeks
Co-
trimoxazole
10 days Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any adverse effects
Smith 1979 1/16 2/17 100.0 % 0.53 [ 0.05, 5.31 ]
Subtotal (95% CI) 16 17 100.0 % 0.53 [ 0.05, 5.31 ]
Total events: 1 (Co-trimoxazole 12 weeks), 2 (Co-trimoxazole 10 days)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Gastrointestinal/hepatic adverse effects
Smith 1979 0/16 2/17 100.0 % 0.21 [ 0.01, 4.10 ]
Subtotal (95% CI) 16 17 100.0 % 0.21 [ 0.01, 4.10 ]
Total events: 0 (Co-trimoxazole 12 weeks), 2 (Co-trimoxazole 10 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 Drop in leukocyte counts
Smith 1979 1/16 0/17 100.0 % 3.18 [ 0.14, 72.75 ]
Subtotal (95% CI) 16 17 100.0 % 3.18 [ 0.14, 72.75 ]
Total events: 1 (Co-trimoxazole 12 weeks), 0 (Co-trimoxazole 10 days)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
0.005 0.1 1 10 200
Favors co-trimoxazole 12 weeks Favors co-trimoxazole 10 days
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Analysis 19.1. Comparison 19 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus
fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin, Outcome 1 Microbiological efficacy
(pathogen eradication) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 19 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg/day Levofloxacin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aliaev 2008 32/34 29/32 100.0 % 1.04 [ 0.90, 1.19 ]
Total (95% CI) 34 32 100.0 % 1.04 [ 0.90, 1.19 ]
Total events: 32 (Levo+Vardenafil 10 mg/day), 29 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors Levofloxacin Favors Levo+Vardenafil 10 mg/day
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Analysis 19.2. Comparison 19 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus
fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin, Outcome 2 Clinical efficacy - NIH-
CPSI score at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 19 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin
Outcome: 2 Clinical efficacy - NIH-CPSI score at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg/day Levofloxacin
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 NIH-CPSI pain score
Aliaev 2008 34 11.57 (2.94) 32 11.9 (1.79) 100.0 % -0.13 [ -0.62, 0.35 ]
Subtotal (95% CI) 34 32 100.0 % -0.13 [ -0.62, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 NIH-CPSI voiding symptom score
Aliaev 2008 34 3.15 (0.63) 32 3.35 (0.71) 100.0 % -0.30 [ -0.78, 0.19 ]
Subtotal (95% CI) 34 32 100.0 % -0.30 [ -0.78, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
3 NIH-CPSI quality of life impact score
Aliaev 2008 34 4.27 (0.89) 32 4.46 (0.68) 100.0 % -0.24 [ -0.72, 0.25 ]
Subtotal (95% CI) 34 32 100.0 % -0.24 [ -0.72, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
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Analysis 19.3. Comparison 19 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus
fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin, Outcome 3 Clinical efficacy -
number of participants with leukocytosis in post-massage urine specimens at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 19 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin
Outcome: 3 Clinical efficacy - number of participants with leukocytosis in post-massage urine specimens at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg/day Levofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aliaev 2008 4/34 7/32 100.0 % 0.54 [ 0.17, 1.66 ]
Total (95% CI) 34 32 100.0 % 0.54 [ 0.17, 1.66 ]
Total events: 4 (Levo+Vardenafil 10 mg/day), 7 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favors Levo+Vardenafil 10 mg/day Favors Levofloxacin
Analysis 19.4. Comparison 19 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus
fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin, Outcome 4 Clinical efficacy - urine
peak flow rate at the end of treatment (mL/s).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 19 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg/day versus levofloxacin
Outcome: 4 Clinical efficacy - urine peak flow rate at the end of treatment (mL/s)
Study or subgroup
Levo+Vardenafil
10 mg/day Levofloxacin
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Aliaev 2008 34 19.01 (5.49) 32 17.69 (5.41) 100.0 % 0.24 [ -0.25, 0.72 ]
Total (95% CI) 34 32 100.0 % 0.24 [ -0.25, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus
fluoroquinolone: levofloxacin plus vardenafil 10 mg on-demand versus levofloxacin, Outcome 1 Microbiological
efficacy (pathogen eradication) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 20 Fluoroquinolonecombinedwith phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg on-demand versus levofloxacin
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg
on-demand Levofloxacin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aliaev 2008 34/37 29/32 100.0 % 1.01 [ 0.88, 1.17 ]
Total (95% CI) 37 32 100.0 % 1.01 [ 0.88, 1.17 ]
Total events: 34 (Levo+Vardenafil 10 mg on-demand), 29 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favors Levofloxacin Favors Levo+Vardenafil 10 mg on-demand
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Analysis 20.2. Comparison 20 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus
fluoroquinolone: levofloxacin plus vardenafil 10 mg on-demand versus levofloxacin, Outcome 2 Clinical efficacy
- NIH-CPSI score at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 20 Fluoroquinolonecombinedwith phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg on-demand versus levofloxacin
Outcome: 2 Clinical efficacy - NIH-CPSI score at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg
on-demand Levofloxacin
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 NIH-CPSI pain score
Aliaev 2008 37 11.79 (2.06) 32 11.9 (1.79) 100.0 % -0.06 [ -0.53, 0.42 ]
Subtotal (95% CI) 37 32 100.0 % -0.06 [ -0.53, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 NIH-CPSI voiding symptom score
Aliaev 2008 37 3.52 (0.52) 32 3.35 (0.71) 100.0 % 0.27 [ -0.20, 0.75 ]
Subtotal (95% CI) 37 32 100.0 % 0.27 [ -0.20, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3 NIH-CPSI quality of life impact score
Aliaev 2008 37 4.82 (0.68) 32 4.46 (0.68) 100.0 % 0.52 [ 0.04, 1.01 ]
Subtotal (95% CI) 37 32 100.0 % 0.52 [ 0.04, 1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
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Analysis 20.3. Comparison 20 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus
fluoroquinolone: levofloxacin plus vardenafil 10 mg on-demand versus levofloxacin, Outcome 3 Clinical efficacy
- number of participants with leukocytosis in post-massage urine specimens at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 20 Fluoroquinolonecombinedwith phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg on-demand versus levofloxacin
Outcome: 3 Clinical efficacy - number of participants with leukocytosis in post-massage urine specimens at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg
on-demand Levofloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aliaev 2008 6/37 7/32 100.0 % 0.74 [ 0.28, 1.98 ]
Total (95% CI) 37 32 100.0 % 0.74 [ 0.28, 1.98 ]
Total events: 6 (Levo+Vardenafil 10 mg on-demand), 7 (Levofloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 20.4. Comparison 20 Fluoroquinolone combined with phosphodiesterase-5 inhibitor versus
fluoroquinolone: levofloxacin plus vardenafil 10 mg on-demand versus levofloxacin, Outcome 4 Clinical efficacy
- urine peak flow rate at the end of treatment (mL/s).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 20 Fluoroquinolonecombinedwith phosphodiesterase-5 inhibitor versus fluoroquinolone: levofloxacin plus vardenafil 10 mg on-demand versus levofloxacin
Outcome: 4 Clinical efficacy - urine peak flow rate at the end of treatment (mL/s)
Study or subgroup
Levo+Vardenafil
10 mg
on-demand Levofloxacin
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Aliaev 2008 37 18.21 (4.89) 32 17.69 (5.41) 100.0 % 0.10 [ -0.37, 0.57 ]
Total (95% CI) 37 32 100.0 % 0.10 [ -0.37, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 21.1. Comparison 21 Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin
plus vardenafil 10 mg/day versus levofloxacin plus vardenafil 10 mg on-demand, Outcome 1 Microbiological
efficacy (pathogen eradication) at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 21 Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin plus vardenafil 10 mg/day versus levofloxacin plus vardenafil 10 mg on-
demand
Outcome: 1 Microbiological efficacy (pathogen eradication) at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg/day
Levo+Vardenafil
10 mg
on-demand Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aliaev 2008 32/34 34/37 100.0 % 1.02 [ 0.90, 1.16 ]
Total (95% CI) 34 37 100.0 % 1.02 [ 0.90, 1.16 ]
Total events: 32 (Levo+Vardenafil 10 mg/day), 34 (Levo+Vardenafil 10 mg on-demand)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 21.2. Comparison 21 Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin
plus vardenafil 10 mg/day versus levofloxacin plus vardenafil 10 mg on-demand, Outcome 2 Clinical efficacy -
NIH-CPSI score at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 21 Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin plus vardenafil 10 mg/day versus levofloxacin plus vardenafil 10 mg on-
demand
Outcome: 2 Clinical efficacy - NIH-CPSI score at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg/day
Levo+Vardenafil
10 mg
on-demand
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 NIH-CPSI pain score
Aliaev 2008 34 11.57 (2.94) 37 11.79 (2.06) 100.0 % -0.09 [ -0.55, 0.38 ]
Subtotal (95% CI) 34 37 100.0 % -0.09 [ -0.55, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 NIH-CPSI voiding symptom score
Aliaev 2008 34 3.15 (0.63) 37 3.52 (0.52) 100.0 % -0.64 [ -1.11, -0.16 ]
Subtotal (95% CI) 34 37 100.0 % -0.64 [ -1.11, -0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0091)
3 NIH-CPSI quality of life impact score
Aliaev 2008 34 4.27 (0.89) 37 4.82 (0.68) 100.0 % -0.69 [ -1.17, -0.21 ]
Subtotal (95% CI) 34 37 100.0 % -0.69 [ -1.17, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
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Analysis 21.3. Comparison 21 Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin
plus vardenafil 10 mg/day versus levofloxacin plus vardenafil 10 mg on-demand, Outcome 3 Clinical efficacy -
number of participants with leukocytosis in post-massage urine specimens at the end of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 21 Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin plus vardenafil 10 mg/day versus levofloxacin plus vardenafil 10 mg on-
demand
Outcome: 3 Clinical efficacy - number of participants with leukocytosis in post-massage urine specimens at the end of treatment
Study or subgroup
Levo+Vardenafil
10 mg/day
Levo+Vardenafil
10 mg
on-demand Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aliaev 2008 4/34 6/37 100.0 % 0.73 [ 0.22, 2.35 ]
Total (95% CI) 34 37 100.0 % 0.73 [ 0.22, 2.35 ]
Total events: 4 (Levo+Vardenafil 10 mg/day), 6 (Levo+Vardenafil 10 mg on-demand)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 21.4. Comparison 21 Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin
plus vardenafil 10 mg/day versus levofloxacin plus vardenafil 10 mg on-demand, Outcome 4 Clinical efficacy -
urine peak flow rate at the end of treatment (mL/s).
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 21 Fluoroquinolone combined with phosphodiesterase-5 inhibitor: levofloxacin plus vardenafil 10 mg/day versus levofloxacin plus vardenafil 10 mg on-
demand
Outcome: 4 Clinical efficacy - urine peak flow rate at the end of treatment (mL/s)
Study or subgroup
Levo+Vardenafil
10 mg/day
Levo+Vardenafil
10 mg
on-demand
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Aliaev 2008 34 19.01 (5.49) 37 18.21 (4.89) 100.0 % 0.15 [ -0.31, 0.62 ]
Total (95% CI) 34 37 100.0 % 0.15 [ -0.31, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 22.1. Comparison 22 Fluoroquinolone plus herbal extracts or supplements versus fluoroquinolone:
prulifloxacin plus supplements versus prulifloxacin, Outcome 1 Clinical efficacy - NIH-CPSI total score.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 22 Fluoroquinolone plus herbal extracts or supplements versus fluoroquinolone: prulifloxacin plus supplements versus prulifloxacin
Outcome: 1 Clinical efficacy - NIH-CPSI total score
Study or subgroup Prulifloxacin+supplements Prulifloxacin
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 NIH-CPSI total score at the end of treatment
Cai 2009 106 1.96 (2.2) 37 11.02 (5.88) 100.0 % -2.56 [ -3.04, -2.08 ]
Subtotal (95% CI) 106 37 100.0 % -2.56 [ -3.04, -2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.44 (P < 0.00001)
2 NIH-CPSI total score at follow-up (6 months)
Cai 2009 106 1.35 (1.75) 37 10.51 (3.72) 100.0 % -3.78 [ -4.36, -3.20 ]
Subtotal (95% CI) 106 37 100.0 % -3.78 [ -4.36, -3.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.75 (P < 0.00001)
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Analysis 22.2. Comparison 22 Fluoroquinolone plus herbal extracts or supplements versus fluoroquinolone:
prulifloxacin plus supplements versus prulifloxacin, Outcome 2 Clinical efficacy - IPSS score.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 22 Fluoroquinolone plus herbal extracts or supplements versus fluoroquinolone: prulifloxacin plus supplements versus prulifloxacin
Outcome: 2 Clinical efficacy - IPSS score
Study or subgroup Prulifloxacin+supplements Prulifloxacin
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 IPSS score at the end of treatment
Cai 2009 106 5.36 (2.58) 37 12.24 (4.27) 100.0 % -2.21 [ -2.66, -1.75 ]
Subtotal (95% CI) 106 37 100.0 % -2.21 [ -2.66, -1.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.50 (P < 0.00001)
2 IPSS score at follow-up
Cai 2009 106 4.63 (2.29) 37 11.72 (3.98) 100.0 % -2.50 [ -2.98, -2.03 ]
Subtotal (95% CI) 106 37 100.0 % -2.50 [ -2.98, -2.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.30 (P < 0.00001)
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Analysis 22.3. Comparison 22 Fluoroquinolone plus herbal extracts or supplements versus fluoroquinolone:
prulifloxacin plus supplements versus prulifloxacin, Outcome 3 Adverse effects of treatment.
Review: Antimicrobial therapy for chronic bacterial prostatitis
Comparison: 22 Fluoroquinolone plus herbal extracts or supplements versus fluoroquinolone: prulifloxacin plus supplements versus prulifloxacin
Outcome: 3 Adverse effects of treatment
Study or subgroup Prulifloxacin+supplementsPrulifloxacin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cai 2009 3/106 1/37 100.0 % 1.05 [ 0.11, 9.76 ]
Total (95% CI) 106 37 100.0 % 1.05 [ 0.11, 9.76 ]
Total events: 3 (Prulifloxacin+supplements), 1 (Prulifloxacin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. The order of the primary outcomes has been inverted. The first primary outcome is microbiological efficacy, whereas the second
is clinical efficacy.
2. Studies in which a pool of different antibacterial agents were administered to participants within a single treatment arm were
excluded if the effects of single antibiotics were not analyzed separately (subgroup analysis).
3. During the review process, the authors became aware of their lack of knowledge concerning traditional Chinese medicine. It was
decided to exclude all studies involving traditional Chinese medications. Exclusion of such studies was performed either during title
and abstract screening or during full article examination.
4. In the protocol, we proposed an imputation strategy as follows: “In case data were likely not missing at random, we considered
what the event rates might have been in the missing data by imputing a range of possible outcome rates (including observed risk rates),
as described in Chapter 16.2.2 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2009).” We subsequently
decided to avoid imputation, and modified the Methods section as follows: “Because imputation strategies may significantly increase
heterogeneity, we limited our analysis to participants for whom outcomes were obtained (available case analysis).”
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [∗therapeutic use]; Bacterial Infections [∗drug therapy; microbiology]; Chlamydia Infections [drug therapy];
Chronic Disease; Fluoroquinolones [∗therapeutic use]; Macrolides [∗therapeutic use]; Prostatitis [∗drug therapy; microbiology]; Ran-
domized Controlled Trials as Topic
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MeSH check words
Humans; Male
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